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Abstract 
 
myo-Inositol is ubiquitous in nature and is found at the structural core of a diverse range 
of biologically important derivatives, including phosphatidylinositols, inositol phosphates 
and mycothiol.  The synthesis of myo-inositol derivatives is notoriously difficult due to 
the need to control both regio- and enantioselectivity.  As a result, synthetic routes to 
derivatives of this type are often lengthy and low yielding.  The first biosynthetic step in 
the production of all myo-inositol metabolites is the isomerisation of D-glucose 6-
phosphate to L-myo-inositol 1-phosphate as mediated by L-myo-inositol 1-phosphate 
synthase (INO1).  For the protozoan parasite Trypanosoma brucei, INO1 is essential for 
survival and its version of the enzyme (TbINO1) has a high turnover.  This makes 
TbINO1 an attractive candidate for the biocatalytic production of L-myo-inositol 1-
phosphate, and a potential starting point for drastically shortened syntheses of important 
myo-inositol derivatives. 
 
 
 
The production of L-myo-inositol 1-phosphate by TbINO1 has been optimised to achieve 
complete conversion in reaction conditions that facilitate product isolation.  Due to 
problems with an in-batch process, the TbINO1 enzyme was immobilised and the process 
was transferred to a flow system.  This has allowed for production of significant 
quantities of L-myo-inositol 1-phosphate with a high level of purity.  L-myo-inositol 1-
phosphate obtained from the flow system has been used to prepare mycothiol 
glycosylation acceptor, 1,2,4,5,6-penta-O-acetyl-D-myo-inositol, in a concise synthesis 
with a greatly improved yield over the literature.   
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Chapter One 
 
1  Introduction 
 
1.1  Structure and Nomenclature of Inositols 
 
The inositols are the nine isomeric forms of cyclohexane-1,2,3,4,5,6-hexol (Figure 1.1.1), 
which are small, polar and chemically very stable molecules with versatile properties.1  
They were discovered in 1850, when Scherer2 isolated an optically inactive isomer of 
cyclohexanehexol from muscle.  He named the molecule “inosit” and as more isomers 
were discovered or synthesized, the –ol suffix was added to give the name as it stands 
today.3 
 
 
Figure 1.1.1 – The nine isomeric forms of cyclohexane-1,2,3,4,5,6-hexol, or inositol. 
 
Six of the nine isomers have been found to occur within nature, these are myo-inositol (1), 
epi-inositol (2), neo-inositol (3), L-(+)-chiro-inositol (4), D-(-)-chiro-inositol (5), and 
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scyllo-inositol (6).  The other three isomers (cis-inositol (7), allo-inositol (8) and muco-
inositol (9)) are unnatural synthetic compounds.1  myo-Inositol (1) is the most abundant 
isomer of inositol within nature, and it is accepted that when literature refers to inositol 
without a prefix it is to be assumed that this is the isomer being described.  This isomer is 
a meso-isomer of inositol, as although it contains more than two chiral centres, it can be 
superimposed upon a mirror image of itself.  It possesses a plane of symmetry that runs 
through the centre of the molecule as it has one axial alcohol and five equatorial alcohols 
in its lowest energy conformer.3 
 
The nomenclature of myo-inositol derivatives was outlined by the International Union of 
Biochemistry Nomenclature Committee in 1989.4  These rules were put forward in an 
attempt to address the difficulties in nomenclature that the subtle differences in myo-
inositol derivatives can produce.  Placing the myo-inositol ring in its most 
thermodynamically stable conformation (with one axial and five equatorial substituents, 
Figure 1.1.2), the ring is numbered by designating C-2 to the carbon bearing the axial 
substituent.  The other carbons within the ring are then numbered from C-1 to C-6 by 
choosing to label one of the carbons adjacent to C-2 as C-1 and continuing to number in a 
clockwise or anti-clockwise fashion (directions taken as if looking down onto the 
molecule from the face containing the axial substituent).3  Independent of which direction 
the ring is numbered, the carbon opposite the C-2 position will be labelled as C-5.  This 
means that the plane of symmetry in myo-inositol (1) passes through C-2 and C-5, and 
substitution at either of these two positions will not disturb the symmetry of the ring.5 
 
 
Figure 1.1.2 – myo-Inositol (1) contains a plane of symmetry that passes through C-2 and 
C-5, whilst D-myo-inositol 1,4,5-trisphosphate (10) is chiral due to the substitution 
around the ring. 
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Substitution at any of the other carbon atoms (C-1, C-3, C-4, or C-6) will disrupt the 
symmetry of the ring, producing a chiral compound.  Therefore, a D- or L- prefix must be 
given to the name of the molecule in order to account for this.  An anti-clockwise 
numbering is given a D- prefix, whereas numbering in a clockwise fashion gives a L- 
prefix.  The prefix, and thus the direction to number the ring, is usually determined by 
choosing the numbering that gives the ring substituents the lowest numbering possible.3  
For example, the myo-inositol trisphosphate 10 (Figure 1.1.2) is labelled with a D- prefix 
to give the phosphate groups in the positions with the lowest numbering.  It is thus named 
D-myo-inositol 1,4,5-trisphosphate and not L-myo-inositol 3,5,6-trisphosphate. 
 
 
1.2  myo-Inositol Derivatives in Nature 
 
Derivatives of myo-inositol (1) have acquired diverse functions over the course of 
evolution.  Their innate chemical versatility coupled with the stability of the myo-inositol 
core allow these derivatives to play a central role in a plethora of cellular signalling 
processes and recognition events6 that take place inter- and intracellularly, also between 
different cell types.7 The vast majority of natural myo-inositol derivatives are part of the 
extremely diverse family of signalling molecules comprised of inositol phosphates, 
diphosphoinositol polyphosphates and phosphatidylinositol phosphates. Variation of 
biological properties within these biosynthetically interrelated species leads to control 
over numerous cellular processes.8  myo-Inositol (1) can also form part of a larger 
structure such as a glycosylphosphatidylinositol (GPI) anchor or bioactive natural 
products such as discoside. 
 
1.2.1  Inositol phosphates   
 
The essence of what makes inositol phosphates so useful within biology is the versatility 
provided by compounds that are seemingly very simple.  It is very easy for a cell to 
interchange between different inositol phosphates using various kinases and 
phosphatases, controlling which inositol phosphates are present at any one time.  This 
allows the cell to control the wide-ranging processes that inositol phosphates govern as 
needed. 
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Probably the most well known example of an inositol phosphate is D-myo-inositol 1,4,5-
trisphosphate (10, InsP3) as a secondary messenger used within signal transduction and 
lipid signalling in cells.  The role of InsP3 (10) within a cell is very much intertwined with 
calcium signalling.  
 
Modulation of the cytoplasmic concentration of calcium ions (Ca2+) is incredibly 
important for cellular signalling.  Cells receive signals via electrical, hormonal or 
mechanical stimulation and use a “toolkit” of channels, pumps and cytosolic buffers to 
control Ca2+ levels within the cytoplasm.9  An increase in Ca2+ ion concentration will 
exert allosteric regulatory effects on many enzymes, which can be reverted back to 
normal once Ca2+ levels have been lowered.10  The processes that are controlled by this 
mechanism are as diverse as cell motility, gene transcription, muscle contraction, and 
exocytosis.9,11  
 
  
 
Figure 1.2.1 – Modulation of calcium ion concentration via action of D-myo-inositol 
1,4,5-trisphosphate (10, InP3).12 
 
InsP3 (10) has been well established as a ubiquitous and essential secondary messenger in 
Ca2+ release.  The pathways that link the molecule to Ca2+ signalling are generally well 
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understood.  The InsP3 (10)-mediated Ca2+ signalling cascade (Figure 1.2.1) is initiated 
by the binding of hormones to specific G-protein coupled receptors (GPCRs) on the cell’s 
outer surface.  This leads to the activation of phospholipase C (PLC)-β and PLC-γ, which 
both act to hydrolyse membrane-bound phosphatidylinositol 4,5-bisphosphate, producing 
the secondary messengers diacylglycerol (DAG) and InsP3 (10).10   DAG stays tethered 
within the cell membrane where it can activate protein kinase C enzymes, with the 
downstream effect of potentially opening voltage-gated Ca2+ channels.  InsP3 (10) 
diffuses into the cytoplasm and can bind to its receptor.  The InsP3 receptor (InsP3R) is 
located in the endoplasmic reticulum (ER) membrane, and acts as an intracellular ligand-
gated Ca2+ release channel.9 
 
InsP3 (10)-mediated Ca2+ signals are responsible for a wide variety of roles within a cell.  
This versatility stems from the complexity that can be involved in how these signals are 
organised in both time and space, utilising repetitive spikes or oscillations and 
propagating waves that initiate in specific areas within the cell.13 
 
 
Figure 1.2.2 – The most abundant myo-inositol derivatives within cells: myo-Inositol 
1,2,3,4,5,6-hexakisphosphate (11) and myo-inositol 1,3,4,5,6-pentakisphosphate (12). 
 
Without consideration of pyrophosphate examples, there are 63 possible structural 
permutations of inositol phosphates, and at least half of these compounds have been 
identified as metabolites in various biological systems.8 myo-Inositol 1,2,3,4,5,6-
hexakisphosphate (11, InsP6, phytate, Figure 1.2.2) and myo-inositol 1,3,4,5,6-
pentakisphosphate (12, InsP5) are the most abundant inositol phosphate isomers with 
cellular concentrations generally maintained between 10 and 100 µM.8,14  Both of these 
compounds are very versatile, with InsP5 associated with cell proliferation, viral 
assembly, chromatin remodelling and regulation of calcium channels.  InsP6 has roles 
within neurotransmission, immune responses, regulation of protein kinases and 
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phosphatases, and calcium channel activation.  It also has antioxidant properties and acts 
as an anti-neoplastic agent for several different carcinomas.8 
 
1.2.2  Phosphatidylinositol and Glycosylphosphatidylinositol 
 
Phosphatidylinositol (13, PI, Figure 1.2.3) and phosphatidylinositol phosphates (PIPs) are 
another biologically important class of myo-inositol derivatives.  The inositol ring forms 
the head group for the structure, with attachment to the glycerophospholipid through a 
phosphodiester linkage at the D-1 position.  There are seven known examples of PIPs 
within nature, with phosphate decoration at the 3-, 4- or 5- positions of the myo-inositol 
ring.8 
 
 
Figure 1.2.3 – Structure of phosphatidylinositol (13, PI). 
 
The lipid portion of PIs and PIPs anchor these compounds within the lipid bilayer of a 
cell membrane, presenting the myo-inositol headgroup at the membrane surface.  
Therefore, when a protein binds to a headgroup of one of these compounds, it will be 
reversibly tethered to the cell surface.8 Interactions between proteins and PIPs regulate 
many crucial cellular processes through the regulation of protein function and subcellular 
localisation.  Control is exerted by either direct conformational changes to the protein 
upon binding or the protein being led to interaction with binding partners situated on the 
membrane surface.8,15 
 
A glycosylphosphatidylinositol (GPI) anchor (14, Figure 1.2.4) is a glycolipid that is 
added posttranslationally to the C-terminus of a protein to tether it to the cell membrane.  
The proteins involved are very diverse in function, playing important roles within signal 
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transduction, prion disease pathogenesis, immune response and the pathobiology of 
trypanosomal parasites.16 The structure of a GPI anchor (14) is highly complex with three 
domains: a phosphoethanolamine linker, glycan core and phospholipid tail.17 
 
 
Figure 1.2.4 – General structure of a glycosylphosphatidylinositol (GPI) anchor (14). 
 
The phosphoethanolamine linker is used to covalently bind the protein to the third 
mannose of the glycan core, which is a highly conserved structure comprising three 
mannose, one glucosamine and one inositol ring.  Whilst the core of the glycan is highly 
conserved, a plethora of modifications is possible, including additional 
phosphoethanolamine groups or sugars, such as mannose, galactose or sialic acid.16  The 
transition between the glycan core and phospholipid is achieved via a PI moiety.  The 
lipid moiety can be a diacylglycerol, alkylacylglycerol or ceramide depending on protein 
and species of origin.18  An additional fatty acid is present on the OH-2 of the myo-
inositol ring in many GPI anchors, which makes them resistant to the enzyme 
phosphoinositide phospholipase C (PI-PLC) that normally cleaves the head group from PI 
and PIPs.16,18 
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1.2.3  Bioactive Natural Products 
 
The roles discussed so far have shown the importance of myo-inositol derivatives within 
the cell, and how they can be used to control a large number of cellular processes.  There 
are other examples in the literature of myo-inositol derivatives that have been isolated in 
small quantities from nature.  Discoside19 (15, Figure 1.2.5) and Plakohopanoid20 (17) are 
natural products that have been isolated from the marine sponges Discodermia dissoluta 
and Plakortis simplex, respectively.  Both contain a mannose attached to the myo-inositol 
via the OH-2.  Mycothiol21 (16) is a low molecular weight thiol that has a high prevalence 
within mycobacteria, where it is used to relieve oxidative stress within cells, and will be 
discussed in more detail in Chapter 4. 
 
 
Figure 1.2.5 – myo-Inositol containing natural products Discoside (15), Mycothiol (16) 
and Plakohopanoid (17). 
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1.3  Biosynthesis of myo-Inositol 
 
Cells can obtain myo-inositol (1) from the extracellular environment, the turnover of 
inositol phospholipids and dephosphorylation of inositol phosphates, or it can be de novo 
synthesised.22 The de novo synthesis (Scheme 1.3.1) utilises two enzymes: L-myo-inositol 
1-phosphate synthase (INO1) and myo-inositol monophosphatase (IMPase).  INO1 acts to 
convert D-glucose 6-phosphate (18) into L-myo-inositol 1-phosphate (19) in a three step 
process that utilises nicotinamide adenine dinucleotide (NAD+) as a cofactor.23 IMPase is 
a specific phosphatase that acts to cleave the phosphate from L-myo-inositol 1-phosphate 
(19) to produce myo-inositol (1).3  Either of these two compounds, L-myo-inositol 1-
phosphate (19) and myo-inositol, can then be modified by the organism to produce 
compounds of need or used without further elaboration. 
 
 
Scheme 1.3.1 – Biosynthesis of myo-inositol (1).  Reagents and conditions:  i. INO1, 
NAD+;  ii. IMPase, Mg2+. 
 
INO1 has been identified in a wide variety of evolutionarily diverse organisms including 
Cyanobacteria, eubacteria, Archaebacteria, plants, fungi and animals.24,25  The ‘core 
catalytic structure’ of the enzyme is highly conserved throughout the biological kingdom, 
highlighting the essential role within cellular metabolism.24 
 
1.3.1  L-myo-Inositol 1-phosphate Synthase Mechanism 
 
It had been hypothesised that the myo-inositol core is formed via a cyclisation of D-
glucose.  However, it was not until 196226 that isotopic labelling of the 1 and 6 carbons of 
D-glucose proved that they condensed to form myo-inositol (1).  The most studied INO1 
gene is that of Saccharomyces cerevisiae (S. cerevisiae).25 Scheme 1.3.2 shows the 
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mechanism of this enzyme.  The highly conserved structure of the catalytic pocket across 
the biological kingdoms suggests that this is the general mechanism for all INO1 genes. 
 
 
Scheme 1.3.2 – Proposed mechanism of S. cerevisiae L-myo-inositol 1-phosphate 
synthase.25 
 
Studies have shown that the enzyme only binds the acyclic form of D-glucose 6-
phosphate (20), even though this form represents less than 1 % of D-glucose 6-phosphate 
molecules.25 All INO1 proteins within eukaryotes contain a Rossmann fold, which is 
characterised by a GXGGXXG motif.24 This is typical of an oxidoreductase, and 
functions to bind the cofactor, NAD+, more tightly. 
 
Once the acyclic D-glucose 6-phosphate (20) has been bound, a lysine residue will 
deprotonate the alcohol at C-5.  This leads to the formation of keto intermediate 21 
through hydride addition to NAD+.  The enol 22 is then formed via deprotonation at C-6.  
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It is possible that the phosphate oxygen will act as a base for this step (as shown), 
however it is also possible that it could be performed by a second lysine residue.  pKa 
values of these two groups would not normally be considered within the range to perform 
this extraction, however phosphate ester-mediated deprotonation has been observed in 
dehydroquinate synthase,27,28 and lysines that are buried within enzymes can have 
dramatically different pKa’s than those expected.25,29,30 An intramolecular aldol 
cyclisation between C-1 and C-6 forms the key carbon-carbon bond to give inosose 23, 
before selective hydride transfer from NADH produces the product, L-myo-inositol 1-
phosphate (19). 
 
 
1.4  Synthetic Routes to myo-Inositol Derivatives 
 
Synthetic routes to myo-inositol derivatives are notoriously difficult.  Not only are there 
complex regioselectivity issues associated with the six hydroxyl groups, but most 
derivatives are also chiral.  There are four main methods used to produce myo-inositol 
derivatives.  Syntheses can start from a carbohydrate such as D-glucose, D-xylose or D-
mannitol, and utilise some type of rearrangement to produce the myo-inositol core, 
generally via a Ferrier carbocyclisation.  Alternatively, a D-pinitol or L-quebrachitol 
derivative can be converted into a myo-inositol derivative by inversion of the necessary 
stereocentre.  Starting from the microbial oxidation of benzene, it is possible to produce 
myo-inositol derivatives through careful control of epoxidations and subsequent ring 
openings.  It is also possible to synthesise derivatives from myo-inositol (1) itself, with 
various protection strategies and optical resolutions available for use. 
 
1.4.1 Ferrier Transformations 
 
A popular approach to obtain myo-inositol derivatives is to build up functionality on a 
non-inositol skeleton and then transform the compound into the myo-inositol core via a 
carbocyclisation or dihydroxylation reaction.  Methods to do this involve examples of 
Ferrier type-II reactions,31 ring closing metathesis32 and a pinacol type rearrangement.33  
When utilising these methods, it is possible to use protecting group strategies and orders 
of protection that are different from those associated with syntheses starting from myo-
inositol (1) itself. 
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The most popular methods within this approach are based upon the Ferrier-II reaction 
(also known as the Ferrier carbocyclisation).31  This reaction provides an efficient, one-
step conversion of 5,6-unsaturated hexopyranose derivatives into functionalised 
cyclohexanones.  The cyclohexanones produced are convenient for the synthesis of 
enantiopure inositols and their amino-, deoxy-, unsaturated and selectively O-substituted 
derivatives.34 Ferrier31 developed the reaction when he was trying to synthesise 
cyclohexane derivatives via a biomimetic approach.  As detailed previously, the INO1 
enzyme converts D-glucose 6-phosphate (18) into L-myo-inositol 1-phosphate (19) via a 
mechanism that involves an intramolecular aldol cyclisation to form an inosose.25 This 
was the key step that Ferrier emulated in his original work, producing cyclohexanone 25 
(Scheme 1.4.1) from pyranoside 24 in a mercury-mediated ring closure.31 Reaction did 
not proceed in the absence of mercury ions, confirming that the mercury ions were 
responsible for transformation and not simply the acidic reaction conditions. 
 
 
Scheme 1.4.1 – Ferrier-II reaction as originally conducted by Ferrier in 1979.31  Reagents 
and conditions:  i. HgCl2, acetone:water (2:1), 4.5 hr, reflux, 83 %. 
 
There have been several modifications and improvements to the procedure since it was 
originally published.  Mercuric (II) acetate improved the yield of the system to 89 %, and 
also allowed for a larger scope than mercuric (II) chloride.35 Scope was increased even 
further by the use of mercuric (II) trifluoroacetate to convert azide-containing pyranosides 
into the corresponding inososes.36 It was shown37 that mercuric (II) sulfate could be used 
sub-stoichiometrically to produce the same result, and further to this, work by Ogawa38 
demonstrated the catalytic use of mercuric (II) trifluoroacetate and mercuric (II) oxide in 
a dramatic improvement to the methodology.  With his synthesis of Hygromycin A39 and 
(+)-Lycoricidine40, Ogawa showed that as little as 1 mol % mercuric (II) trifluoroacetate 
could be used to effect Ferrier-II reactions. 
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Scheme 1.4.2 – Proposed mechanism for the mercury-mediated Ferrier-II reaction.37 
 
The most well accepted mechanism for the Ferrier-II reaction was proposed by Machado 
et al. (Scheme 1.4.2).37 Taking deoxyhex-5-enopyranoside 26 as an example, the 
proposed mechanism begins with oxymercuration of the alkene.  This leads to reaction 
intermediate 28, where the hydroxyl group has been introduced in a Markovnikov 
fashion.  Ring-opening is accomplished through loss of methanol, to furnish 
ketoaldehydes 29 and 32.  The equilibrium between these two compounds is thought to 
lie far in the favour of 29, giving cyclohexanone 31 as the major product for this reaction.  
It is proposed that 31 is formed via the pseudo chair intermediate 30 in an intramolecular 
aldol-type reaction. 
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Scheme 1.4.3 – Examples of analogous Ferrier-II reactions utilising palladium-, 
aluminium- and titanium-mediated reactions.  Reagents and conditions:  i. Pd(OAc)2 or 
PdCl2 (10-20 mol %), 1,4-dioxane or acetone, H2SO4, 60 °C, 60-80 %;41  ii. iBu3Al, 
toluene, 40 °C, 70 %;42  iii. Ti(OiPr)Cl3, DCM, -78 °C, 98 %.43 
 
The Ferrier-II reaction is not limited to the use of mercury to facilitate the transformation 
(Scheme 1.4.3).  Work by Adam et al.41 discovered that the transformation occurs rapidly 
when using palladium (II) salts in the presence of acid.  The reaction is thought to 
proceed via a different mechanism, however in an analogous manner to the mercury (II)-
mediated process.  Further work by Ikegami et al.44 utilised the palladium-mediated 
reaction in studies towards all nine isomers of inositol.  Their work showed that 
palladium (II) chloride could be used in as little as 5 mol % to effect the transformations 
of 6-deoxypyranosides in dioxane-water mixtures.45 Palladium-mediated reactions were 
generally higher yielding than those mediated by mercury.  On the other hand, there was 
also a higher number of isomeric products observed in the palladium-mediated reactions, 
the majority of which could be separated by chromatography.46 
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It has also been shown that other metals can facilitate Ferrier-type transformations.  Use 
of triisobutylaluminium (iBu3Al),42 and isopropoxytitanium trichloride (Ti(OiPr)Cl3)43 
both complete the transformation with retention of the glycosidic bond and the major 
product maintains the original configuration at the anomeric position (Scheme 1.4.3).  
Use of trimethylaluminium47 in place of triisobutylaluminium introduces an additional 
methyl group at the C-2 equatorial position of alcohol 38. 
 
The Ferrier-II reaction has proved to be a useful tool in the synthesis of myo-inositol 
derivatives.   Conway et al.48 utilised this method in their synthesis of InsP3 (10).  They 
synthesised the Ferrier carbocyclisation precursor 46 (Scheme 1.4.4) starting from α–D-
glucopyranose 41, which they initially selectively protected at the 4- and 6-positions to 
give anisylidene acetal 42.  Selective benzylation arising through the tin acetal gave the 
desired alcohol 43 in a 2:1 ratio in over the unwanted regioisomer.  Silyl protection and 
subsequent diisobutylaluminium hydride (DIBAL-H) mediated cleavage of the 
anisylidene acetal gave primary alcohol 44.  Oxidation using Dess-Martin periodane 
(DMP) gave aldehyde 45, which was subsequently converted into the enol acetate 46 
using potassium carbonate and acetic anhydride (Ac2O).48 
 
They initially attempted the Ferrier carbocyclisation using palladium (II) chloride, but 
discovered that they produced a large number of inseparable isomeric products.  
Treatment of enol acetate 46 (Scheme 1.4.5) with mercuric (II) acetate gave a cleaner 
reaction, producing the desired inosose 47 in a fairly low yield, however with minimal 
isomeric side products. 
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Scheme 1.4.4 – Synthesis of Ferrier carbocyclisation precursor 46.  Reagents and 
conditions:  i. Anisaldehyde dimethyl acetal, amberlyst-15, DMF, 200 mbar, 80 °C, 
58 %;  ii. nBu2SnO, TBABr, BnBr, MeCN, reflux, 54 %;  iii. a. Et3N, TIPSOTf, DCM, 
92 %;  b. DIBAL-H, DCM, 88 %;  iv. DMP, DCM, 82 %; v. K2CO3, Ac2O, DMAP, 
MeCN, reflux, 65 %.48 
 
The reduction of inosose 47 was conducted using tetramethylammonium 
triacetoxyborohydride and gave a good yield of desired diol 48.  They attribute the 
selectivity in this reaction to the coordination of the reducing agent to the axial OH-2 of 
the inosose 47.  This leads to delivery of the hydride from the top face of the molecule.  
Now that they had created the myo-inositol core of the molecule, a series of protecting 
group manipulations afforded them the triol 50, containing the necessary symmetry for 
production of InsP3 (10).  Phosphitylation of the triol 50, followed by oxidation using m-
chloroperbenzoic acid (mCPBA), furnished the perbenzylated trisphosphate 51, which 
was taken through to the desired InsP3 (10) via hydrogenolysis.48 
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Scheme 1.4.5 – Completion of the synthesis of InsP3 (10).  Reagents and conditions:  i. 
Hg(OAc)2, acetone, water, 35 %;  ii. Tetramethylammonium triacetoxyborohydride, 
acetic acid, MeCN, 89 %;  iii. BOMCl, Hünig’s base, 85 °C, 82 %;  iv. a. LiOH, MeOH, 
THF, 97 %;  b. DDQ, DCM, water, 95 %;  c. TBAF, THF, DCM, 90 %;  v. a. 
(BnO)2PN(iPr)2, 1H-tetrazole, MeCN, DCM;  b. mCPBA, -78 °C to RT, 93 % over 2 
steps;  vi. H2, tert-butanol, water, Palladium black, NaHCO3, 95 %.48 
 
Whilst the Ferrier-II reaction is a useful tool for synthesis, it faces criticism for several 
reasons.  Firstly, it is still necessary to synthesise a highly functionalised and enantiopure 
5,6-unsaturated hexopyranose derivative, which is not a trivial task.  Converting the 
produced inosose into the desired myo-inositol derivative will also require careful 
manipulation of protection groups, meaning that the completed syntheses are generally 
still very lengthy and tedious.  Mercury is a very toxic element, and its use will generally 
be avoided if possible.  The palladium-mediated reaction, whilst safer and higher 
yielding, gives no guarantee of separation from isomeric side products from the reaction. 
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1.4.2  Routes from D-Pinitol and L-Quebrachitol 
 
D-Pinitol (52, Figure 1.4.1) and L-quebrachitol (53) are both optically active cyclitol 
natural products.49 They are methyl ethers of D-chiro-inositol and L-chiro-inositol 
respectively, and have been used as building blocks for the synthesis of polyhydroxylated 
natural products and their derivatives.50,51 Within the synthesis of myo-inositol 
derivatives,49,52 the optical purity of these compounds gives them an advantage as no 
chemical or enzymatic resolution is needed to produce optically pure products.  Only a 
single inversion of stereochemistry is necessary to furnish the myo-inositol core from 
either of the chiro-inositols.50 
 
 
Figure 1.4.1 – D-Pinitol (52) and L-quebrachitol (53). 
 
Ozaki et al.53 used L-quebrachitol (53) as a starting material in their synthesis of D-myo-
inositol 1-phosphate (Scheme 1.4.6).  They furnished the final product in 14 steps, in an 
overall yield of 31 %.  L-Quebrachitol (53) was treated with cyclohexanone and para-
toluenesulfonic acid (pTSA) in benzene to afford the L-chiro-inositol 54.  Oxidation 
using Ac2O and dimethyl sulfoxide (DMSO) furnished a ketone, which could be 
subsequently stereoselectively reduced using lithium borohydride (LiBH4) to provide 
myo-inositol 55.  Protection with benzoyl chloride (BzCl) and triethylamine (Et3N) gave 
benzoyl ester 56, which was treated with aluminium chloride and sodium iodide to 
selectively cleave the trans-cyclohexylidene and methyl ether to furnish triol 57.  
Benzoylation was accomplished before acid hydrolysis of the cis-cyclohexylidene gave 
diol 59.  Subsequent treatment with triethylsilyl chloride (TESCl) in the presence of 
pyridine exclusively gave the silyl ether 60.  Benzoylation furnished the 
pentakisbenzoylate 61, which could be transformed in 5 steps to the desired D-myo-
inositol 1-phosphate.53 
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Scheme 1.4.6 – Synthetic route to pentakisbenzoylate (61), an intermediate in the 
synthesis of D-myo-inositol 1-phosphate from L-quebrachitol (53) by Ozaki et al..53 
Reagents and conditions: i. cyclohexanone, pTSA, benzene, reflux, 70 %;  ii. Ac2O, 
DMSO, DCM, reflux, 100 %;  iii. LiBH4, THF, -78 °C, 92 %;  iv. BzCl, Et3N, DMAP, 
DCM, 0 °C, 88 %;  v. AlCl3-NaI, MeCN, 83 %; vi. a. BzCl, Et3N, DMAP, DCM, 99 %; 
b. TFA, MeOH, 96 %;  vii. TESCl, pyridine, 0 °C, 100 %;  viii. BzCl, Et3N, DMAP, 
DCM, 93 %. 
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The main strength of synthetic routes to myo-inositol derivatives starting from D-pinitol 
(52) or L-quebrachitol (53) is that they bypass the need for a chemical or enzymatic 
resolution to achieve an optically pure product, allowing for a higher overall yield.  The 
long and tedious synthetic routes associated with the synthesis of myo-inositol derivatives 
are still necessary, along with the detailed planning needed to consider the reactivity of 
each protecting group being utilised.  The synthetic routes used do not readily lend 
themselves to the synthesis of analogues or similar myo-inositol derivatives. 
 
1.4.3  myo-Inositol Derivatives from Benzene 
 
Ley et al.54 produced syntheses of InsP3 (10), racemic myo-inositol 1-phosphate (±19) 
and other myo-inositol derivatives, based upon the oxidation of benzene by Gram-
negative soil bacterium Pseudomonas putida.55 cis-Cyclohexadiene-1,2-diol (62, Scheme 
1.4.7), the product of the microbial oxidation, was utilised as the starting point for these 
syntheses that introduced the six stereogenic centres sequentially. The two hydroxyl 
groups present in 62 would eventually become hydroxyl groups OH-2 and OH-3 within 
the derivatives synthesised. 
 
Their synthesis of InsP3 (10) is completed with an overall yield of 3.9 % over 12 steps 
starting from cis-cyclohexadiene-1,2-diol (62, Scheme 1.4.7).  It was necessary to use a 
chiral auxiliary in order to achieve optical purity in the final product.  They began their 
synthesis with the formation of the cyclic carbonate and subsequent epoxidation using 
mCPBA to give α- and β-epoxides (64 and 63 respectively) in a 4.6:1 ratio.  Epoxide 64 
was regioselectively ring-opened using (R)-1-phenylethanol, derived from (S)-(+)-
mandelic acid, giving a separable pair of diastereomeric alcohols (65 and 66) in a 1:1 
ratio.  Alcohol 66 was taken on to form diol 67 via benzylation and subsequent carbonate 
group removal.  
 
The diol 67 was treated with mCPBA to form almost exclusively β-epoxide 68 (Scheme 
1.4.8), which was subsequently converted to the acetinide 69 using 2,2-
dimethoxypropane.  The epoxide of 69 was opened in a facial-selective manner using 
alcohol 70.  This gave rise to a mixture of myo- and muco-inositol rings, from which the 
myo-inositol 71 was taken on.  Removal of the chiral auxiliary and the benzyl group via 
hydrogenolysis afforded the 1,4,5-triol 72.  Phosphorylation gave the protected 
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trisphosphate 73, which, after global deprotection, furnished the desired optically pure 
InsP3 (10).54 
 
 
Scheme 1.4.7 – Synthesis of D-myo-inositol 1,4,5-trisphosphate (10, InsP3) by Ley et al. 
(part 1).54  Reagents and conditions:  i. a. Dimethyl carbonate, NaOMe, MeOH;  b. 
mCPBA, DCM, 47 % over 2 steps;  ii. (R)-1-phenylethanol, HBF4.OEt2 (cat.), DCM, 
67 % (racemic);  iii. a. BnBr, Ag2O, DMF, 100 %;  b. Et3N, MeOH, water, 3 days 99 %. 
 
Ley et al.54 have shown that it is possible to set and control each position of the myo-
inositol ring through careful stereocontrol of epoxidations and their subsequent ring 
openings.  The introduction of a chiral auxiliary allows the separation of diasteromeric 
alcohols 65 and 66.  However, this drastically lowers the yield for the synthesis, as the 
diastereomers are present in a 1:1 ratio.  Further to this, due to the restricted arrangement 
of protection groups within this synthesis, the route does not easily facilitate the synthesis 
of analogues.  Work by Trost56 and Altenbach57 has utilised the dihydroxylation concepts 
proposed within this synthesis to produce InsP3 from Conduritol B derivatives. 
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Scheme 1.4.8 – Synthesis of D-myo-inositol 1,4,5-trisphosphate (10, InsP3) by Ley et al. 
(part 2).54 Reagents and conditions:  i. mCPBA, DCM, 87 %;  ii. 2,2-Dimethoxypropane, 
CSA, DCM, 89 %;  iii. Alcohol 70, NaH, TMEDA, 110 °C, 72 hr, 58 %; iv. H2, 10 % Pd-
C, EtOH, 16 hr, 100 %; v. nBuLi, iPr2NH, tetrabenzylpyrophosphate, THF,  -30 °C to RT, 
67 %;  vi. a. H2, 10 % Pd-C, EtOH, 48 hr;  b. TFA (80 %, aq.), 4 hr, 88 % over 2 steps. 
 
1.4.4  Routes from myo-Inositol 
 
The synthesis of myo-inositol derivatives starting from myo-inositol (1) itself is probably 
the most favoured route.  myo-Inositol (1) is inexpensive and readily available, making it 
an ideal starting point in synthesis. There are now several methods available to effect the 
desymmetrisation of myo-inositol derivatives and the resolution of racemic derivatives, 
enabling the synthesis of enantiomerically pure products.50 
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Within the literature, there has been a remarkable push towards the synthesis of partially 
protected myo-inositol derivatives containing free hydroxyl groups at specific positions.  
This work has allowed a deep understanding of the chemistry and reactivity of myo-
inositol (1) and its derivatives.  Researchers have been able to produce various selectivity 
patterns by carefully controlling different factors within their syntheses.  The synthetic 
routes involved rely upon the inherent acidity of the free hydroxyl groups and their 
interactions with neighbouring functional groups (generally through hydrogen bonding), 
the protecting groups that are present, the conformation of the inositol ring, and the 
reaction conditions and reagents used.  The reason for the observed selectivity is not 
always obvious, and there is some debate over how some methods produce their 
selectivity.50 
 
 
Figure 1.4.2 – Hydrogen bonding between cis-vicinal hydroxyls within myo-inositol (1). 
 
From work conducted by Gigg et al.,58 the order of reactivity for the hydroxyl groups 
around the myo-inositol (1) ring is OH-1 ≈ OH-3 > OH-4 > OH-5.  The higher reactivity 
of hydroxyl groups OH-1 and OH-3 can be attributed to the hydrogen bonding interaction 
between the proton of the reacting hydroxyl group and the cis-vicinal oxygen of OH-2 
(Figure 1.4.2).59,60 
 
1.4.4.1  Routes Using Ketals 
 
One of the first myo-inositol (1) protection strategies was the formation of ketals from 
acetone,61 cyclohexanone or cyclopentanone.62  Since then, this method has become 
widely used in the synthesis of myo-inositol derivatives.  An example of ketals being 
utilised in this way comes from Ozaki et al.,63 in what was the first synthesis of InsP3 (10) 
in 1986 (Schemes 1.4.9 and 1.4.10). 
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Scheme 1.4.9 – Ozaki et al.’s synthesis of D-myo-inositol 1,4,5-trisphosphate (10, InsP3) 
starting from myo-inositol (1, part 1).63  Reagents and conditions:  i. 1-
Ethoxycyclohexane, pTSA, DMF, reflux, 26 %;  ii. a. BnCl, NaH, DMF, 90 %;  b. 
ethylene glycol, pTsOH, chloroform, 80 %;  iii. a. AllBr, NaH, DMF, 100 %;  b. AcOH, 
water, 90 °C, 88 %;  iv. 1-menthoxyacetylchloride, pyridine, 39 % of 78. 
 
Starting from myo-inositol (1), they formed the racemic bisketal (±) 74 through reflux in 
DMF with 1-ethoxcyclohexene and catalytic pTSA.  Subsequent perbenzylation and 
selective 4,5-trans ketal cleavage62 produced the diol (±) 75.  Allylation of both hydroxyl 
groups was followed by removal of the cis-ketal to furnish the racemic diol (±) 76.  
Addition of a chiral auxiliary and formation of diastereoisomers 77 and 78, allowed for 
separation by fractional crystallisation and column chromatography to produce single 
diastereoisomer 78 in 39 % yield.   
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Scheme 1.4.10 – Ozaki et al.’s synthesis of D-myo-inositol 1,4,5-trisphosphate (10, InsP3) 
starting from myo-inositol (1, part 2).63  Reagents and conditions:  i. a. NaOH, water, 
MeOH, 98 %;  b. AllBr, NaOH, benzene, reflux, 76 %;  ii. a. BnCl, NaH, DMF, 98 %;  b. 
RhCl(PPh3)3, DABCO, then HCl, MeOH, 58 %;  iii. (PhNH)2P(O)Cl, DMAP, pyridine, 
41 %;  iv. isoamylnitrite, AcOH, pyridine, Ac2O;  v. 5 % Pd-C, H2, MeOH, water. 
 
The chiral auxiliary was removed by alkaline methanolysis, before selective allylation 
produced alcohol 79 (Scheme 1.4.10).  Benzylation and subsequent removal of allyl 
groups using Wilkinson’s catalyst and acidic methanolysis, furnished triol 80 which could 
be converted to InsP3 in three steps.63 
 
Unfortunately, their report on this synthesis did not cite yields for the final two steps as 
they had not been optimised.  The overall yield of the protected trisphosphate 81 was only 
1.1 % and, in total, their synthesis was 13 steps.  The yield of the synthesis was 
dramatically reduced not only by the resolution step, but also by the poor yield in the first 
step of the synthesis. 
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1.4.4.2  Routes Using Orthoesters 
 
A popular method of modifying myo-inositol (1) to produce biologically important 
derivatives is via their orthoesters.  Lee et al.64 were the first to use this method in their 
synthesis of enterobactin analogues and since then it has been used increasingly within 
myo-inositol derivative synthesis.  Orthoformates, orthoacetates and orthobenzoates (83, 
84 and 85, respectively, Figure 1.4.3) are some of the most commonly used orthoesters 
for this purpose. 
 
 
Figure 1.4.3 – Simultaneous protection of OH-1, OH-3 and OH-5 using orthoesters. 
 
Billington et al.65 identified this method as a way to avoid the low-yielding 1,2;4,5-
bisketal formation undertaken by Ozaki et al..63  Orthoesters of this type also allow for 
the simultaneous protection of OH-1, OH-3 and OH-5, whilst inverting the 
axial/equatorial relationship of the remaining free hydroxyl groups.  They produced 
syntheses using this method for myo-inositol 2-phosphate, myo-inositol 1,3-bisphosphate, 
myo-inositol 1,3,4,5-tetrakisphoshate and myo-inositol 4-phosphate.  The syntheses were 
considerably higher yielding than those published previously, however, for the latter two 
syntheses, the racemic product was produced.  myo-Inositol 2-phosphate and myo-inositol 
1,3-bisphosphate are both meso compounds so this was not an issue. 
 
As previously seen in the enantioselective synthesis of myo-inositol derivatives starting 
from myo-inositol (1), it is typically necessary to conduct a resolution.  Holmes et al.66,67 
provided a synthetic route to enantiopure alcohol (90, Scheme 1.4.11), which they used as 
a common intermediate in the production of a range of inositol polyphosphates. 
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Scheme 1.4.11 – Holmes et al.’s route to enantiopure synthesis intermediate alcohol 90.67  
Reagents and conditions:  i. a. triethylorthoformate, pTSA, DMF, 100 °C, 63 %;  b. 
PMBCl, NaH, DMF, 67 %;  ii. a. BnBr, NaH, DMF, 99 %;  b. DIBAL-H, DCM, 96 %;  
iii. AllBr, NaH, imidazole, DMF, 85 %;  iv. HCl, MeOH, reflux, 78 %;  v. 1-(S)-(-)-
camphor dimethylacetal, pTSA, DCM, reflux, 31 %. 
 
The synthesis of alcohol 90 is relatively long considering that this is an intermediate to be 
used in synthesis and not the product itself.  Starting from myo-inositol (1), they form the 
orthoformate under the same conditions as Billington et al..65  Protection of a single axial 
hydroxyl group, using one equivalent of sodium hydride and paramethoxybenzyl chloride 
(PMBCl), furnished racemic diol (±) 86.  Perbenzylation followed by treatment with 
DIBAL-H induced regioselective orthoformate opening and produced alcohol (±) 87.  
Allylation produced the fully O-protected myo-inositol (±) 88 before removal of the 1,3-
methylidene bridge and paramethoxybenzyl (PMB) group by acidic methanolysis 
afforded triol (±) 89.  The optical resolution was then conducted by protection of the 
vicinal 3,4-diol using the camphor acetal strategy.  This produced four diastereoisomers, 
from which the desired alcohol 90 could be isolated in a 31 % yield.  This procedure gave 
the desired intermediate alcohol 90 in 8.2 % yield over 7 steps.67 
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1.4.4.3  Enzymatic Resolutions 
 
As shown so far, routes to myo-inositol derivatives starting from myo-inositol (1) are 
often long and tedious, with various protecting group manipulations necessary to produce 
the desired product.  The optical purity of the products has been achieved in chemical 
resolution steps, by adding a chiral auxiliary to a racemic mixture and then separating the 
diastereoisomers.  Enzymes can also be used to effect optical resolutions on myo-inositol 
derivatives.  These procedures generally work by the enzyme involved only turning over 
one of the enantiomers of the racemic mixture.  Separation of the enzymatic product and 
unreacted starting material therefore leads to production of a single enantiomer.   
 
 
Scheme 1.4.12 – Ozaki’s enzymatic resolution of myo-inositol derivative (±) 91.68  
Reagents and conditions:  i. Ac2O, Amano Lipase AY, Et2O, 48 % of 92 and 50 % of L-
91.  
 
In further work by Ozaki,68 he was able to provide the first enzymatic resolution of a 
racemic myo-inositol derivative.  A small screen of commercially available hydrolytic 
enzymes provided a lipase from Candida cylindracea (Amano Lipase AY) that could 
regio- and enantioselectively acetylate biscyclohexylidene myo-inositol derivatives 
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(Scheme 1.4.12).  Racemate (±) 91 was treated with acetic anhydride in the presence of 
Amano Lipase AY and selectively produced acetate 92 in 48 % yield.  A trace amount of 
acetate 93, the product from acetylation at OH-3 of the D-enantiomer, was also produced.  
However, the L-enantiomer of (±) 91 was left unreacted. 
 
1.4.4.4 Enantioselective Catalysis 
 
The synthetic routes to myo-inositol derivatives shown so far are generally long and 
suffer from poor yields due to the critical steps to achieve control over stereochemistry 
and enantioselectivity.  Miller and coworkers69,70 set out to develop low-molecular weight 
peptide-based catalysts that could overcome these problems and perform enantioselective 
phosphorylation of a meso myo-inositol derivative.  They hoped to produce catalysts that 
could control regio- and stereoselectivity through their secondary structures much in the 
way that proteins do. 
 
Miller et al.69 chose to work with 2,4,6-tribenzyl myo-inositol (95, Scheme 1.4.13) as this 
compound maintained the meso nature of myo-inositol (1) whilst reducing the number of 
potential reaction sites from six to three.  They had previously seen that they could obtain 
high levels of selectivity with this type of reaction in non-polar solvents, and using 95 
instead of myo-inositol (1) facilitated use of less polar solvents.  The starting material 95 
can be accessed relatively straightforwardly from myo-inositol (1) in a 52 % yield 
(Scheme 1.4.13).64,65,71  Formation of the orthoformate of 1 was followed by 
perbenzylation to furnish the tribenzyl ether 94.  Removal of the orthoformate produced 
the desired triol 95. 
 
 
Scheme 1.4.13 – Synthesis of 2,4,6-tribenzyl myo-inositol (95).64,65,71    Reagents and 
conditions:  i. a. HC(OEt3), pTSA, DMF, 100 °C, 76 %;  b. BnBr, NaH, DMF, 79 %; ii. 
HCl, MeOH, reflux, 87 %. 
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With this compound in hand, Miller et al.69 wished to discover peptide catalysts that 
could selectively phosphorylate either the 1- or 3-position of the molecule.  This would 
desymmetrise the molecule and give an enantiopure product.  They screened a small 
library of random peptides based on modified histidine residues, designed to be small 
kinase mimics.  Screening for the regio- and enantioselectivity of the 
monophosphorylation of triol 95, they showed that peptide 96 (Figure 1.4.4) and peptide 
97 had excellent selectivity of the 1- and 3-positions respectively, in >98 % ee.69  It is 
important to note that these peptides are not enantiomers of each other, but produce 
opposing selectivities due to their secondary structure. 
 
 
Figure 1.4.4 – Peptide catalysts selected from the screen to have selectivity for 
phosphorylation at OH-1 (96) and OH-3 (97). 
 
Upon the discovery of these catalysts, Miller et al.69 completed the synthesis of L-myo-
inositol 1-phosphate (19) and D-myo-inositol 1-phosphate (100) in concise syntheses 
from triol 95 (Scheme 1.4.14).  Treatment of 95 with diphenylchlorophosphate, Et3N and 
either peptide 96 or 97, gave protected L-myo-inositol 1-phosphate 98 and protected D-
myo-inositol 1-phosphate 99, respectively.  Removal of protection groups via Birch 
reduction, produced the desired enantiopure myo-inositol phosphates 19 and 100. 
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Scheme 1.4.14 – Use of peptide catalysts to produce L-myo-inositol 1-phosphate (19) and 
D-myo-inositol 1-phosphate (100).69  Reagents and conditions:  i. 
Diphenylchlorophosphate, peptide 96 (2.5 mol %), Et3N, toluene, 0 °C, 56 % (>98 % ee);  
ii. Li, NH3(l), THF, -78 °C, 95 %;  iii. Diphenylchlorophosphate, peptide 97 (2.0 mol %), 
Et3N, toluene, 0 °C, 65 % (>98 % ee);  iv. Li, NH3(l), THF, -78 °C, 96 %.  
 
Miller has extended this work to the synthesis of myo-inositol polyphosphates,72 
phosphatidylinositols and their phosphates73–75 and even dimeric myo-inositol 
phosphates.76,77  Within each piece of work, the catalytic desymmetrising phosphorylation 
was the key step to provide the desired myo-inositol derivatives.  This step could only 
furnish a moderate 65 % yield, however, the remaining starting material could be 
recovered from the reaction.  The requirement to start with 2,4,6-tribenzyl myo-inositol 
(95) is a small inconvenience, and the desired myo-inositol derivatives are generally 
obtained with good yields in relatively short syntheses.  Availability of the peptide 
catalysts is a potential issue for this methodology. 
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1.5  Biocatalysis 
 
Biocatalysis comprises the use of bacteria, fungi and, more specifically, enzymes to 
catalyse chemical reactions.78  The benefits of using biocatalysis over traditional chemical 
methods are the high levels of selectivity achieved within reactions, the mild reaction 
conditions needed, and the fact that biocatalysts are obtainable from renewable resources 
and are biodegradable.78  This field has developed enormously in the past decade and it 
can now offer solutions to many of synthetic chemistry’s challenging problems in the 
pharmaceutical, fine chemical and lower value industrial sectors.79 
 
In its crudest forms, biocatalysis has been used for thousands of years as a way of 
producing and preserving food such as beer, wine and cheese.  It wasn’t until the late 
1800s that a more refined use of biocatalysis was demonstrated when Louis Pasteur used 
Penicillin glaucum as a way to enantiomerically enrich an aqueous solution of racemic 
tartaric acid.  Since then, the use of biocatalysis within organic synthesis has steadily 
grown as scientists have developed methods to overcome the inherent difficulties 
associated with using enzymes or whole cell organisms as a synthetic tool.79 
 
One of the major problems hurdles to overcome in the use of enzymes in synthesis was 
the synthesis of the enzymes themselves.  With no fixed method for the production of 
enzymes on a large scale, the utility of enzymes was very much restricted.  However, in 
the 1970s, the development of a recombinant DNA methodology allowed scientists to 
obtain large quantities of a given enzyme via overexpression within a host organism, such 
as Escherichia coli (E. coli) or Bacillus subtilis.79  The exact conditions needed for the 
methodology vary from protein to protein, but, since the introduction of the method, 
modifications and new techniques have vastly improved the diversity of proteins that can 
be produced in this way. 
 
By the 1990s, improvements in the processes involved in biocatalysis meant that it was 
increasingly viable within an industrial setting, and many enzymes had already been 
commercialised.79  It had found particular use in the preparation of chiral compounds, and 
was being used in preference of chemical methods to produce complex intermediates 
within the pharmaceutical, agrochemical and other industries.80  The biotechnological 
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design of reactors, immobilisation of enzymes and optimization of downstream work ups 
can all be attributed to aiding the rapid development of biocatalysis within industry.79 
 
There are a vast number of enzymes within nature that conduct a large variety of 
transformations, however it is very rare that they lend themselves for use in industrial 
applications.  The problems associated with using enzymes in synthesis are the limited 
solvent tolerance, poor stability at temperatures outside their normal range, low levels of 
expression, poor activity, and high selectivity for substrates, which limits their ability to 
turnover non-natural substrates.81  As new methods have been developed it has become 
possible to overcome the majority of these issues, more often than not by altering the 
properties of the enzyme itself. 
 
Engineering of enzymes is generally conducted at the DNA sequencing level, involving 
modification of amino acids by chemical or genetic methods.  The enzyme produced can 
then be tested for novel, optimal or improved properties.82  There are two main methods 
used to engineer proteins, and it is common to conduct a mixture of both methods to 
obtain desired enzyme modifications.   
 
Firstly, enzymes can be modified by rational design.  Mutations are introduced in the 
protein-encoding gene at specific postions based upon knowledge of sequence, structure, 
function and catalytic mechanism.  In order to conduct this method, a lot of information 
about the enzyme’s structure and energy functions is needed to correctly predict the 
outcome of modification.83 
 
The second method is via directed evolution.84  Repeated cycles of random mutagenesis 
are conducted with variants of the gene to create a library of genes that have slightly 
different sequences.  The resulting enzymes are submitted to high throughput screening or 
genetic selection to determine which of the enzymes display an improvement in the 
desired property.  This process is repeated on the improved enzymes / gene sequences 
until an enzyme is produced that has the desired properties.  No structural or mechanistic 
information is needed for the enzyme, and it is likely that changes that occur far from the 
active site of the enzyme would not have been selected by rational design.83 
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Scheme 1.5.1 – Biocatalytic production of sitagliptin (102).85  Reagents and conditions:  
i. R-Selective transaminase (R-ATA, ATA-117), isopropylamine, 50 % DMSO in water, 
40 °C, 92 %. 
 
Sitagliptin (102, Scheme 1.5.1) is a drug used to treat type II diabetes. It is currently 
produced from the amination of prositagliptin ketone (101) using a transaminase to 
achieve the desired enantioselectivity.86  R-Selective transaminase (R-ATA, ATA-117) 
from Arthrobacter sp. was engineered by Codexis and Merck using directed enzyme 
evolution to overcome the large substrate size.85  Coupled with process engineering, the 
system produced can convert 200 g L-1 of the  ketone 101 into sitagliptin (102) with an 
enantiopurity of >99.5 %.85  The process can tolerate large quantities of isopropylamine 
and runs with 50 % DMSO as the solvent at temperatures greater than 40 °C.87 
 
This biocatalytic step provides a number of advantages over the previously used rhodium-
catalysed method.  Total waste production was reduced and the need for a rare heavy 
metal was eliminated, making the process more “green”.  The overall yield of the process 
was increased by 10 %, and the overall productivity within an industrial setting could be 
increased by 53 % (measured by Kg L-1 per day).85,86 
 
1.5.1  Isolated Enzymes versus Whole Cell Systems 
 
There are numerous approaches within biocatalysis that use either isolated enzymes or 
whole cell systems to achieve a desired transformation.  The selection and utility of one 
of these methods ultimately depends on the nature of the enzyme, substrate, product and 
reaction involved.78 
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Use of isolated enzymes over whole cell systems is advantageous as there is greater 
access for the substrate and enzyme with respect to each other, and unwanted side 
reactions from interference of additional cellular enzymes is eliminated.88  However, the 
enzyme may have dramatically reduced stability in an isolated state, and isolated enzymes 
do not tolerate extremes in temperature, pH or ion concentration, shear stress or organic 
solvents very well.88  Within a whole cell system, the cell can act to protect enzymes from 
harsh external conditions and allow the enzyme to keep its structure and activity.  On the 
other hand, the conditions used may also be toxic to the cell.   
 
The preparation of whole cell reactions is simpler than with isolated enzymes.  Potentially 
lengthy enzyme purification procedures are not needed, and the whole cell is able to 
conduct multi-step syntheses involving multiple enzymes.88  Enzymes that require a 
cofactor, such as NAD+ or adenosine triphosphate (ATP), also benefit from a whole cell 
system as these cofactors are present as part of the cell’s natural metabolism.89  If 
cofactors are needed for an isolated enzyme, it could be necessary to use stoichiometric 
amounts of potentially very expensive materials or set up a method for cofactor 
recycling.89 
 
It is possible to improve isolated enzymes by increasing their structural rigidity, either by 
directed evolution90 or multipoint immobilisation.91  Immobilisation of enzymes has other 
advantages, including ease of removal from a reaction vessel, enzyme recycling and use 
of continuous flow reactors.88  Unfortunately, increasing the rigidity of the enzyme may 
have a detrimental effect on enzyme performance.  Whereas this is not the case in all 
enzymes, too much conformational stability can restrict the flexibility of the enzyme that 
may be needed for activity.88 
 
Whole cell processes are well established commercially, but they are mostly limited to 
batch processes and cannot be reused.78  Immobilisation of whole cells is possible, but 
this reduces the mass to catalytic activity ratio and requires more laborious preparation, 
which will add to the cost.88 
 
In general, whole cell systems are used for reactions that involve unstable, multi-
component or membrane-bound enzymes, and / or require cofactors.  On average, within 
an industrial setting whole cell systems are less expensive than isolated enzymes.78  
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However, there are various factors that need to be taken into account, and the 
immobilisation of isolated enzymes has provided new methodologies with attractive 
advantages.  The modification of enzymes using directed evolution or rational design and 
site-directed mutagenesis has provided scientists to overcome the many obstacles that 
biocatalysis faces. 
 
1.5.2  Synthesis of myo-Inositol Derivatives using Biocatalysis 
 
Within the synthesis of myo-inositol derivatives biocatalysis has seen very limited use.  
As mentioned previously (section 1.4.4.3), enzymes have been used to perform 
resolutions on myo-inositol (1)-based synthetic intermediates to produce an enantiopure 
product.  The isomerisation of D-glucose 6-phosphate (18) to L-myo-inositol 1-phosphate 
(19) as accomplished by INO1 has scarcely been used within synthesis92,93 even though 
the product is highly desirable.   
 
Both whole cell systems and isolated enzymes have been used to produce L-myo-inositol 
1-phosphate (19).  In an effort to provide a convenient synthetic route to 
polyhydroxybenzenes that contain the oxygenation pattern of 1,2,3,4-
tetrahydroxybenzene (104), Frost et al.92 utilised a whole cell synthesis of myo-inositol 
(1) within E. coli (Scheme 1.5.2). 
 
D-Glucose is taken up by E. coli JWF1/pAD1.88A and converted to D-Glucose 6-
phosphate (18) by the phosphotransferase system of the organism, which uses 
phosphoenolpyruvate as a source of the phosphoryl group.  Expression of the 
Saccharomyces cerevisiae INO1 gene within the E. coli JWF1/pAD1.88a on plasmid 
pAD1.88A allowed isomerisation of D-Glucose 6-phosphate (18) to L-myo-inositol 1-
phosphate (19).  Unidentified phosphatase activity then hydrolysed the phosphoester to 
produce myo-inositol (1).  Under fed-batch fermentor conditions, this whole-cell system 
could produce 21 g L-1 myo-inositol (1) and 4 g L-1 L-myo-inositol 1-phosphate (19) in a 
combined yield of 11 % from D-glucose.92  The myo-inositol (1) obtained in this process 
could be oxidised to myo-2-inosose (103) by incubation with Gluconobacter oxidans 
ATCC 621, before reflux in sulphuric acid (0.5 M, aq.) produced 1,2,3,4-
tetrahydroxybenzene (104).92 
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Scheme 1.5.2 – Synthesis of 1,2,3,4-tetrahydroxybenzene (104) using the whole cell 
biocatalytic synthesis of myo-inositol (1).92  Reagents and conditions:  i. E. coli 
phosphotransferase system;  ii. a. Saccharomyces cerevisiae INO1;  b. phosphatase 
activity, 9 % over 3 steps;  iii. dehydrogenase activity, 95 %;  iv. sulphuric acid, water, 
reflux, 66 %. 
 
This whole cell system is able to produce large quantities of L-myo-inositol 1-phosphate 
(19, 4 g L-1), however this work clearly demonstrates a major issue with using a whole 
cell organism for the production of this compound.  Phosphatase enzymes already present 
within the E. coli quickly hydrolyse L-myo-inositol 1-phosphate (19) to myo-inositol (1), 
thus a large quanitity (84 %) of the product is lost.  With a combined yield of only 11 % 
from the D-glucose fed into the system, this means that 4 g L-1 is a less than 2 % yield of 
L-myo-inositol 1-phosphate (19).  Whereas a large quanitity could still be produced, no 
comment is made on the isolation of L-myo-inositol 1-phosphate (19) from the 
supernatant and this may not be a trivial process.   
 
As an isolated enzyme, INO1 has been used to prepare small quantities of L-myo-inositol 
1-phosphate (19) within studies of mycothiol glycosyltransferase (MshA).93  MshA 
catalyses the transfer of N-acetylglucosamine onto L-myo-inositol 1-phosphate (19) in the 
first step of mycothiol (16) biosynthesis (discussed in more detail in Chapter 4).  To study 
the structure and mechanism of MshA, the investigators needed a source of L-myo-
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inositol 1-phosphate (19) and chose the INO1 gene from hyperthermophile 
Archaeoglobus fulgidus as it had previously been used to clone and express 
Archaeoglobus fulgidus INO1 (AfINO1) in a 9 mg L-1 preparation.93,94 
 
As the INO1 gene was taken from a hyperthermophile, the optimum temperature for 
enzyme activity was 85 °C.  Their reaction mixture contained 125 mM D-glucose 6-
phosphate (18), 0.625 mM zinc (II) chloride, 1.25 mM NAD+ and 3.6 mg of AfINO1 in 
50 mM tris(hydroxymethyl)methylammonium (Tris) buffer (pH 7.5, NH4OH) and was 
held at 85 °C in a heat block for the course of the reaction.  Every 45 minutes the 
concentration of NAD+ was increased by 0.5 mM and a further 2 mg of AfINO1 was 
added.  The reaction was monitored via a BgMshA/pyruvate kinase/lactate assay and was 
completed after 3 hours.93 
 
There is no comment on the quantity of L-myo-inositol 1-phosphate (19) produced in this 
procedure, but they were able to produce enough to determine the crystal structure of 
MshA with L-myo-inositol 1-phosphate (19) bound within the active site.  The reaction is 
conducted at a very high temperature, which would complicate procedures within an 
industrial setting and also potentially have a detrimental effect on the product or 
cofactors.  The AfINO1 was expressed obtaining only 9 mg L-1.94  This is quite a low 
amount of protein to be produced when such a large amount is used in the procedure 
(9.6 mg).  Continuous dosing of NAD+ and AfINO1 was also needed to furnish full 
conversion to the product. 
 
The use of INO1 within the literature has shown that there is precedence for this enzyme 
to be used in a biocatalytic setting to produce large quantities of the highly desirable L-
myo-inositol 1-phosphate (19).  In an industrial setting these methods may fail to provide 
an efficient and economical route to the product. 
 
 
1.6  Conclusions and Project Aims 
 
Routes to myo-inositol derivatives have long been unsatisfactory.  The complexity of 
these compounds has led to the development of a vast number of techniques to try and 
provide the shortest possible synthetic routes to a high yield of enantiopure product.  The 
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biosynthesis of L-myo-inositol 1-phosphate (19) from D-glucose 6-phosphate (18) is a 
one step process catalyzed by INO1 and furnishes an optically pure myo-inositol 
derivative.  Whilst INO1 has been used to produce L-myo-inositol 1-phosphate (19) 
synthetically, the processes involved have not been optimised to produce large quantities 
of this product.  With careful consideration of the processes involved, biocatalysis could 
provide an efficient route to the highly desirable product.  The recycling of NAD+ is an 
added bonus as it allows for a lower amount of the relatively expensive cofactor to be 
used. 
 
Further to this, with the production of an optically pure myo-inositol derivative, we 
believe that protection of the phosphate and subsequent selective protection of hydroxyl 
groups will produce dramatically reduced syntheses of myo-inositol derivatives.  Access 
to large quantities of these derivatives and analogues to be used as novel chemical probes, 
will mean that important biological questions can be addressed. 
 
The work undertaken here details the optimisation and scale up of the biotransformation 
to a scale that can produce synthetically viable quantities (~500 mg) of pure L-myo-
inositol 1-phosphate (19).  Subsequent demonstration of the utility of this process within 
synthesis is an important target to achieve.  Thus providing evidence for the power of this 
biotransformation within organic synthesis. 
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Chapter Two 
 
2  Identification and Utility of a Suitable INO1 
 
2.1  Trypanosoma brucei 
 
Roughly 15 % of the world’s population is affected by infectious diseases caused by 
parasitic protozoa, with millions of fatalities.95  Human African Trypanosomiasis (HAT), 
also known as African sleeping sickness, is an infectious disease caused by the 
extracellular protozoan parasite Trypanosoma brucei (T. brucei).96  The parasite is 
transmitted to the mammalian host via the bite of an infected tsetse fly and the disease is 
endemic in sub-Saharan Africa, where the tsetse fly thrives.97  
 
The life cycle of T. brucei is relatively complex, with the parasite adopting different 
morphologies depending upon environment (Figure 2.1.1).98  The life cycle can be seen to 
begin with the procyclic form inside the tsetse fly’s midgut.  This is where the procyclic 
form of the parasite replicates and the number of parasites proliferates.  Migration of the 
parasite into the salivary gland of the insect induces transformation into the metacyclic 
form.  When the tsetse fly takes a blood-meal, it is the metacyclic form of the parasite that 
is injected into the mammalian host.  Upon entry into the bloodstream of the mammalian 
host, the parasites morph into the bloodstream form and can replicate as the slender form.  
Some parasites will morph into a non-replicative stumpy form, which is pre-adapted to 
the environment presented to the parasite after a tsetse fly blood-meal.  This allows the 
cycle to continue.  Eventually the bloodstream form of the parasite will cross the blood-
brain barrier and invade the host’s central nervous system.96  Once the parasite has 
crossed this barrier, the more obvious symptoms of the disease appear.  These include 
changes in behaviour, slurred speech and disturbance to the sleep cycle.99  Without 
treatment, HAT will lead to progressive mental deterioration before death of the host. 
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Figure 2.1.1 – Life cycle of protozoan parasite Trypanosoma brucei.98 
 
T. brucei has three subspecies: Trypanosoma brucei gambiense (T. b. gambiense), 
Trypanosoma brucei rhodesiense (T. b. rhodesiense) and Trypanosoma brucei brucei (T. 
b. brucei), which only infects humans very rarely.100  Over 95 % of current cases of HAT 
are caused by T. b. gambiense,97 which is endemic in Western and Central Africa.  T. b. 
rhodesiense is responsible for the remaining cases and endemic in Eastern and Southern 
Africa.97 
 
The disease came close to eradication in the late 1960s, however in the last 50 years the 
disease has re-emerged and the number of cases has risen to levels as high as they were in 
the 1920s.96  This can be attributed to the rarity of cases leading to a loss in interest in 
sustained surveillance and the possible re-emergence of the disease being overlooked.101  
Further to this, control of HAT was complicated during the 1990s due to civil wars and 
social upheavals that prevented access to a large number of HAT-endemic areas.101  Since 
2001, drugs to treat HAT have been supplied for free by the pharmaceutical companies 
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that produce them.  This, coupled with increased funding for WHO led sleeping sickness 
control programmes, has helped decrease the prevalence of HAT.  In 2012, the number of 
reported cases dropped to 8,000, even though it is thought that due to incomplete 
surveillance this number may be as high as 20,000.97 
 
The World Health Organization (WHO) reports that HAT is a serious health risk to 
roughly 60 million people in sub-Saharan Africa.95  However, more recently, increased 
efforts in vector control have decreased the annual rate of infections to 50,000 per year.95  
The estimated number of fatalities has also dropped to 7,000 per year.95  In addition to the 
human risk, the animal form of the disease, called Nagana, continues to affect the cattle 
population of Africa.  This has a major impact on African economy with the WHO 
estimating a loss of roughly 4 billion US dollars per year.95 
 
The current human and animal drug therapies have long been considered unsatisfactory, 
and with T. brucei having a growing resistance to established drugs, the situation is only 
growing worse.95  Different stages of the disease require different treatment regimens, 
and it is currently necessary to perform a lumbar puncture (or spinal tap) to determine the 
appropriate drug.97 
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Figure 2.1.2 – Current drugs used to treat HAT. 
 
The first-line drugs used for the treatment of T. b. gambiense and T. b. rhodesiense are 
suramin (105, Figure 2.1.2) and pentamidine (106), respectively.  The first-line drugs are 
less toxic and also easier to administer than the second-line drugs melarsoprol (107) and 
eflornithine (108).97  Melarsoprol (107) was introduced in 1949, however it fails to cure 
between 10 % and 30 % of patients.  On top of this, serious side effects from the arsenic 
content of the drug kill between 4 % and 10 % of those who take it.96  Eflornithine (108) 
is the most recent anti-HAT drug, and faces criticism because it is expensive, difficult to 
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administer and only effective against T. b. gambiense.  A combination therapy of 
eflornithine (108) and nifurtimox (109) was introduced in 2009 which simplifies the 
administration of eflornithine (108), however the treatment is still not effective for T. b. 
rhodesiense.97  The poor quality of the current therapies for this disease means that there 
is an urgent need for new therapeutic approaches for HAT and Nagana.  The treatment of 
other Third World diseases caused by closely related protozoan parasites, such as 
Leishmania spp. and Trypanosoma cruzi, may also benefit from new therapies for HAT.95 
 
When designing new drugs for the treatment of parasitic disease, the obvious place to 
target the parasite is somewhere that it differs with the host.  Melarsoprol (107) does not 
do this as it works by giving the host a dose of arsenic that is large enough to kill the 
parasite, but not large enough to kill the host.  This means that the drug is incredibly toxic 
to the host, and has many side effects associated with it.  By targeting an area which is 
completely different to the host, not only will the parasite be killed, but the host should 
encounter a fewer number of side effects. 
 
As part of its life cycle, T. brucei needs to be able to survive vastly different 
environments of the mammalian host’s bloodstream and various tissues within the tsetse 
vector.95  To account for this, the outer surface of the parasite is covered in a dense cell-
surface coat of roughly 5 million variant surface glycoprotein (VSG) dimers, which act as 
a diffusion barrier (Figure 2.1.3).96  The parasite has a repertoire of roughly 1000 
immunologically distinct VSG genes that it can utilize in a process called antigenic 
variation to adapt and constantly evade the host’s immune system,96,102 thus making 
vaccines non-viable.  Independent of which variant is present, the VSG is linked to the T. 
brucei cell membrane via GPI anchors.96  Genetic and chemical validations have shown 
that T. brucei GPI anchor biosynthesis is a valid drug target against HAT.96 
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Figure 2.1.3 – Dimeric N-terminal domain of VSG from T. brucei variant MITat shown 
embedded within the lipid bilayer via a GPI anchor and an example of the dense cell 
surface coat.103 
 
Metabolism of myo-inositol (1) within T. brucei is compartmentalised.104  myo-Inositol 
(1) scavenged from the environment is used for the synthesis of bulk phosphatidylinositol 
within the golgi, whereas de novo synthesised myo-inositol is used solitarily for GPI 
anchor biosynthesis within the ER.104  Coupled with the fact that GPI anchor biosynthesis 
is essential for the survival of T. brucei, this suggests that the de novo synthesis of myo-
inositol (1) is also essential and therefore a valid drug target.  Previous work conducted 
within the Smith group has demonstrated this through creation of a conditional double 
knockout.22  Increasing the concentration of myo-inositol within the growth media from 
40 µM to 100 mM did not allow conditional knockout cells to overcome the deletion of 
the gene, further strengthening the hypothesis that GPI biosynthesis only uses de novo 
synthesised myo-inositol (1).22 
 
As detailed previously, the de novo synthesis of myo-inositol (1) is conducted by the 
action of two enzymes: INO1 and IMPase.  The rate-limiting step is the conversion of D-
glucose 6-phosphate (18) to L-myo-inositol 1-phosphate (19) by INO1 in the presence of 
NAD+ (Scheme 2.1.1).  Within the previous work of the Smith group,22 an INO1 was 
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identified within the T. brucei genome database (Sanger centre) and the putative open 
reading frame was PCR-amplified, cloned and sequenced (GenBank, Accession 
#AJ86670).  Alignment of the predicted translated sequence for the T. brucei INO1 
(TbINO1) and INO1s from other organisms showed several similarities.  Firstly, the 
TbINO1 has a perfect copy of the GWGGNNG motif within a Rossmann fold, associated 
with NAD+ binding.24  A further three motifs were also identified from other eukaryotic 
INO1s: LWTANTERY, NGSPQNTFVPGL and SYNHLGNNDG.24  At 58 kDa, the size 
of the predicted TbINO1 is also in good agreement with other INO1s, which typically fall 
within the range of 58-67 kDa.22,23 
 
 
Scheme 2.1.1 – Biosynthesis of myo-inositol (1).  Reagents and conditions:  i. INO1, 
NAD+;  ii. IMPase, Mg2+. 
 
TbINO1 was overexpressed in E. coli using a pBAD TA vector, causing the encoding of a 
C-terminal hexa-His-tag.  This allowed for purification of the recombinant protein 
through affinity chromatography using a Ni2+-charged Sepharose column and elution 
using an increasing concentration of imidazole.  MALDI analysis showed the molecular 
weight of the purified recombinant protein to be 64 kDa, as predicted.22 
 
They took advantage of the IMPase enzyme to develop a coupled assay and show 
catalytic activity of the recombinant TbINO1.  Saturation kinetics were conducted, giving 
an apparent Km of 0.58 mM.  This is very close to the human INO1, which has a Km of 
0.57 mM.105  However, at 756 nmol mL-1 mg-1, the specific activity of the recombinant 
TbINO1 is over 10 times higher than the human recombinant INO1.  This high activity 
may be due to the importance of the de novo synthesis of myo-inositol (1) to the survival 
of T. brucei.22 
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2.1.1  Suitability of TbINO1 for Biocatalysis 
 
As discussed previously (Section 1.5.2), previous methods in the biocatalytic production 
of L-myo-inositol 1-phosphate (19) have been conducted using a whole cell system92 and 
isolated AfINO1.93  The whole cell system faces criticism due to low yields of L-myo-
inositol 1-phosphate (19) compared to the amount of D-glucose that is fed into the 
system.  A 2 % yield of the desired product is obtained, with the majority (84 %) of the L-
myo-inositol 1-phosphate (19) being produced being hydrolysed by unidentified 
phosphatases within the cell.92  There is no comment on isolation of the product from the 
supernatant either.  With such a low yield of L-myo-inositol 1-phosphate (19) this system 
is not viewed as efficient enough for industrial scale up. 
 
The use of isolated enzyme AfINO193 does have advantages.  The enzyme comes from a 
hyperthermophile organism and is therefore extremely stable at high temperatures.  The 
enzyme also has an incredibly high specific activity of 13.1 µmol mL-1 mg-1.94  Coupled 
with a Km of 0.12 mM, this makes AfINO1 a more attractive candidate than TbINO1 for 
biocatalysis when considering the enzyme kinetics.  Kinetics is not the only consideration 
when choosing which enzyme to use for biocatalysis, and other, more practical, 
considerations have to be taken into account. 
 
The AfINO1 enzyme is expressed and purified in a preparation that produces 9 mg mL-1 
of culture.94  Compared with TbINO1, which is expressed and purified from preparations 
that produce 75 mg mL-1,106 this is a low level of expression.  The high temperatures used 
within the reaction with AfINO1 (85 °C) are harder to achieve on an industrial scale than 
the 37 °C needed for TbINO1.  The high temperature also has the potential to cause 
decomposition of starting materials or products.  When AfINO1 was used previously to 
prepare L-myo-inositol 1-phosphate (19) for studies on the MshA enzyme, the reaction 
required additional dosing of both NAD+ and AfINO1 to furnish full conversion.   
 
The reaction conditions required for AfINO1 differ from all other previously studied 
INO1 enzymes.  Instead of ammonium ions the archaeal INO1 requires divalent metal 
ions to be present, with manganese or zinc ions being preferred.94  Using TbINO1 instead 
of AfINO1 therefore avoids the need to use, and subsequently remove, metal ions from 
the reaction. 
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TbINO1 has a relatively high specific activity of 756 nmol mL-1 mg-1 when compared to 
those from humans (7 nmol mL-1 mg-1) and other organisms.105,107,108  Compared to the 
INO1 from Archaeoglobus fulgidus the enzyme activity is optimal at 37 °C and does not 
require metal ions for the reaction to proceed.  For these reasons we believe that TbINO1 
is an attractive candidate for biocatalysis.  L-myo-Inositol 1-phosphate (19), the product 
of the biotransformation, has a market value of £163 mg-1 (Cayman Chemical, at time of 
writing).  On top of this, the optical purity of the product means that the biocatalysis 
could be used as a starting point for the synthesis of inositol derivatives.  Offering 
dramatically shortened synthetic routes to access the highly valuable myo-inositol 
derivatives important for research. 
 
 
2.2  Considerations for Scale-Up 
 
The initial work conducted on the biotransformation was undertaken under an 
investigative mindset.  The protein was being studied and screened for inhibitors so only 
a very small scale was necessary to see the desired results.  Therefore, the conditions used 
within the experiments were optimised without taking into account a potential scale up of 
the process.  This presented several obstacles when faced with the task of scaling the 
process up to produce a synthetically viable amount of L-myo-inositol 1-phosphate (19). 
 
The biggest problem with this biotransformation is the high polarity of the starting 
material and product.  D-Glucose 6-phosphate (18) and L-myo-inositol 1-phosphate (19) 
are so similar in polarity that separation of the two compounds by conventional methods 
is going to be incredibly difficult, if not impossible.  This means that the only way to 
produce high purity L-myo-inositol 1-phosphate (19), without a convoluted purification 
method, will require the biotransformation to proceed with 100 % conversion.  
Maintaining this conversion throughout the scale up of the process proved to be a difficult 
task. 
 
Calculation of conversion itself also needed to be taken into consideration.  Direct 
measurement of conversion on the initial system was not possible due to the experiments 
being conducted on such a small scale (0.4 mg of D-glucose 6-phosphate (18) was being 
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used per experiment).  Fortunately, the work conducted on this biotransformation 
previously had developed an assay to measure the conversion.  They took advantage of 
the IMPase enzyme that selectively cleaves phosphate from L-myo-inositol 1-phosphate 
(19), whilst leaving D-glucose 6-phosphate (18) untouched (Scheme 2.2.1).  By pushing 
this second biotransformation to completion, it can be assumed that any free phosphate 
present in the sample is an indication of the amount of L-myo-inositol 1-phosphate (19) 
that was present.  The amount of phosphate that is present can be measured by addition of 
Malachite Green.  This reagent turns green in the presence of free phosphate, emitting 
light at 650 nm.  Absorbance readings can then be used to determine the conversion as 
these readings are directly proportional to the free phosphate concentration, and hence the 
concentration of L-myo-inositol 1-phosphate (19) within the sample. 
 
 
Scheme 2.2.1 – IMPase assay used to calculate INO1 reaction conversion.  IMPase does 
not hydrolyse phosphate of D-glucose 6-phosphate (18).  Reagents and conditions:  
i. IMPase (1 mU), MgCl2 (4 mM), Tris-acetate (50 mM, pH 8.0), 37 °C. 
 
In the initial work, the biotransformation was conducted in a 
tris(hydroxymethyl)methylammonium (Tris) acetate buffer.  This buffer was ideal for 
their work as its pH range is consistent with that of the protein’s activity, whilst it doesn’t 
contain any free phosphate to interfere with the IMPase assay.  The removal of the 
associated Tris acetate salt at the end of the biotransformation was highlighted as a 
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potential problem.  Therefore, a different buffer was sought that maintained high enzyme 
activity and a lack of free phosphate, whilst being easy to remove.  Ammonium 
bicarbonate seemed like an ideal candidate, as the buffer salt should easily decompose 
into ammonia, carbon dioxide and water.  
 
The final factor to take into consideration was protein removal.  With an “in-batch” 
process this would be an issue, however if immobilisation of the protein was necessary 
then it would not be a problem.  Two methods could be used to remove the protein from 
the solution: acidification and subsequent filtration to remove the denatured protein, or 
passing the reaction mixture through a centrifugal size-exclusion filter.  Both of these 
methods were found to be satisfactory during this project, even though the size-exclusion 
filtration took longer to conduct.  Whilst choosing between these two methods, it was 
necessary to think about the next step in the process: selective phosphate benzylation 
using phenyldiazomethane.  This step requires the phosphate to be in its free acid form, 
which can be achieved by acidification.  Therefore, when an “in-batch” process was 
conducted the preferred method of protein removal was acidification followed by 
filtration. 
 
 
2.3  Preliminary Results 
 
2.3.1  TbINO1 Protein Overexpression and Purification 
 
TbINO1 was recombinantly expressed and purified on a large scale using the construct 
pET15b-TbINO1 in BL21 Rosetta (DE3) cells.102  The protein was purified by Ni affinity 
chromatography, eluted with an increasing imidazole gradient (10 mM to 400 mM) in a 
20 mM Tris acetate (pH 7.5) buffer containing 300 mM NaCl.  Removal of imidazole was 
achieved by dialysis against 20 mM Tris acetate (pH 7.5), 50 mM NaCl and 5 mM 
dithiothreitol (DTT).  The protein was then stored containing 20 % glycerol at -80 °C.102 
When conducted, 8 L of E. coli cultures were grown and, typically, 600 mg of TbINO1 
was collected after purification.  This gives 75 mg L-1 of TbINO1, a very high yielding 
expression.  Electrophoresis gels provided evidence of a good level or purity from the 
procedure (Figure 2.3.1). 
 
 71 
 
Figure 2.3.1 – Protein electrophoresis gel from a standard protein purification.  A – 
Whole cell,  B – supernatant,  C – Flow through,  D – 10 mM imidazole wash,  E – 20 
mM imidazole wash,  F – 50 mM imidazole wash,  G – 100 mM imidazole wash,  H – 
250 mM imidazole wash,  I – 400 mM imidazole wash. 
 
2.3.2  Initial Optimisation 
 
Before any work could be done on the scale up of the biotransformation, it was necessary 
to optimise the process on a small scale.  As high conversion had been highlighted as an 
important target, work on the scale up of the process would not be started until a 
conversion of >95 % had been achieved.  The original system22 had achieved such 
conversions, but switching to an ammonium bicarbonate buffer could have a big effect on 
the proficiency of the process.  The first experiments used the same amount of protein (87 
µg), D-glucose 6-phosphate (18, 10 mM) and DTT (1 mM) throughout, and the total 
volume of the reaction mixture was 150 µL.  The concentration of ammonium 
bicarbonate in the buffer was kept at 50 mM and the temperature of the reaction was 
always 37 °C.  The pH and concentrations of NAD+ and ammonium acetate were 
investigated. 
 
Initial results were poor, with the IMPase assay demonstrating conversions as low as 8 %.  
The first variable that was investigated was the pH of the ammonium bicarbonate buffer.  
Experiments were conducted at three pH values: 8.0, 8.5 and 9.0.  Overnight conversions 
 72 
for these reactions were again very low, with only 16 %, 23 % and 20 % being observed 
respectively (Table 2.3.1).  With conversions this low, it was hypothesised that the 
TbINO1 used had lost some activity after a long period of storage.  Therefore, a new 
batch of TbINO1 was expressed and purified.  Utilising the new TbINO1, the reaction 
gave a 53 % conversion with the buffer at pH 8.5. 
 
TbINO1 pH [NAD+] Conversion 
Old 8.0 1 mM 16 % 
Old 8.5 1 mM 23 % 
Old 9.0 1 mM 20 % 
New 8.5 1 mM 53 % 
New 8.5 2 mM 56 % 
New 8.5 4 mM 50 % 
 
Table 2.3.1 – Calculated conversions showing differences in pH, old and new TbINO1 
batches and NAD+ concentration.  Other variables were set to 87 µg of TbINO1, 10 mM 
D-glucose 6-phosphate (18), 2 mM ammonium acetate and 50 mM ammonium 
bicarbonate as buffer.  Reactions incubated at 37 °C overnight. 
 
As the cofactor, NAD+ plays an essential role in the reaction.  Potential optimisation of 
the NAD+ concentration was conducted by running three overnight experiments in 
parallel, with varying concentrations of NAD+ (Table 2.3.1).  With only a small variation 
in conversion observed between these reactions, it is difficult to draw any conclusions as 
to the optimal concentration of NAD+.  A concentration of 2 mM was chosen for 
remaining experiments.  The concentration of ammonium acetate within the reaction 
mixture, seemed to have little or no effect on conversion.  The previous work22 had 
shown that ammonium ions were needed for the biotransformation to progress.  The 
selected ammonium bicarbonate buffer now contained this ion in high abundance.  
Doubling the ammonium acetate concentration to 4 mM had little to no effect, and 
indeed, in later experiments, completely omitting the addition of ammonium acetate had 
no effect on conversion.  The DTT is included in the reaction mixture to prolong the life 
of the protein by relieving oxidative stress.  It reduces and prevents enzyme S-S bonds 
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forming intra- or intermolecularly with cysteine residues.  Reaction conversion was 
therefore not affected by an increase in DTT concentration. 
 
Having investigated each of the components of the reaction, it was hypothesised that 
there could be an issue with the IMPase assay.  If the IMPase was not efficiently cleaving 
the phosphate from L-myo-inositol 1-phosphate (19) then a true representation of the 
conversion would not be observed.  The reaction conditions used for the IMPase reactions 
were initially 50 mM ammonium bicarbonate (pH 8.5), 5 mM magnesium chloride and 
1.25 mU IMPase (bovine brain, Sigma) for 3 hours at 37 °C.  Increasing the reaction time 
had little to no effect on the conversions observed.  Leaving the reaction overnight led to 
the reaction standard (containing no TbINO1) being observably very green in colour after 
addition of Malachite Green, suggesting that IMPase is able to cleave the phosphate from 
D-glucose 6-phosphate (18).  Although this suggests that IMPase is not selective for the 
reaction product, D-glucose 6-phosphate (18) is hydrolysed at a much slower rate than L-
myo-inositol 1-phosphate (19), and within the preferred 3 hour reaction time for the 
IMPase reaction, the amount of free phosphate present from the starting material would 
be negligible.  Using an increased amount of IMPase gave no discernible increase in 
conversion, and changes to magnesium chloride concentration also had little to no effect. 
 
Finally, the Tris acetate buffer was used for this reaction.  This was the original buffer 
used by the previous work,22 but had been changed to ammonium bicarbonate in error 
causing the IMPase to act less efficiently.  Using the original buffer for this reaction, 
pushed the conversion of 56 % that had been observed previously, up to 80 %. 
 
On this initial 150 µL scale, the desired conversion of >95 % had still not been observed 
up to this point.  It was hypothesised that switching the buffer of the stored enzyme prior 
to addition to the reaction mixture, may have a desirable effect.  The enzyme had been 
stored in the previously used Tris acetate buffer, and it was discovered that by switching 
this to the ammonium bicarbonate buffer the reaction conversion was pushed to 92 % on 
the first occasion and since then, conversions >98 % have been observed.  The buffer was 
switched using centrifugal filters with 30 kDa cut off, washing the protein with 
ammonium bicarbonate buffer three times before adding to the reaction. 
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Variable Optimum 
D-Glucose 6-phosphate (18) 10 mM 
TbINO1 87 µg 
NAD+ 2 mM 
DTT 1 mM 
Ammonium bicarbonate 50 mM (pH 8.5) 
  
Table 2.3.2 – Table showing the required conditions to achieve full conversion of D-
glucose 6-phosphate (18) to L-myo-inositol 1-phosphate (19) at 37 °C overnight.  Total 
reaction volume of 150 µL. 
 
The final system used to obtain >95 % conversion on this 0.4 mg scale (10 mM D-
glucose 6-phosphate (18) in 150 µL reaction) was therefore 87 µg TbINO1, 50 mM 
ammonium bicarbonate (pH 8.5), 2 mM NAD+ and 1 mM DTT conducted at 37 °C 
overnight (Table 2.3.2). 
 
 
2.4  Scale-Up “In-Batch” 
 
2.4.1  10 mg 
 
With the biotransformation optimised to obtain a conversion >95 % on 0.4 mg of D-
glucose 6-phosphate (18), it was now possible to investigate the scale-up of the process.  
The first target was to scale-up to using 10 mg of starting material, which would be a 
scale-up of 25 times magnitude.   
 
There were no observed problems with this scale up.  Using 300 µg of TbINO1, 
increasing the reaction volume to 600 µL and extending the reaction time to 3 days gave 
quantitative conversions.   
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2.4.2  100 mg 
 
The initial attempt using 100 mg of D-glucose 6-phosphate (18) was not as successful as 
the 10 mg scale.  In this experiment, the total reaction volume was increased to 4 mL, 
whereas the amount of TbINO1 was left at 300 µg.  This amount of protein should be 
more than enough turnover 100 mg of substrate in a reasonable time period.  The reaction 
was assayed every 24 hours, and the initial conversion calculated, 26 %, looked 
promising.  However, the next day the reaction had only progressed to 32 % conversion 
and, after a further 2 days, the reaction did not progress any further.  At this point, an 
extra 300 µg of TbINO1 was added to the reaction.  Unfortunately, the additional protein 
only pushed conversion to 40 %.  The D-glucose 6-phosphate (18) being used was in the 
form of a disodium salt, meaning that the high concentration of the starting material 
would not dramatically alter the buffer pH.  Potential differences in pH were, therefore, 
not hypothesised as a reason for low conversion. 
 
The second experiment on this scale was conducted with a higher concentration.  Using 
only 1 mL for the total volume would make the D-glucose 6-phosphate (18) and protein 4 
times as concentrated.  To better accommodate this increase in enzyme concentration, the 
amount of NAD+ present was increased from 2 mM to 4 mM.  The reaction was also 
placed within an incubator with shaking. 
 
The results for this experiment are shown in Graph 2.4.1.  There was a steady increase in 
conversion over the first 4 days, however after this point the conversion plateaued at 
62 %.  Extra NAD+ was added at this point, however this produced no further reaction.  
This addition of NAD+ was conducted because within the literature109 it is stated that 
NAD+ is subject to decomposition for prolonged periods in aqueous solution at basic pH.  
At pH 8.5, this reaction is slightly more basic than the recommended pH of 7 to 7.5.109  
the reaction had gradually turned yellow over the course of the experiment.  The major 
mechanism for NAD+ decomposition is from nucleophilic attack on C-4 of the 
nicotinamide moiety, leading to a 1,4-dihydropyridine.109 
 
 76 
 
Graph 2.4.1 – Calculated conversion as time progressed.  Reaction conditions: 100 mg 
D-glucose 6-phosphate (18), 4 mM NAD+, 1 mM DTT, 50 mM ammonium bicarbonate 
(pH 8.5), 300 µg TbINO1, 37 °C with shaking, and 1 mL total reaction volume. 
 
Conducting the reaction in the dark and under an inert atmosphere had a positive effect 
and experiment showed a steady increase of conversion for 6 days, allowing the reaction 
to reach 76 % conversion.  At this point, the reaction gave no further increase in 
conversion and a white precipitate had formed within the reaction mixture.  It is 
hypothesised that the white precipitate is denatured TbINO1 and that six days is the 
longest that this protein is stable to the conditions of the reaction.  Indeed, with further 
experiments, the protein was never observed to survive longer than this.  This problem 
meant that there was only a window of 6 days to achieve a quantitative conversion with 
this process. 
 
The obvious way to achieve this would be to increase the protein to substrate ratio.  Using 
600 µg of TbINO1 in this system caused the protein to denature quicker, in only 2 days, 
and halted the reaction at 26 %.  To accommodate the increase in protein, a separate 
experiment was conducted in which the total volume was increased to 5 mL.  This 
allowed the reaction to progress to 50 % over the course of 5 days before the protein 
precipitated. 
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One factor that needed to be looked into was the mixing of the reaction mixture.  The 
reaction definitely had a higher conversion when the reaction mixture was placed in an 
incubator with shaking, as evidenced in experiments after the initial one on this scale.  
However, with a total volume of 5 mL the reaction vessel being used was a 15 mL Falcon 
tube, which are very narrow.  The Falcon tube was being stood vertically within the 
shaker, which did not allow for very thorough mixing.  An experiment was conducted by 
placing the Falcon tube on its side within the shaking incubator, with the thought that this 
would lead to a more effective agitation of the reaction mixture.  This was indeed the 
case, however the mixing was now too vigorous and all that this accomplished was the 
protein becoming denatured more quickly.  Within 2 hours the protein had precipitated.   
 
A potential solution to this problem was conducting the reaction mixture within a 50 mL 
Falcon tube.  This vessel is much wider than its 15 mL counterpart and would allow the 
reaction mixture to mix more effectively, without being mixed too aggressively.  
Unfortunately, this had no positive effect and the reaction only gave a 32 % conversion. 
 
A rotating wheel was also assessed as a potential solution to this problem.  Placing the 
Falcon tube in this piece of apparatus allows it to be gently inverted, allowing for a non-
vigorous mixing of the reaction mixture.  Unfortunately, an incubated rotating wheel was 
not available, however the reaction was conducted at room temperature in parallel with a 
reaction being run in an incubator with shaking.  After 2 days, the reaction in the 
incubator showed a conversion of 30 %, whereas the reaction in the rotating wheel gave a 
conversion of 28 %.  Although this experiment contained two variables (method of 
mixing and temperature), it is known22 that TbINO1 has an optimum temperature of 
37 °C, and a 12 °C decrease in temperature will slow down the reaction rate.  The fact 
that the two conversion values are comparable suggests that the rotating wheel is a better 
method to mix the reaction. 
 
As stated, an incubated rotating wheel was not available for use.  As time progressed it 
became apparent that an “in-batch” process may not be viable for the scale-up of this 
process.  Even if this piece of apparatus was available, there was no guarantee that this 
would allow for the achievement of quantitative conversion in this system.  Protein 
lifetime under the reaction conditions would always remain the same, and scaling up 
further would exacerbate the problem.  It is possible that the enzyme is experiencing 
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product inhibition, and as the concentration of product increases in the solution the 
protein becomes less active.  The high concentration of D-glucose 6-phosphate (18) being 
used in these reactions could possibly explain why this was not observed on a smaller 
scale.  Alternatives to an “in-batch” process were therefore sought, and the 
immobilisation of TbINO1 was identified as an attractive and accessible alternative. 
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Chapter Three 
 
3  Biocatalysis in Flow 
 
3.1  Advantages of a Flow System 
 
The use of continuous flow processes in biocatalysis has become more common in recent 
years.  As the ability of scientists to modify and control enzymes has increased with 
techniques such as site-directed mutagenesis and directed evolution, the technology 
implemented in utilising these enzymes has needed to improve.  Isolated enzymes are 
generally criticised as a synthetic method due to their instability and difficult recovery 
and re-use.110  Immobilisation of an enzyme can overcome these issues.  With the enzyme 
embedded on a solid it can be easily removed from reaction mixtures, therefore aiding 
enzyme re-use and purity of the product.  Immobilised enzymes are normally more stable 
in general, with increased tolerance to temperature changes or organic solvents.  This 
technique has greatly improved enzyme performance with higher catalyst 
productivities.110 
 
There have been a number of enzymatic resolutions of racemic substrates using flow 
processes reported in recent years.111  One such example is the kinetic resolution of 
racemic 1-phenylethanol ((±) 110, Scheme 3.1.1) by an immobilised lipase (Candida 
antartica, Novozym 435).112 
 
 
Scheme 3.1.1 – Kinetic resolution of 1-phenylethanol ((±) 110) using immobilised 
Candida antartica, Novozym 435.112  Reaents and conditions: i. Immobilised lipase, 
vinyl acetate, scCO2. 
 
In continuous flow, this system provided the (R)-acetate 111 in 99.7 % e.e. and 47 % 
yield, and the (S)-alcohol (S)-110 in 99.8 % e.e. and 47 % yield.  At 25 mmol hr-1, in a 
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5 mL flow reactor, 221 g of the (S)-alcohol (S)-110 was produced over 3 days.  This is a 
great improvement over the batch conditions, which could only produce 0.83 mmol in 
7 hours.111,112 
 
Immobilisation of TbINO1 and conducting the reaction within a flow system has several 
advantages over an in-batch process.  Firstly, it removes the issue of being unable to 
obtain full conversion within a certain time frame.  The in-batch process was not able to 
maintain stability of the protein for long enough to facilitate desired substrate conversion.  
Issues with concentration and mixing meant that this was not a problem that could be 
easily overcome and would only be exacerbated on further scale up.  With the 
introduction of a flow system, the reaction mixture should be passed through the system 
at a concentration that ensures full conversion in one pass.  The exact concentration being 
dependent on the amount of TbINO1 immobilised, the reactivity of the bound TbINO1 
and the flow rate of the system (how long the substrate has in contact with the protein).  
Once the immobilised protein loses it’s activity, the reaction can be stopped.  By 
collecting fractions from the column, it is possible to combine and continue with only 
those containing a fully converted product. 
 
If product inhibition of the enzyme is an issue then conducting the reaction in a flow 
process will overcome this.  As the substrate is converted into product, the product is then 
washed away from the immobilised enzyme, meaning that it cannot inhibit the reaction. 
 
It is possible to automate flow systems with much less effort than in-batch processes, and 
they also lend themselves to scale-up procedures.  As long as the ratio of substrate to 
protein remains the same and they have the same contact time, a flow system will easily 
accommodate scale up.  Additional considerations, such as cofactor concentration, would 
also come into play, but these should be trivial to resolve.  
 
Within the flow system, the TbINO1 will be used to it’s full potential.  Using an in-batch 
process it may be necessary to use a non-catalytic amount or even excess of protein to 
effect full conversion.  The flow system effectively matches the amount of substrate to 
the longevity and activity of the protein, allowing for a more efficient reaction 
stoichiometry and system.  On top of these points, the immobilisation of the protein aids 
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the purification of the final product.  The tedious process of removing protein from the 
reaction by acidification and filtration through centrifugal filter columns will be removed.  
 
3.1.1  Resin Choice and Binding of TbINO1 
 
Originally, an azlactone-based polyacrylamide resin was trialled for the immobilisation of 
TbINO1.  This resin should bind to the protein (113, Scheme 3.1.1) through the azlactone 
residues situated on the beads (112).  Following the manufacturer’s protocol for protein 
immobilisation, the resulting beads had no activity in a test reaction.  Increasing the 
contact time between the beads and protein within the binding step from 1 to 16 hours 
produced no improvement in the results.  This suggests that the binding TbINO1 via this 
method produced an inactive protein, or the protein was simply not binding to the beads.  
 
 
Scheme 3.1.2 – Attachment of a protein to an azlactone-based resin.   
 
At the same time, another avenue was being explored.  The His-Tag that was used for 
purification of the TbINO1 had not been cleaved from the protein.  It was hypothesised 
that this moiety could be used to immobilise the protein to a Ni2+-Sepharose column, in 
very much the same way as when the protein is purified.  This would not be as strong an 
attachment as the azlactone resin would produce as it is non-covalent, but it may be 
sufficient for proof of principle studies in this biocatalytic flow system. 
 
Ni2+-charged Sepharose beads that make up the protein purification columns were mixed 
with a TbINO1 containing solution for 30 minutes.  They were then washed with 
ammonium bicarbonate buffer (50 mM, pH 8.5) to remove any unattached protein.  The 
prepared TbINO1 beads were added to a reaction solution containing 10 mM D-glucose 
6-phosphate (18), 2 mM NAD+, 1 mM 2-mercaptoethanol, and 50 mM ammonium 
bicarbonate (pH 8.5).  The DTT for protein stabilisation was replaced with 2-
mercaptoethanol as the Ni2+ ions are known to react with DTT and this would hamper the 
reaction process.  After incubation with shaking at 37 °C for 3 days, the IMPase assay 
 82 
showed 80 % conversion.  This was seen as sufficient evidence to begin working on the 
development of a flow system. 
 
3.2  Experiments with a 1 mL Ni2+-Sepharose Column 
 
Within the flow system, the columns being used were pre-packed with Ni2+- Sepharose 
and reusable.  Initial work was conducted using a column size of 1 mL, which should 
hold up to 40 mg of protein as per the manufacturers specifications.  All of the 
experiments being conducted were completed with an excess of TbINO1 being loaded 
onto the column, in order to ensure the column was holding the full capacity of protein.  
Washing the protein from the 1 mL column after reaction and measuring the amount 
collected gave a reading of 39 mg of protein.  Meaning that the columns were loaded and 
saturated with TbINO1 protein during these experiments. 
 
One of the main practical issues for the flow system was how to maintain the reaction at 
an optimal temperature of 37 °C.  The first experiments conducted were done at room 
temperature as a method of determining the feasibility of this system, before more 
expensive equipment (a column oven) was invested in for the project.  A solution 
containing D-glucose 6-phosphate (18), 2 mM NAD+, 1 mM 2-mercaptoethanol and 
50 mM ammonium bicarbonate (pH 8.5) was passed through the 1 mL Ni2+-Sepharose 
column loaded with TbINO1.  A peristaltic pump powered the flow through the system, 
and the slowest setting on the pump was used in order to allow the substrate an increased 
contact time with the protein. 
 
As experiments progressed, a gradual decrease in conversion was noted and this was 
attributed to the reuse of the Ni2+-Sepharose columns.  Whilst the drop in conversion was 
only slight, for the optimisation of the process a new column was used each time to 
achieve reproducible results.  Each new column was treated the same way in the set up of 
the flow system.  The Ni2+-Sepharose column comes stored in a 20 % ethanol solution 
(aq.), which must be washed off prior to use.  Passing five column volumes of water 
through the column is seen as a thorough wash of the column.  This volume was used for 
each wash of the column being conducted.  The columns were prepared by washing with 
water, followed by 50 mM ammonium bicarbonate (pH 8.5), water again, 200 mM nickel 
(II) sulfate solution, water, and finally 50 mM ammonium bicarbonate (pH 8.5).  As 
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previously stated, the initial water wash is needed to remove the 20 % ethanol solution 
from the column.  The first ammonium bicarbonate wash adjusts the pH of the column to 
8.5 as desired for the reaction.  The next water wash will remove any remaining 
ammonium bicarbonate solution.  The wash with nickel (II) sulfate recharges the column 
with Ni2+ ions, and is generally conducted on a cycle for 1 hour to ensure the column is 
holding as many of these ions as possible.  The following water wash removes any of the 
remaining nickel (II) sulfate solution, before the column can be washed with ammonium 
bicarbonate prior to protein loading.  It was important to establish a procedure that would 
be used in each experiment, to avoid any inconsistencies that this may produce on results. 
 
The first results at this temperature are shown in Table 3.2.1.  This experiment was 
conducted by passing a 10 mM D-glucose 6-phosphate (18) solution through the TbINO1 
column at a flow rate of 2.5 mL hr-1.  A sample was taken and a second pass of the eluted 
solution was conducted through the column, before a third pass was completed.  The 
eluting tube and feeding tube were then connected to make a closed system, which would 
slowly pump the reaction mixture through the column overnight, repeatedly. 
 
Passes Conversion 
1 50 % 
2 55 % 
3 60 % 
Cycle 60 % 
 
Table 3.2.1 – Calculated conversion at room temperature with a 1 mL TbINO1 loaded 
Ni2+-Sepharose column and flow rate of 2.5 mL hr-1.  Reaction solution contained 10 mM 
D-glucose 6-phosphate (18), 2 mM NAD+, 1 mM 2-mercaptoethanol, 50 mM ammonium 
bicarbonate (pH 8.5).  
 
As can be seen from the results in Table 3.2.1, the first pass through the system was able 
to convert 50 % of the substrate.  Passing the same solution through the column again 
increased the conversion to 55 %, and repeating the process again gained an extra 5 % 
conversion.  The overnight cycle plateaued at 60 % conversion.  This, coupled with the 
incremental increases in conversion noted in subsequent passes, suggests that possibly 
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product inhibition could be playing a role in the reaction.  The immobilisation of the 
protein could lower the activity, due to potential conformational restriction of the 
enzyme, or where the active site is positioned in respect to where the protein is tethered.  
The lower temperature will undoubtedly cause a lower activity because the optimum 
temperature for the protein is 37 °C.  It was hypothesised that by increasing the 
temperature of the system to 37 °C, the protein would be more active and potentially be 
able to overcome the product inhibition. 
 
With no specific equipment to run the flow system at 37 °C, a system was trialled that 
contained a reservoir for the reaction solution.  The idea was that by sitting the reservoir 
in a water bath at 37 °C, the heat would carry through the reaction and be sufficient to 
increase enzyme activity and achieve full conversion.  After 24 hours of reaction, the 
calculated conversion was only 33 %.  After 4 days, the conversion increased to 40 %, but 
no progress was observed after this time.  In subsequent attempts, this procedure 
remained poor, with only a 45 % conversion being achieved at best.   
 
The introduction of a column oven for the TbINO1 loaded Ni2+-Sepharose column meant 
that progress could be made with the flow system.  This provided a consistent method of 
maintaining the reaction at 37 °C and allowed for demonstration of an effective flow 
system.  The first experiments conducted at this temperature demonstrated the systems 
ability to produce full conversion to L-myo-inositol 1-phosphate (19), but also highlighted 
the need to scale-up this process further. 
 
Passes Conversion 
1 81 % 
2 100 % 
Cycle 100 % 
 
Table 3.2.2 - Calculated conversion at 37 °C with a 1 mL TbINO1 loaded Ni2+-Sepharose 
column and flow rate of 2.5 mL hr-1.  Reaction solution contained 5 mM D-glucose 6-
phosphate (18), 2 mM NAD+, 1 mM 2-mercaptoethanol, 50 mM ammonium bicarbonate 
(pH 8.5). 
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Taking the same system used in the first 1 mL TbINO1 loaded Ni2+-Sepharose column 
experiments, a solution containing 5 mM D-glucose 6-phosphate (18) was passed through 
the system.  The same solution was taken and passed through the system again, before 
being cycled through it overnight.  The results are shown in Table 3.2.2. 
 
A subsequent experiment completed single passes of varying D-glucose 6-phosphate (18) 
concentrations through the system.  The same Ni2+-Sepharose column was used 
throughout the experiment, with freshly made reaction solutions being passed through.  
Each of the different concentration solutions were thoroughly washed from the system 
before the new solution was passed through.  It was ensured that samples were only 
collected from the system once a sufficient amount of each solution had passed through, 
maintaining the substrate / product concentration.  The results are shown in Graph 3.2.1.  
It should be noted that this experiment was conducted on a non-fresh Ni2+-Sepharose 
column, and this is the reason for the drop in conversion for the 5 mM result, and 
potential lower conversions for the other concentration results.  
 
 
Graph 3.2.1 – The ability of the 1 mL TbINO1 loaded Ni2+-Sepharose flow system to 
convert different concentrations of D-glucose 6-phosphate (18) in one pass. 
 
With the amount of protein remaining constant, as the substrate concentration is increased 
the percentage of the substrate being converted will be decreased.  The protein is only 
able to turnover a certain number of moles of substrate in a single pass, and as the amount 
of substrate increases this limit will be reached.  Once this is reached as the concentration 
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of substrate doubles, the % conversion will half, resulting in a graph that looks like Graph 
3.2.1.  It is possible that high amounts of substrate will cause substrate inhibition of the 
protein, but it does not look like this has been observed in this experiment as it is a flow 
system. 
 
From these results it is possible to postulate that a 4 mM concentration of D-glucose 6-
phosphate (18) should be able to pass through this system and achieve full conversion to 
L-myo-inositol 1-phosphate (19).  At this concentration and rate of flow through the 
system, it is calculated that 42 mg of product would be produced within a 16 hour time 
period.  This was extrapolated from the system being able to convert 81 % of a 5 mM D-
glucose 6-phosphate (18) solution, and a flow rate of 2.5 mL hr-1.  With a scale up to a 
5 mL column this amount should be increased to 210 mg, a much more synthetically 
viable quantity.  
 
It should be noted that at this stage in the project, Sigma Aldrich discontinued their 
source of IMPase enzyme.  This presented an issue because this was the source of the 
IMPase that was being used for the assay to determine conversion of the reaction.  
Fortunately, other members of the group were investigating the IMPase from T. brucei.  
This parasite has two forms of the IMPase protein, IMPase 1 and IMPase 2, which have 
been shown to work together in a 3:1 ratio to cleave the phosphate from L-myo-inositol 1-
phosphate (19).113 These two proteins could be expressed and purified for use within the 
IMPase assay used within this project.  However, the low levels of these proteins being 
expressed and purified meant that this had to be conducted quite often and was quite time 
consuming.  A new method to determine reaction conversion was sought, and with a 
scale-up in reaction this was possible. 
 
 
3.3  Ni2+-Sepharose Column Scale-Up 
 
By scaling the process up to using a 5 mL Ni2+-Sepharose column, the amount of material 
being passed through the system means that it is now suitable to use 1H Nuclear Magnetic 
Resonance (NMR) to monitor the reaction.  This means that the calculation of conversion 
will now be a direct measurement of the reaction, and not reliant upon the action of 
IMPase. 
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According to the manufacturer, the Ni2+-Sepharose columns being used (IMAC 
SepharoseTM 6 Fast Flow) can hold 40 mg of protein per 1 mL of Sepharose.  This means 
that a 5 mL column should be able to hold 200 mg of protein.  The overexpression of 
TbINO1 produces roughly 600 mg of protein per 8 L of culture.  Therefore, by taking the 
TbINO1 produced from 4 L of culture and loading this amount onto the 5 mL column, 
there will be an excess of protein and the column will be saturated.  In the purification of 
TbINO1, the protein is washed off the column with an increasing gradient of imidazole.  
As can be seen in Figure 3.3.1, the first wash containing 10 mM imidazole removes all of 
the undesired protein and cell extracts that remain on the column after loading.  After this 
wash, all that remains on the column is the desired TbINO1 protein.  By leaving the 
protein on the column at this stage, the purification is effectively complete and column is 
ready for use in the flow system. 
 
 
Figure 3.3.1 – Protein gel from a standard protein purification.  A – Whole cell,  B – 
supernatant,  C – Flow through,  D – 10 mM imidazole wash,  E – 20 mM imidazole 
wash,  F – 50 mM imidazole wash,  G – 100 mM imidazole wash,  H – 250 mM 
imidazole wash,  I – 400 mM imidazole wash. 
 
Aside from the larger TbINO1 loaded Ni2+-Sepharose column, the system used remained 
the same as the 1 mL experiments.  A solution containing D-glucose 6-phosphate (18), 
1 mM NAD+, 1 mM 2-mercaptoethanol and 50 mM ammonium bicarbonate (pH 8.5) was 
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slowly passed (2.5 mL hr-1, single pass) through the new Ni2+-Sepharose column at 37 °C.  
With a 5 times increase in the amount of TbINO1 present immobilised in the system, it 
was hypothesised that 5 times the amount of substrate could be converted by the system 
as the flow rate was remaining the same.  This meant that if 4 mM D-glucose 6-phosphate 
(18) could be tolerated by the 1 mL system, then 20 mM D-glucose 6-phosphate (18) 
should be tolerated by the 5 mL system.  During the first experiment, the concentration of 
D-glucose 6-phosphate (18) was initially chosen as 10 mM, and after 12 hours the 
concentration of this substrate was increased to 20 mM.  This was to check that 10 mM 
could be tolerated, and then test 20 mM.   
 
The reaction was then allowed to continue for 48 hours in total (Figure 3.3.2), with 4 
fractions being collected: A – initial 12 hours with 10 mM D-glucose 6-phosphate (18), B 
– 12 to 24 hours with a switch to 20 mM D-glucose 6-phosphate (18), C – 24 to 36 hours 
with 20 mM D-glucose 6-phosphate (18), and D – 36 to 48 hours with 20 mM D-glucose 
6-phosphate (18).  Each of the fractions collected were acidified to pH 2 using 
concentrated hydrochloric acid before being lyophilised.  NMR samples were prepared in 
D2O of the resulting solid products. 
 
As can be seen from Figure 3.3.2, the 1H NMR of sample A shows 100 % conversion to 
L-myo-inositol 1-phosphate (19), with no D-glucose 6-phosphate (18) peaks present 
within the spectrum.  The NMR of sample B looks like it may contain a small amount of 
D-glucose 6-phosphate (18).  This is the sample that would have contained the remainder 
of the 10 mM D-glucose 6-phosphate (18) solution pass.  This suggests that the flow 
system was not able to fully convert the 20 mM substrate solution in one pass, unless the 
protein had begun to lose its activity.  Samples C and D show that as time progressed the 
TbINO1 steadily lost activity, with sample D containing solely D-glucose 6-phosphate 
(18).   
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Figure 3.3.2 – 1H NMR data showing the activity of immobilised TbINO1 over time.  A 
– initial 12 hours with 10 mM D-glucose 6-phosphate (18), B – 12 to 24 hours with a 
switch to 20 mM D-glucose 6-phosphate (18), C – 24 to 36 hours with 20 mM D-glucose 
6-phosphate (18), and D – 36 to 48 hours with 20 mM D-glucose 6-phosphate (18). 
 
It may have been the case that the drop in activity of the system was due to the protein 
being slowly stripped from the column.  Tests using the Bradford reagent suggested that 
this was not the case, as the reagent did not turn blue when added to the solution eluting 
from the system.  Coupled with the results from the experiment, this suggests that the 
protein begins to significantly lose activity after roughly 24 hours under these conditions.  
This is shorter than the in-batch reaction conditions, and this is thought to be due to the 
immobilisation of the protein.  Although the TbINO1 is less stable when bound to the 
column, the advantages that the flow system offers completely outweigh this issue.   
 
 
 
 
 
H2ino 
H1glu 
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Fraction Conversion 
0 – 10 hr 100 % 
10 – 20 hr 100 % 
20 – 30 hr 
30 – 40 hr 
100 % 
58 % 
 
Table 3.3.1 – Table showing protein activity as time passed.  Solution containing 18 mM 
D-glucose 6-phosphate (18), 1 mM NAD+, 1 mM 2-mercaptoethanol, 50 mM ammonium 
bicarbonate solution (aq., pH 8.5) was passed through the column at a flow rate of 2.5 mL 
hr-1 and 37 °C.  Conversions were calculated from 1H NMR data. 
 
In subsequent experiments, 18 mM D-glucose 6-phosphate (18) was chosen as a 
concentration that the immobilised TbINO1 could fully convert to L-myo-inositol 1-
phosphate (19) in one pass.  At this concentration the system is able to achieve full 
conversion for a time period of roughly 30 hours, after which the protein loses activity 
(Table 3.3.1).  Fractions are collected every 10 hours and, before they are combined, the 
conversion of each is checked by 1H NMR.  Each flow reaction produces roughly 350 mg 
of L-myo-inositol 1-phosphate (19, Scheme 3.3.1). 
 
 
Scheme 3.3.1 – Synthesis of L-myo-inositol 1-phosphate (19) using immobilised TbINO1 
(~200 µg) on a 5 mL Ni2+-Sepharose column.  Solution containing 18 mM D-glucose 6-
phosphate (18), 1 mM NAD+, 1 mM 2-mercaptoethanol, 50 mM ammonium bicarbonate 
solution (aq., pH 8.5) was passed through the column at a flow rate of 2.5 mL hr-1 and 
37 °C.   
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3.3.1  Further Considerations 
 
Throughout this process, one factor that needed to be considered was product isolation.  
The need to obtain complete conversion stems from a product isolation standpoint rather 
than a process efficiency one.  Conducting the biotransformation “in-flow” has major 
advantages when it comes to isolation of the product.  Obviously, the protein does not 
need to be removed from the reaction mixture, which bypasses one step in purification.  
By collecting fractions from the biotransformation it is possible to deduce the exact point 
when the protein is unable to turnover all of the substrate, so only fractions containing no 
D-glucose 6-phosphate (18) can be collected. 
 
The solution that elutes from the column is acidified to pH 2 using concentrated 
hydrochloric acid.  This ensures that the L-myo-inositol 1-phosphate (19) is in the free 
acid form, and not the sodium salt, which is necessary for the next step of the process.  
Use of Amberlite H+ was also trialled, which was efficient at forming the free acid.  
However, using this method had no added benefits and ultimately just led to more water 
having to be removed from the final product.   
 
After acidification, the solution is lyophilised to remove the water, buffer salt and 2-
mercaptoethanol.  Having previously considered the isolation of L-myo-inositol 1-
phosphate (19) in the scale up of the process, the product obtained from this process is 
relatively pure with the only real contaminant as NAD+/NADH.  As soon as any synthetic 
manipulation is conducted and subsequent purification takes place, this contaminant will 
be removed.  
 
 
3.4  Selective Phosphate Benzylation 
 
One potential problem with using L-myo-inositol 1-phosphate (19) as a starting material 
is the reactivity of the phosphate.  We obviously need this phosphate present, at least until 
substitution of the inositol ring in order to retain optical purity.  To avoid complications 
with the phosphate, it was decided to protect it using benzyl groups that would also allow 
for better organic solvent solubility.  Phenyldiazomethane (115, PhCHN2) was 
highlighted as a potential reagent to use in order to achieve selective phosphate 
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benzylation and produce 1-bis(benzyloxy)phosphoryl L-myo-inositol (116, Scheme 
3.4.1).  There is precedence in the literature of diazomethane as a selective methylating 
reagent of phosphates in the presence of alcohols.114,115 
 
 
Scheme 3.4.1 – Proposed selective benzylation using phenyldiazomethane (115).  
Reagents and conditions:  i. Et2O, 0 °C. 
 
Phenyldiazomethane (115) was synthesised via the route outlined in Scheme 3.4.2.  
Starting from the sulfonyl chloride 117, addition of hydrazine afforded the hydrazide 118.  
This could then be converted into hydrazide 119 through reaction with benzaldehyde.  
Phenyldiazomethane (115) was synthesised as needed, which was feasible as the 
formation of this reagent only requires reflux in methanol with potassium hydroxide for 
20 minutes.116  In initial experiments, the reaction was cooled to room temperature and 
ice-cold water was added to quench the reaction.  The reagent was then extracted into 
diethyl ether and used as a crude ethereal solution.  In subsequent work, washing the 
combined diethyl ether layers with sodium carbonate solution (sat., aq.), water and brine 
gave a much cleaner reaction for the benzylation. 
 
Before conducting the benzylation on the highly precious L-myo-inositol 1-phosphate 
(19), preliminary experiments were conducted on D-glucose 6-phosphate (18).  This 
allowed for development of the benzylation process on a material that is very similar in 
terms of solubility and reactivity.  As previously stated, for reaction with a diazo 
compound, the phosphate must be present in its free acid form.  The disodium salt of D-
glucose 6-phosphate (18) was dissolved in water, acidified to pH 2 using concentrated 
hydrochloric acid and finally lyophilised to furnish the free acid.  On a small scale 
(<10 mg) the benzylation could be accomplished via addition of an ethereal solution of 
phenyldiazomethane in small aliquots at 0 °C, until the orange colour of the reagent 
persisted (showing an excess of reagent).  After 10 minutes at this temperature, the 
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reaction was allowed to warm to room temperature and the highly volatile reagent was 
able to evaporate from the reaction. Mass spectrometry showed the success of the 
benzylation on this small scale, with presence of a peak for 1-bis(benzyloxy)phosphoryl 
L-myo-inositol (116) and no peaks representing starting material or monobenzylated 
products within the data. 
 
 
Scheme 3.4.2 – Synthesis of phenyldiazomethane (115).  Reagents and conditions:  i. 
Hydrazine monohydrate, THF, 0 °C, 4 hr, 95 %;  ii. benzaldehyde, MeOH, 5 °C, 16 hr, 
91 %;  iii. KOH, MeOH, reflux, 30 min. 
 
On a larger scale (>20 mg) incomplete benzylation of the phosphate was observed (Table 
3.4.1), with mass spectrometry data showing only a trace of benzylated products 
compared D-glucose 6-phosphate (18).  This is thought to be due to poor mixing of the 
ethereal reagent solution and the insoluble D-glucose 6-phosphate (18).  A biphasic 
reaction with an aqueous solution of D-glucose 6-phosphate (18) was attempted with 
vigorous mixing.  Unfortunately, this did not solve the problem.  Dissolving the D-
glucose 6-phosphate (18) in methanol had a better effect on the reaction, allowing for 
some benzylation to occur, (16 % monobenzylation and 16 % dibenzylation).  Addition of 
the D-glucose 6-phosphate (18) to the reaction mixture would not be productive as the 
reaction mixture is highly basic and would convert the phosphate away from it’s reactive 
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free phosphate form.  It could also lead to cleavage of the phosphate completely, with 
hydroxide ions being present in excess.   
 
PhCHN2 
Solvent 
PhCHN2 
washed? 
D-Glucose 6-phosphate 
solvent 
Amount of 
monobenzylation 
Amount of 
dibenzylation 
Et2O No Neat Trace Trace 
Et2O No Water None None 
Et2O Yes Methanol 16 % 16 % 
DCM Yes Methanol 15 % 15 % 
Et2O Yes Methanol (high dilution) None >99 % 
 
Table 3.4.1 – Reagents and conditions used in the selective phosphate benzylation of D-
glucose 6-phosphate (18) using phenyldiazomethane (PhCHN2, 115).  Conversions to 
monobenzylated and dibenzylated products were determined using 1H NMR 
spectroscopy. 
 
Introduction of partial purification of the phenyldiazomethane (115) by washing with 
sodium carbonate solution (sat., aq.), water and brine, had a slight improvement on the 
reaction outcome.  Extraction of the phenyldiazomethane into dichloromethane instead of 
diethyl ether could have been advantageous for dissolution within methanol, however this 
had little to no effect on reactivity.  With both diethyl ether and dichloromethane as 
solvents for the reagent it was noted that upon addition of the phenyldiazomethane 
solution, the D-glucose 6-phosphate (18) crashed out of the methanol and diethyl ether or 
dichloromethane mixture.  With the hypothesis that this was responsible for the 
incomplete benzylation, a very highly diluted solution of D-glucose 6-phosphate (18) was 
used in an attempt to keep it in solution throughout the reaction.  Upon addition of 
ethereal phenyldiazomethane, the D-glucose 6-phosphate (18) remained in solution, and 
complete phosphate benzylation was observed by mass spectrometry. 
  
With a method developed for selective phosphate benzylation, it was possible to move 
onto the actual substrate for the reaction, L-myo-inositol 1-phosphate (19) from the 
biotransformation.  The crude material obtained from the biocatalytic flow system was 
treated with phenyldiazomethane under the same conditions developed for the 
 95 
benzylation of D-glucose 6-phosphate (18).  Unfortunately, this process did not achieve 
any benzylation, and only starting material was recovered from the reaction. 
 
With this starting material, achieving any benzylation at all proved to be an issue.  
Methods using benzyl bromide and a base, such as Et3N or diisopropylethylamine 
(Hünig’s base), failed to achieve benzylation at any position of the L-myo-inositol 
phosphate (19).  Even moving to the highly reactive bromomethyl acetate failed to 
furnish a benzylated product. 
 
With all of these benzylation methods failing, it was hypothesised that there must be 
some artifact from the biocatalytic step that was interrupting subsequent reactions.  This 
was supported by the fact that unreacted D-glucose 6-phosphate (18) from the biocatalytic 
step also did not react under the same conditions that benzylated the substrate previously.  
The reaction solution was passed through the system after TbINO1 had lost its activity.  
This sample was then treated in the same way that the L-myo-inositol 1-phosphate (19) 
had been (acidification to pH 2 and lyophilisation).  The resulting product was subjected 
to the benzylation reaction and furnished none of the desired product.  Within the flow 
system, the His-tagged TbINO1 protein is tethered to the Ni2+-Sepharose column via 
coordination to the Ni2+ ions that are embedded within the Sepharose’s nitrilotriacetic 
acid (NTA) residues.  It is possible that within the reaction conditions, the Ni2+ ions could 
leach from the Sepharose column, and subsequently contaminate the L-myo-inositol 1-
phosphate (19) produced.   
 
A simple test and remedy for this problem was found by placing a Ni2+ stripped 
Sepharose column at the end of the flow system (Scheme 3.4.3).  This “Ni2+-scrubbing” 
column was prepared by washing a Ni2+-Sepharose column with 50 mM 
ethylenediaminetetraacetic acid (EDTA) solution, which binds and removes any Ni2+ ions 
from the column.  The L-myo-inositol 1-phosphate (19) produced from the modified flow 
system, was successfully benzylated using the previously developed phenyldiazomethane 
procedure. 
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Scheme 3.4.3 – Synthesis of L-myo-inositol 1-phosphate (19) using immobilised TbINO1 
(~200 µg) on a 5 mL Ni2+-Sepharose column.  Solution of 18 mM D-glucose 6-phosphate 
(18), 1 mM NAD+, 1 mM 2-mercaptoethanol, 50 mM ammonium bicarbonate solution 
(aq., pH 8.5) was passed through the column at 2.5 mL hr-1 and 37 °C.  Including a “Ni2+-
scrubbing” column in the flow set up allows for removal of unwanted Ni2+ ions. 
 
The benzylation of L-myo-inositol 1-phosphate (19) was optimised to produce a 97 % 
yield of 1-bis(benzyloxy)phosphoryl L-myo-inositol (116, Scheme 3.4.4).  The modified 
flow system produced a white fluffy solid after lyophilisation rather than the observed 
dark brown or black product achieved from earlier attempts.  When dissolving the L-myo-
inositol 1-phosphate (19) in methanol for the benzylation, it was noted that a significant 
proportion of the white solid did not dissolve.  NMR data showed that this was NAD+ or 
NADH, which are only sparingly soluble in methanol.  A quick filtration therefore led to 
the removal of the vast majority of this from the L-myo-inositol 1-phosphate (19). 
 
 
Scheme 3.4.4 – Selective benzylation of L-myo-inositol 1-phosphate (19) using 
phenyldiazomethane (115).  Reagents and conditions:  i. Et2O, MeOH (large excess), 
0 °C, 97 %. 
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With the L-myo-inositol 1-phosphate (19) dissolved in a large volume of methanol 
(300 mL per 100 mg), a freshly prepared and washed ethereal solution of 
phenyldiazomethane could be added in excess at 0 °C without precipitation of the starting 
material.  Stirring the reaction mixture for 4 hours allowed complete benzylation of the 
phosphate, with selectivity over the inositol hydroxyl groups.  The reaction was quenched 
by addition of acetic acid before being concentrated.  At this stage, side products from the 
formation of phenyldiazomethane remained within the crude product.  These could be 
removed by dissolution of the product in water, and washing with diethyl ether.  
Lyophilisation then produced substantially pure 1-bis(benzyloxy)phosphoryl L-myo-
inositol (116). 
 
The L-myo-inositol 1-phosphate (19) produced from this methodology is achieved with 
complete conversion.  As a result of this, and the way in which it is worked up, the L-
myo-inositol 1-phosphate (19) produced is highly pure, as can be seen in the 1H NMR in 
Figure 3.4.1.   
 
 
Figure 3.4.1 – 1H NMR of L-myo-inositol 1-phosphate (19) obtained from the 
biocatalytic flow system. 
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Possibly the most important factor to consider with the product is the enantiopurity.  The 
literature suggests57,117 that the measurement of optical rotation of inositol phosphates is 
dependent upon the pH of the solution being measured.  The L-myo-inositol 1-phosphate 
(19) produced in this system has an [α]D of -4.6 (pH 9), which is in reasonable agreement 
with the measurement of Miller et al.,69 [α]D -3.4 (pH 9). 
 
 
3.5  Secondary Function of INO1 
 
The versatility of myo-inositol (1) allows the compound and its derivatives to play central 
roles within a plethora of cellular processes.  This is a phenomenon that is seen across 
nature and, as such, INO1 genes have been characterised from a small number of 
prokaryotic and various eukaryotic organisms.  These include Porteresia coarctata,118 
Arabidopsis thaliana,108 Mycobacterium tuberculosis (M. tuberculosis),119,120 
Mycobacterium smegmatis,121 Drosphila melanogaster,122 S. cerevisiae,107 Entamoeba 
histolytica,123 Leishmania mexicana124 and Homo sapiens.105,125  It has been revealed by 
genetic studies that within both Leishmania mexicana124 and M. tuberculosis120 INO1 
plays a major role in regulation of myo-inositol (1) levels.  In addition to T. brucei,22 this 
highlights INO1 as a potential drug target for Leishmania mexicana and M. tuberculosis.  
 
In work being conducted parallel to this project, the Smith group was screening 
compounds as potential inhibitors of TbINO1.  They were initially using the IMPase 
assay to determine reaction conversion and inhibition data for the TbINO1 reaction.  
However, this assay had two major disadvantages within this work: potential inhibition of 
IMPase and the high levels of free phosphate in some of the potential inhibitors being 
tested.  They decided to employ high performance ion-exchange chromatography to 
quantify the enzyme activity and overcome these issues.   
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Figure 3.5.1 – Reaction standards D-glucose 6-phosphate (18), D-fructose 6-phosphate 
(120) and L-myo-inositol 1-phosphate (19) by high performance anion-exchange 
chromatography using a Dionex HPLC system with a CarboPacPA-1 column and PA-1 
guard column (Dionex). 
 
This method was able to separate D-glucose 6-phosphate (18) and L-myo-inositol 1-
phosphate (19), as well as the other components of the reaction mixture, allowing them to 
obtain a quantitative reading of conversion.  Within these experiments, they often 
observed an additional peak in the spectra from the assays. This peak was not present 
within control reactions for enzyme and substrate blanks (Figure 3.5.1), which suggests 
that this peak was present as a result of enzyme activity.  It correlates with the expected 
peak for D-fructose 6-phosphate (120, Scheme 3.5.1), and suggests that TbINO1 was able 
to form D-fructose 6-phosphate (120) in addition to L-myo-inositol 1-phosphate (19). 
 
 
Scheme 3.5.1 – Conversion of D-fructose 6-phosphate (120) into D-glucose 6-phosphate 
(18) and L-myo-inositol 1-phosphate (19) via action of TbINO1.  Reagents and 
conditions:  i. TbINO1, NAD+. 
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By switching the substrate for the reaction to D-fructose 6-phosphate (120) they were able 
to observe peaks with identical elution times to D-fructose 6-phosphate (120), D-glucose 
6-phosphate (18) and L-myo-inositol 1-phosphate (19, Figure 3.5.2).  Extension of the 
reaction for longer periods only produced L-myo-inositol 1-phosphate (19).  So TbINO1 
is able to convert D-fructose 6-phosphate (114) into L-myo-inositol 1-phosphate (19), via 
conversion to D-glucose 6-phosphate (18).  It is thought that the production of D-glucose 
6-phosphate (18) is reversible due to the initial discovery of D-fructose 6-phosphate (114) 
being produced in the reaction. 
 
 
Figure 3.5.2 – Conversion of D-fructose 6-phosphate (120) to both D-glucose 6-
phosphate (18) and L-myo-inositol 1-phosphate (19), shown by high performance anion-
exchange chromatography using a Dionex HPLC system with a CarboPacPA-1 column 
and PA-1 guard column (Dionex).  Reaction mixture contained 2 mM Tris acetate (pH 8), 
2 mM D-fructose 6-phosphate (120), 1 mM NAD+, 1 mM DTT, 2 mM ammonium acetate 
and 5 µg TbINO1 in a final volume of 20 µL. The reaction was incubated at 37 oC.  
Samples were taken at selected time points and terminated by heating at 100 oC for 
10 minutes and the addition of 80 µL of 10 mM NaOH (aq.).  
 
The flow system developed within this project was being conducted on a scale large 
enough for 1H NMR to be used as a method of conversion determination.  Feeding D-
fructose 6-phosphate (120) into the system in place of D-glucose 6-phosphate (18), 
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provided further demonstration of the protein’s ability to convert D-fructose 6-phosphate 
(120) into L-myo-inositol 1-phosphate (19) via D-glucose 6-phosphate (18).  The 
biocatalytic flow system was set up as usual and the substrate was replaced in the reaction 
mixture by D-fructose 6-phosphate (120) at a 15 mM concentration.  By conducting a 
slow pass through the system, at the normal rate of 2.5 mL hr-1, conversion to L-myo-
inositol 1-phosphate (19) was observed by 1H NMR (Spectrum A, Figure 3.5.3).  
Increasing the rate to 7.5 mL hr-1 allowed partial conversion of the substrate into D-
glucose 6-phosphate (18) and L-myo-inositol 1-phosphate (19, Spectrum B). 
 
 
Figure 3.5.3 – 1H NMR spectra for standards D-fructose 6-phosphate (120), D-glucose 6-
phosphate (18) and L-myo-inositol 1-phosphate (19), and products of the reaction 
conducted at different flow rates through the system, 2.5 mL hr-1 (Spectrum A) and 7.5 
mL hr-1 (Spectrum B). 
 
These results show that the recombinant TbINO1 is able to catalyse the reversible aldose-
ketose isomerisation of D-glucose 6-phosphate (18) to D-fructose 6-phosphate (120).  
This activity is normally only observed by D-glucose 6-phosphate isomerases,126 and has 
not been reported for INO1s from any other organisms.  The scale of the biocatalysis in 
the flow system has allowed NMR spectroscopy to further show this transformation.  
Also, D-fructose 6-phosphate (120) could be used instead of D-glucose 6-phosphate (18) 
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as a starting material for the production of L-myo-inositol 1-phosphate (19) if that was 
advantageous.   
 
 
3.6  Conclusions 
 
The biocatalytic production of L-myo-inositol 1-phosphate (19) on a synthetically viable 
scale has been a success.  Using a flow system for this process has dramatically improved 
the scale up of the process, and has meant that further scale up of the process can be 
conducted more easily.  Use of a larger Ni2+-Sepharose column or setting up two columns 
in series, would allow for a higher concentration and larger amounts of D-glucose 6-
phosphate (18) to be passed through and be fully converted into L-myo-inositol 1-
phosphate (19). 
 
The process as a whole, whilst able to produce significant quantities of L-myo-inositol 1-
phosphate (19), is not fully optimised.  Further work would be necessary to make this a 
commercially viable process.  The protein is very crudely immobilised, with the His-tag 
being used to attach it to a Ni2+-Sepharose column non-covalently.  There are many 
methods available to immobilise proteins and these should be fully investigated to 
achieve the most efficient system possible.   
 
Enzymes can be immobilised by binding to a support, entrapment in a polymer network, 
or by cross-linking of enzyme aggregates or crystals.109  Enzymes can be bound to a 
support using physical, ionic or covalent interactions.  The type of supports involved are 
generally resins, biopolymers, or inorganic solids, such as silicas or zeolites.  Physical 
binding is generally too weak to be used in industrial applications.109  In this work, 
TbINO1 is bound to a Ni2+-Sepharose column in an ionic binding to a resin.  This type of 
interaction is stronger than physical, but in this system Ni2+ leaching was observed so a 
new ionic method or covalent method of enzyme attachment should be investigated. 
 
The current system uses a large amount of NAD+ within the reaction solution, and whilst 
this can be easily removed from the product, it may be possible to remove it and recycle 
it.  Aside from the incorporation of a His-tag into the protein, the TbINO1 gene being 
used has not been modified in any way.  It is now possible to modify proteins to allow for 
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a wider substrate scope, have activity within a larger range of solvents and temperatures, 
improve lifetime, or switch the stereoselectivity of the reaction.127  Directed evolution 
could be used to produce an INO1 gene that produces an enzyme that is much more stable 
or active.  With no crystal structure of TbINO1 available at this time, design and 
mutagenesis of specific sites would not be viable. 
 
The starting material for the biocatalysis, D-glucose 6-phosphate (18), is inexpensive 
when compared to the highly valuable product that it is used to produce.  However, 
within a commercial setting it is always better to start from a material that is as low in 
cost as possible.  D-Glucose 6-phosphate (18) could be obtained from a glucose 
phosphorylase and fed directly into the TbINO1 reaction.  The D-glucose itself could 
even be produced from starch.  This really would be a cheap starting material that could 
be converted into a highly valuable product in as little as three steps.  It is probable that 
the most expensive component for this process would be adenosine triphosphate (ATP) in 
the phosphorylation of D-glucose.  However, methods can be used in parallel to recycle 
cofactors, such as ATP, and produce an efficient system.128 
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Chapter Four 
 
4  Studies Towards The Synthesis Of epi-Mycothiol 
 
4.1  Introduction 
 
The actinomycetes form a diverse group of Gram-positive bacteria containing species that 
are of high pharmacological interest.129  A member of this family of organisms is 
mycobacteria, which contain a number of pathogenic organisms that cause serious 
diseases in mammals, including M. tuberculosis, Mycobacterium leprae, Mycobacterium 
bovis and Mycobacterium avium.130  The disease tuberculosis (TB) is caused by M. 
tuberculosis, and remains a major global health problem.   An estimated 9 million people 
developed TB in 2013 and it is second to only human immunodeficiency virus (HIV) as 
the leading cause of death from an infectious disease worldwide (1.5 million deaths 
estimated in 2013).131 
 
Treatment of diseases that are caused by mycobacteria is very difficult.130  These 
organisms are incredibly adept at surviving in macrophages and can tolerate a variety of 
environmental conditions.  Changes in oxidative levels caused by oxidative stress or 
hypoxia are well tolerated by these organisms, as well as varying pH conditions and 
changes to metal ion concentrations.  Variation of available nutrients can be easily dealt 
with, and they are also well protected against reactive oxygen and nitrogen 
species.130,132,133  Treatment for TB therefore requires multidrug therapy over extended 
periods of time (typically 6-9 months) and it is often unsuccessful.134,135 
 
The first drug used to treat TB was streptomycin, which was introduced in 1944.  Drug 
resistance emerged not long after its introduction, thought mainly to be due to its use as a 
monotherapy.  Several other drugs have now been identified as having anti-TB activity, 
and it is now common practise to use multidrug therapy to treat the disease.136  The 
current recommended treatment for drug-susceptible TB requires a minimum of 6 months 
of treatment with two phases: the intensive phase of taking four different drugs (isoniazid 
(121, Figure 4.1.1), rifampicin (122), pyrazinamide (123) and ethambutol (124)) for a 2 
month period, and the continuation phase, typically consisting of taking isoniazid and 
rifampicin for 4 months.137  This therapy achieves cure rates of >95 % when administered 
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under directly observed therapy.  There are, however, significant issues associated with 
the current therapeutic regime: drug intolerance and associated toxicities, 
pharmacokinetic drug-drug interactions (particularly amongst patients co-infected with 
TB and HIV), and, due to the lengthy treatment duration needed for a non-relapsing cure, 
patient adherence to the regimen.137  
 
 
Figure 4.1.1 – Drugs currently used in the first-line treatment of TB. 
 
One of the biggest obstacles in the treatment of TB is drug resistance.  Multi-drug-
resistant TB (MDR-TB) is caused by strains of M. tuberculosis that are resistant to at 
least rifampicin and isoniazid.136 It can be treated by the second-line drugs: kanamycin, 
capreomycin, amikacin, para-aminosalicylic acid, cycloserine, terizidone, thionamine, 
protionamide and fluoroquinolones: levofloxacin, moxifloxacin and ofloxacin (Table 
4.1.1).138  3.5 % of new and 20.5 % of previously treated TB cases were determined to 
have MDR-TB in 2013, giving a total of 480,000 people with MDR-TB in 2013.131  Out 
of these patients, 9.0 % were determined to have extensively drug-resistant TB (XDR-
TB).131  This is categorised by TB strains that are resistant to both rifampicin and 
isoniazid, and are further resistant to any of the fluoroquinolones and to at least one of the 
second-line drugs kanamycin, capreomycin and amikacin.136  With aggressive treatment 
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regimens it is possible to achieve cure rates of up to 60 % of patients with XDR-TB.  
Instances of drug resistance beyond that of XDR-TB have been described and highlight 
the need for new drugs for drug-resistant TB.137   
 
First-line Second-line 
Isoniazid Kanamycin 
Rifampicin Capreomycin 
Pyrazinamide Amikacin 
Ethambutol para-Aminosalicylic acid 
Streptomycin Cycloserine 
 Terizidone 
 Thionamide 
 Protionamine 
 
Fluoroquinolones: levofloxacin, 
moxifloxacin and ofloxacin. 
 
Table 4.1.1 - Drugs used to treat TB, MDR-TB and XDR-TB. 
 
4.1.1  Mycothiol 
 
Many organisms make use of low molecular weight thiols to help cells deal with 
oxidative stress and maintain redox homeostasis.139  These molecules primarily act as 
redox buffers and reducing cofactors, aiding important biological functions such as DNA 
synthesis and formaldehyde reduction.139 Most higher organisms utilise glutathione (125, 
Figure 4.1.2), a cysteine containing tripeptide, as the dominant thiol for this purpose.  
However, in some eukaryotic parasites glutathione is not the dominant thiol and a range 
of different thiols, such as trypanothione in kinetoplastids, are utilised instead of 
glutathione for this role.140  
 
Studies of Streptomyces clavuligerus141 led to the discovery of a novel cysteine 
derivative.  It was noted that this thiol was produced throughout the growth cycle of the 
organism in millimolar levels, suggesting that this compound acts as an antioxidant 
thiol.142 Sakuda et al.143 were the first to report the structure of this compound, first as the 
symmetrical disulfide isolated from Streptomyces sp. AJ 9463 and later as the sulfide 16 
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derived from Mycobacterium bovis and Streptomyces clavuligerus.142,144  The sulfide 16, 
1-O-(2-[N-acetyl-L-cysteinyl]amido-2-deoxy-α-D-glucopyranosyl)-D-myo-inositol was 
given the common name mycothiol due to its prevalence in mycobacteria.129 
 
 
Figure 4.1.2 – Structures of glutathione (125) and mycothiol (16). 
 
Studies141,145 have shown that mycothiol 16 is the major low molecular weight thiol in 
most actinomycetes, but is not even present in other representative bacteria or 
eukaryotes.129 The actinomycetes form a diverse group of Gram-positive bacteria 
containing species that are of high pharmacological interest.  One of the species with the 
highest mycothiol 16 content has been shown to be M. tuberculosis.145 
 
As a low molecular weight thiol, mycothiol (16) acts to help reduce toxic oxidants and 
maintain an intracellular reducing environment within mycobacteria thereby playing a 
key role in oxidative stress management and drug resistance.129  Mycothiol (16) can 
detoxify electrophilic species, including drugs, within the cell by formation of a conjugate 
126 (Scheme 4.1.1).  The enzyme mycothiol S-conjugate amidase (MCA) or mycothiol 
deacetylase (MshB) will then cleave the conjugated cysteinyl residue from the rest of the 
molecule, producing a mercapturic acid 127.146  This is just one method by which 
mycothiol (16) is used by mycobacteria to maintain a healthy cellular environment. 
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Scheme 4.1.1 – Detoxification of electrophilic species (EX) within a cell by mycothiol 
(16).  Reagents and conditions:  i. Mycothiol S-conjugate amidase (MCA) or mycothiol 
deacetylase (MshB). 
 
It is hypothesised that M. tuberculosis could become vulnerable to therapeutics and other 
stress factors if the enzymatic pathways in the biosynthesis of mycothiol (16) or it’s roles 
within the cell are interrupted.147  For this reason, mycothiol (16) and analogues thereof 
are important synthetic targets that could lead to therapeutic treatments for 
tuberculosis.146  With access to mycothiol (16) and intermediates within its biosynthesis, 
scientists can investigate the properties and mechanisms of the enzymes involved in this 
process.  With a deeper understanding of the enzymes, inhibitors can be designed to 
interrupt this biosynthesis. 
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Scheme 4.1.2 – Biosynthesis of mycothiol (16).  Reagents and conditions:  i. INO1;  ii. 
MshA;  iii. a. MshA2  b. MshB;  iv. L-cysteine, MshC, adenosine triphosphate (ATP);  v. 
MshD, acetyl-coenzyme A. 
 
The biosynthesis of mycothiol (16) is accomplished in six steps, starting from D-glucose 
6-phosphate (18, Scheme 4.1.2).  In the first step of the biosynthesis, myo-inositol 1-
phosphate synthase (INO1) acts to convert this compound into L-myo-inositol 1-
phosphate (19).  Mycothiol glycosyltransferase (MshA) produces a glycosidic linkage 
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between N-acetylglucosamine and the 3-position of L-myo-inositol 1-phosphate (129) 
before the phosphate and acetyl groups are cleaved by mycothiol phosphatase (MshA2) 
and MshB respectively.  Coupling of amine 128 and L-cysteine by action of mycothiol 
ligase (MshC) in the presence of adenosine triphosphate (ATP) produces 130, which 
undergoes acetylation by mycothiol synthase (MshD) and acetyl coenzyme A to produce 
mycothiol (16).148 
 
From previous studies149,150 on the biosynthesis of mycothiol (16) within M. tuberculosis, 
MshA and MshC have been shown to be crucial to this process.  With convenient access 
to the substrates and products of these enzymes mechanistic and inhibitory studies can be 
conducted to potentially furnish new therapeutics for tuberculosis.  The synthesis of 
mycothiol (16) and its biosynthetic intermediates is not trivial, with the presence of a 
myo-inositol ring attached through the 1-position. 
 
4.1.2  Synthetic Routes to Mycothiol and Analogues 
 
With mycothiol (16) highlighted as an important synthetic target in the search for 
therapeutics for TB, there are published syntheses of the natural product and analogues.  
The routes are quite lengthy and are also criticized because they have only been 
conducted on small scales.   Both of these issues can be attributed to the requirement of 
introducing an enantiopure myo-inositol moiety within the structure. 
 
Synthetic routes to mycothiol (16) all follow the same general retrosynthetic approach 
(Scheme 4.1.3).  Disconnections at the glycosidic and amide bonds lead to glucosamine 
(131), L-cysteine (132) and a protected myo-inositol derivative (133).129  There are three 
main issues in the synthesis of mycothiol (16) that synthetic routes need to overcome: 
anomeric selectivity within the glycosylation reaction, cysteine epimerisation during side 
chain addition, and synthesis of the enantiopure myo-inositol derivative (133).129 
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Scheme 4.1.3 – General retrosynthetic route for mycothiol (16). 
 
The first total synthesis of mycothiol (16) was conducted in 200421 with a total of 11 
steps in the longest linear sequence, and a total yield of only 0.4 % from myo-inositol (1).  
The first key building block in the synthesis was the enantiopure myo-inositol derivative 
137 (Scheme 4.1.4).  They formed the racemic diol (±) 74 with 1-ethoxycyclohexene 
before selective benzylation gave alcohol (±)134.  The D- and L-myo-inositol isomers 
were separated by conversion to their diastereoisomeric camphanate esters using a chiral 
auxiliary.  Taking single diastereoisomer 135, they produced pentaacetate 136 via 
cleavage of the camphanate ester and ketals, and peracetylation.  Removal of the benzyl 
group afforded enantiopure alcohol 137.21 
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Scheme 4.1.4 – Synthesis of glycosylation acceptor 137.21  Reagents and conditions:  i. 
1-Ethoxycyclohexene, pTsOH, DCM, 100 °C, 23 %;  ii. NaH, BnBr, toluene, 130 °C then 
RT, 54 %;  iii. (1R)-(+)-camphanic chloride, DMAP, Et3N, DCM, 49 %;  iv. a. KOH, 
EtOH, 97 %;  b. AcOH, water, 100 °C;  c. Ac2O, pyridine, 89 % over 2 steps;  v. H2, Pd-
C, EtOAc, 97 %. 
 
With the desired alcohol 137 in hand, the completion of mycothiol (16) is outlined in 
Scheme 4.1.5.  Trimethylsilyl trifluoromethanesulfonate (TMSOTf) mediated 
glycosylation of alcohol 137 and trichloroacetamidate 138 (synthesised in 3 steps, 13 % 
yield) gave a 9:1 ratio of anomers (α:β) in a 65 % yield.  Reduction of the azide 139 gave 
the amine 140, which could be coupled to N,S-diacetyl-L-cysteine using O-(7-
azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) with 
1-hydroxy-7-azabenzo-triazole (HOAt) and collidine.  It should be noted that 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC) and N,N’-dicyclohexylcarbodiimide (DCC)  
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Scheme 4.1.5 – The first total synthesis of mycothiol (16).21  Reagents and conditions:  i. 
TMSOTf, molecular sieves, DCM, 0 °C, 56 %;  ii. H2, Pd-C, EtOAc, HCl (2 M, aq.), 
81 %;  iii. N,S-diacetyl-L-cysteine, HATU, HOAt, collidine, DMF, 0 °C to RT, 25 %;  iv. 
Mg(OMe)2, MeOH, 69 %;  v. bis(2-mercaptoethyl)sulfone, water, 100 %. 
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were also used for this coupling, however they both gave epimerisation of the cysteine 
and lower yields.  Treatment of protected mycothiol 141 with dimethoxymagnesium 
removed the acetate groups from the hydroxyls and thiol, giving mycothiol (16) and 
mycothiol disulfide (142), which could be converted into mycothiol (16) by treatment 
with bis(2-mercaptoethyl)sulfone in water for 5 days.21 
 
 
Scheme 4.1.6 – α–Selective glycosylation.151  Reagents and conditions:  i. MeSCHCl, 
NaI, NaH, THF, 74 %;  ii. SO2Cl2, DCM, 0 °C, then 145, BEMP, THF, 98 %;  iii. PhSCl, 
AgOTf, DCM, MeCN, -78 to -20 °C, 93 %. 
 
Since then a considerable effort has been made to improve the glycosylation reaction.  
Knapp et al.151 synthesised mycothiol (16) utilising an intramolecular glycosylation 
reaction.  When complex glycosylation donors and acceptors are required, this method 
has several advantages over intermolecular glycosylation.  Firstly, the donor and acceptor 
are absolutely present in a 1:1 ratio, meaning that there will be less potential for loss of 
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highly valuable starting materials.  The tether between the donor and acceptor means that 
the aglycon is delivered in a syn fashion.  It holds the two species within close proximity, 
allowing for rapid reaction and less likelihood of nonproductive donor elimination or 
hydrolysis.151  By careful design and synthesis of glycosylation substrates 144 and 145 
(Scheme 4.1.6), Knapp et al. demonstrated that selective intramolecular α-glycosylation 
was indeed possible.151  For the synthesis of the glycosylation substrate 146, the protected 
myo-inositol 143 was initially converted into the methylthiomethyl ether 144.  2-tert-
Butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphine (BEMP) was 
used to couple sulfonamide 145 (prepared in 2 steps from 1,3,4,6-tetra-O-acetyl 
glucosamine) with in situ formed chloromethylether of 144, producing desired substrate 
146.  They could furnish the α-glycosylation product 147 in 93 % yield by treatment with 
phenylselenyl chloride and catalytic silver (I) trifluoromethanesulfonate (AgOTf).151   
 
 
Scheme 4.1.7 – Completion of mycothiol (16).151  Reagents and conditions:  i. a. 
NaOMe, MeOH;  b. Na(Hg), Na2HPO4, MeOH, 74 % over 2 steps;  c. H2, Pd(OH)2, HCl 
(2 M, aq.), tert-butanol (aq.);  ii. N-Boc-S-acetyl-L-cysteine, HATU, Hünig’s base, DMF, 
0 to 20 °C, 77 %;  iii. a. trifluoroacetic acid, DCM;  b. pyridine;  c. concentrate. 
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They went on to complete the synthesis of mycothiol (16, Scheme 4.1.7) via global 
deprotection to produce amine 128, before coupling with N-tert-butyloxycarbonyl-S-
acetyl-L-cysteine gave protected thiol 148.  tert-Butyloxycarbonyl (Boc) deprotection and 
dissolution in pyridine allowed acetyl group migration from the thiol to the amine, and 
subsequent removal of pyridine furnished mycothiol (16).151 
 
 
Scheme 4.1.8 – Synthesis of optically pure protected myo-inositol 143.151  Reagents and 
conditions:  i. a. BnCl, KOH, reflux, 16 hr;  b. AcOH, water, 75 % over 2 steps;  ii. a. 
nBu2SnO, benzene, reflux, 24 hr, then AllBr, TBABr, 60 °C, 36 hr, 96 %;  b. NaH, BnBr, 
DMF, 24 hr, 97 %;  iii. Wilkinson’s catalyst, DABCO, ethanol (90 %, aq.), reflux, 3 hr, 
then AcOH, water, THF, reflux, 4 hr, 93 %;  iv. (+)-menthoxycarbonyl chloride, pyridine, 
72 %;  v. HCl, MeOH, 93 %.   
 
The protected myo-inositol 143 was prepared via a resolution methodology based upon 
purification of a mixed (+)-menthol carbonate (Scheme 4.1.8).151,152  Racemic (±) 143 
was synthesised in six steps from myo-inositol (1).153  Initially the OH-1 and OH-2 were 
protected as the ketal (±) 149 in 74 % yield.  Benzylation, followed by ketal cleavage 
produced diol (±) 150, which was selectively allylated at the more reactive equatorial 
hydroxyl.  Subsequent benzylation produced the fully protected myo-inositol (±) 151, 
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before removal of the allyl group gave the racemic protected myo-inositol (±) 143.  
Introduction of the (+)-menthol carbonate allowed separation of diastereoisomers and 
isolation of carbonate 152.152  Removal of the carbonate group then furnished the 
optically pure protected myo-inositol 143. 
 
In this work, Knapp et al.151 completed the synthesis of the natural product mycothiol 
(16) more efficiently than the first total synthesis.  They were able to conduct a more 
efficient glycosylation using an intramolecular methodology, and their incorporation of 
the N-acetyl-L-cysteine moiety was completed in an elegant fashion with the observed 
acetyl migration.  However, their route to synthesise the optically pure protected myo-
inositol 143 that they required for the synthesis of their glycosylation substrate 144, was 
long, tedious and low yielding.  This moiety of the mycothiol (16) structure continues to 
be a stumbling point for synthesis.   
 
When initially designing potential inhibitors of mycothiol (16) biosynthesis, Knapp et 
al.147 replaced this moiety with a thioglycoside.  This not only removed the issue of myo-
inositol derivative synthesis, but thioglycosides have been shown to be more resistant to 
degradation by glycosidases.154  They were able to synthesise thioglycoside 158 (Scheme 
4.1.9) in an overall yield of 54 %. 
 
Treatment of peracetylated glucosamine 153 with Lawesson’s reagent gave the thiazoline 
154.  Hydrolysis furnished the thiol 155, which could be converted into a free radical 
using azobisisobutyronitrile (AIBN) and added into cyclohexene to produce the 
cyclohexyl thioglycoside 156.  Removal of the acetyl groups using hydrazine furnished 
the triol 157, before introduction of N-Boc-S-acetyl-L-cysteine and subsequent treatment, 
as conducted previously (Scheme 4.1.7), gave the thioglycoside 158 in excellent yield.147   
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Scheme 4.1.9 – Synthesis of thioglycoside 158.147  Reagents and conditions:  i. 
Lawesson’s reagent, toluene, 80 °C, 100 %;  ii. TFA, wet MeOH, 100 %;  iii. 
cyclohexene, AIBN, chloroform, reflux, 79 %;  iv. hydrazine monohydrate, 120 °C, 
84 %;  v. a. N-Boc-S-acetyl-L-cysteine, EDCI, DMF, 82 %;  b. TFA;  c. pyridine;  d. 
Sephadex, 100 % over 3 steps. 
 
Using thioglycoside 158 they were able to show that thioglycosides of this type were 
turned over by the MCA enzyme, and therefore have the potential to serve as a good 
foundation to build inhibitors.147  Testing with this enzyme was conducted by initially 
converting thioglycoside 158 and mycothiol 16 into their bimane derivatives 159 and 160 
(Scheme 4.1.10), respectively.  They could then subject these derivatives to cleavage by 
the M. tuberculosis MCA enzyme, and use a fluorescence-detected HPLC assay to 
monitor production of the cysteine-S-bimane product 161.  The specific activities for the 
thioglycoside-S-bimane 159 and mycothiol-S-bimane 160 were determined to be 7500 
and 14200 nmol min-1 mg-1 protein-1 respectively.147 
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Scheme 4.1.10 – Assay used to determine thioglycoside 158 activity with the M. 
tuberculosis mycothiol S-conjugate amidase (MCA) enzyme.147  Reagents and 
conditions:  i. Bromobimane, Tris hydrochloride buffer (20 mM, pH 8.0);  ii. MCA 
(recombinant M. tuberculosis), Tris buffer (50 mM, pH 7.4), 32 °C. 
 
Whilst the thioglycoside-S-bimane 159 is a good substrate for the M. tuberculosis MCA 
enzyme, the mycothiol-S-bimane 160 has a greater specific activity.  This can be 
attributed to better binding within the enzyme active site, which can only be made 
possible by the natural product’s myo-inositol moiety.  If an antibiotic was produced 
based upon the thioglycoside structure then it would have to compete with the natural 
mycothiol derived substrates.  Inclusion of the myo-inositol moiety will be important to 
increase the efficacy of any future antibiotics produced. 
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4.2  epi-Mycothiol Synthesis 
 
The large scale biocatalytic production of L-myo-inositol 1-phosphate (19) as conducted 
in this project, provides vast quantities of an important biosynthetic intermediate in the 
biosynthesis of mycothiol (16).  MshA has been highlighted as a crucial enzyme in the 
synthesis of mycothiol (16) within M. tuberculosis.150 The previous work93 on this 
enzyme had used a very inefficient method of producing L-myo-inositol 1-phosphate (19) 
and, now, with access to large quantities of both of the substrates for this enzyme, further 
studies on enzyme structure and mechanism can be conducted with more ease. 
 
With 1-bis(phenyloxy)phosphoryl-L-myo-inositol (116) in hand, the synthesis of 
mycothiol (16) and, in particular, epi-mycothiol (164, Scheme 4.2.1) should be rapidly 
achieved.  Intermediates within a mycothiol (16) synthesis, can be used to form amine 
128, an advanced intermediate in the biosynthesis of mycothiol (16).  This compound is 
the substrate for MshC, an enzyme that has also been shown as crucial for the 
biosynthesis of mycothiol (16) within M. tuberculosis.149 This is a better point to target 
the biosynthesis of mycothiol (16) than MshA as it is later in the process and should have 
less resemblance to molecules present within the human cell.  
 
Although it is not the original natural product, epi-mycothiol (164) is also desirable as it 
could help answer questions about the biosynthesis or chemistry of mycothiol (16) within 
a cell.  Within the synthesis of epi-mycothiol (164), we would therefore have access to a 
diastereomer of 128 and a diastereomer of the natural product.  This may be useful in 
studying the binding site of the enzymes involved, as the hydroxyls of the myo-inositol 
moiety will be presented slightly differently.   
 
Our retrosynthesis of these compounds uses the same initial strategy as those routes 
within the literature.  Retrosynthetic disconnections of the glycosidic bond and the amide 
bond of epi-mycothiol (164) initially gave the fluoride 165, N-acetyl thiazolidine 166 and 
the inositol glycosylation acceptor 167 (Scheme 4.2.1). 
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Scheme 4.2.1 – Retrosynthetic analysis of epi-mycothiol (164). 
 
As previously discussed in section 4.1.2, the synthesis of a protected inositol 
glycosylation acceptor, such as 167, is extremely difficult to achieve.  We envisage that 
by utilising the L-myo-inositol 1-phosphate (19) produced from the biocatalysis, we can 
furnish the glycosylation acceptor 167 in a concise and efficient synthesis.  The synthesis 
of a glycosylation acceptor for mycothiol (16) would require extra steps, this is something 
that we hope to achieve once a proof of principle is conducted with 167. 
 
4.2.1  Glucosamine Section 
 
Flouride 165 is a common intermediate in the synthesis of mycothiol (16), and as a result 
there are already a number of synthetic routes to this compound.  Following the work of 
Seeberger et al.,155 introduction of the azide functionality was initially accomplished by 
treatment of glucosamine (131, Scheme 4.2.2) with trifluoromethanesulfonyl azide (triflic 
azide, TfN3) with catalytic copper (II) sulfate (CuSO4).  Subsequent peracetylation gave 
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the tetraacetate 168, which could be selectively deprotected at the anomeric position 
using benzylamine.  The resulting alcohol 169, could then be converted into the fluoride 
165 via treatment with diethylaminosulfur trifluoride (DAST). 
 
 
Scheme 4.2.2 – Synthesis of fluoride 165.  Reagents and conditions:  i. a. TfN3, 
CuSO4.5H2O, K2CO3, DCM, MeOH, water;  b. Ac2O, pyridine, DMAP, 73 % over 2 
steps  ii.  Benzylamine, Et2O, 77 %;  iii. DAST, THF, -30 °C then RT, 87 %. 
 
The initial step in the synthesis, the azidation of glucosamine (131), furnished the desired 
tetraacetate 168 in good yield after peracetylation.  This procedure can achieve very high 
yields in mild reaction conditions, with retention of configuration and good compatibility 
with most functional groups.156  However, this procedure has many issues associated with 
it.156,157  
 
Firstly, triflic azide is explosive when not in solution and has a fairly poor shelf-life, 
meaning that it must be prepared immediately prior to use.  The original procedure to 
prepare triflic azide was to add trifluoromethanesulfonyl anhydride (triflic anhydride) to a 
vigorously stirred biphasic mixture of dichloromethane and saturated aqueous sodium 
azide solution.  With these conditions, hydrolysis of triflic anhydride will occur and, 
therefore, it is necessary to use a large excess of the reagent and sodium azide.156  These 
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are both highly toxic reagents and triflic anhydride is relatively expensive.157  This 
procedure also leaves triflic azide as a solution in dichloromethane after extraction, a 
solvent that is not very versatile for use in general diazotransfer reactions.156  The 
diazotransfer reaction being conducted here is carried out in a mixture of methanol, water 
and dichloromethane.  The ratio of these solvents must be exactly 3:10:3 
(methanol:water:dichloromethane) to minimise precipitation of salts from the reaction.158  
This ratio can have a dramatic influence the reaction, and the reaction can still be 
unpredictable and troublesome.156  In replicate experiments, the yield of this reaction 
varied greatly, with a 72 % yield after acetylation only being produced on one occasion. 
 
Ultimately, a different method was needed to accomplish the azidation with a consistent 
yield.  Work by Stick et al.,157 had already addressed this problem.  They were able to 
develop a method of diazotransfer that bypasses the majority of these problems.  By using 
imidazole-1-sulfonyl azide (170, Scheme 4.2.3) as a replacement for triflic azide, they 
discovered a method that is inexpensive, robust and safe.  Conversion of imidazole-1-
sulfonyl azide (170) to the hydrochloride salt makes the new reagent a crystalline solid 
and very easy to handle.  Impact tests, vigorous grinding and prolonged heating did not 
produce an explosive reaction.  They used imidazole-1-sulfonyl azide (170) in a very 
similar system to that used for triflic azide and were able to affect the azidation of a range 
of amines under mild conditions with retention of stereochemistry and in high yields.157 
 
 
Scheme 4.2.3 – Synthesis and utilisation of imidazole-1-sulfonyl azide (168) as a 
diazotransfer reagent.  Reagents and conditions:  i. Sodium azide, MeCN, then imidazole, 
0 °C, 90 %;  ii. a. glucosamine hydrochloride, CuSO4.5H2O, K2CO3, MeOH;  b. Ac2O, 
pyridine, DMAP, 68 % over 2 steps. 
 
Using imidazole-1-sulfonyl azide (170) in the synthesis of the desired azide 168 gave 
good results (Scheme 4.2.3), and was preferred over the use of triflic anhydride mainly 
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due to the consistency that this method provided.  Synthesis of the reagent (170) was 
achieved readily from imidazole, sodium azide and sulfonyl chloride. 
 
4.2.2  Cysteine Section 
 
In the retrosynthesis, it was envisaged that the N-acetyl L-cysteine moiety could be 
introduced into epi-mycothiol (164) via an amide coupling.  Routes from the literature 
utilise a protected thiol in this step to avoid side reactions.  There are many options 
available for this, but a thiazolidine was initially chosen.  In work by Payne et al.,159 they 
utilised the thiazolidine functionality to protect cysteine residues as they built long 
peptide chains.  Treatment with methoxyamine after completion of the chain converted 
the thiazolidine back into the required cysteine residue.  This route was favoured in our 
synthesis of epi-mycothiol (164) as it would allow protection of the amine with an acetyl 
group that could be carried through the synthesis.  Final unmasking of the thiazolidine 
should then leave the required N-acetyl group.  With this route in mind, N-acetyl-L-
thiazolidine-4-carboxylic acid (172, Scheme 4.2.4) was synthesised. 
 
 
 
Scheme 4.2.4 – Synthesis of N-acetyl thiazolidine 172.  Reagents and conditions:  i. 
Formaldehyde, water, 78 %;  ii. Ac2O, pyridine, 96 %. 
 
Starting from L-cysteine (132), treatment with formaldehyde formed the thiazolidine 171.  
Acetylation then produced desired acid 172 in good yield.  The final steps in the synthesis 
of epi-mycothiol (164) via this route would be the removal of the thiazolidine 
functionality.  In the literature,159 this is accomplished using methoxyamine.  However, in 
practise reactions on the N-acetyl thiazolidine 172, this procedure did not furnish any 
reaction and the desired N-acetyl cysteine 173 was not produced (Scheme 4.2.5). 
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Scheme 4.2.5 – Unproductive thiazolidine deprotection reaction.  Reagents and 
conditions:  i. Methoxyamine, water, pH 4. 
 
It was hypothesised that this problem could be overcome by using cyclopentanone (174, 
Scheme 4.2.6) instead of formaldehyde to form a spirothiazolidine (175).  Within this 
type of moiety the thiazolidine ring will be more strained, as it has to accommodate the 
bond geometries needed for the attached cyclopentane ring, and as a result much easier to 
remove.  Indeed, this proved to be the case.  However, the spirothiazolidine being formed 
(175) was too unstable, and would ring open within the reaction conditions for its 
formation.  This was observed by 1H NMR spectroscopy, with the ratio of starting 
material to product fluctuating throughout the course of the reaction.  A starting material 
to product ratio of 2.5:1 was generally observed, with no improvement upon heating the 
reaction to 40 °C or reflux.  Starting with the methyl ester of L-cysteine (176) gave no 
advantage, and the fluctuation between starting material and product (177) was still 
observed.  Therefore, using a thiazolidine functionality to protect the thiol of the L-
cysteine was abandoned.   
 
 
Scheme 4.2.6 – Spirothiazolidine formation using cyclopentanone (174).  Reagents and 
conditions:  i. Water, pH 2, 16 hr. 
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In work by Knapp et al.,151 they accomplished introduction of the L-cysteine moiety into 
mycothiol (16) via addition of N-Boc-S-acetyl-L-cysteine (179, Scheme 4.2.7).  
Subsequent Boc deprotection and dissolution in pyridine allowed for the transfer of the 
acetyl group from the thiol to the amine, as required for the natural product.  Following 
this route (Scheme 4.2.7), N-Boc-S-acetyl-L-cysteine (179) was prepared from N,N’-
bis(Boc)-L-cystine (178) via zinc reduction and in situ S-acetylation.  Unfortunately, the 
product was only obtained in a 27 % yield as a mixture of the acid 179 and mixed 
anhydride 180.   
 
 
Scheme 4.2.7 – Formation of N-Boc-S-acetyl-L-cysteine (179) and its mixed anhydride 
180.  Reagents and condition:  i. a. Zinc (dust), AcOH;  b. Ac2O, pyridine. 
 
The idea of using a protected derivative of cystine (182, Scheme 4.2.8) as a means to 
introduce the cysteine moiety is attractive as it would allow amide couplings on both ends 
of the molecule, before reduction can produce the free thiol.  Procedures from the 
literature160,161 were able to furnish N,N’-diacetyl-L-cystine (183, Scheme 4.2.8) from L-
cysteine (132) by treatment with acetic anhydride under aqueous basic conditions.  
Attempts to follow these procedures resulted in the formation of N,S-diacetyl-L-cysteine 
(181) and the desired cystine 183 was not observed.  
 
Initial attempts at the straight acetylation of L-cystine (182) were not productive, with no 
acetylation occurring from treatment with acetic anhydride in saturated sodium 
bicarbonate solution.  In the end, acetylation of L-cystine (182) was achieved by careful 
manipulation of the pH of the reaction.  The starting material was dissolved in sodium 
hydroxide solution (15 %, aq.) and cooled to 0 °C.  Drops of acetic anhydride and sodium 
hydroxide solution (30 %, aq.) were added alternately until complete addition of the 
acetic anhydride was completed.  The reaction was then stirred at the same temperature 
for 2 hours, before being concentrated.  Fortuitously, the product was solely soluble in 
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acetic acid and dissolution within this solvent followed by filtration and concentration 
furnished pure N,N’-diacetyl-L-cystine (183). 
 
 
Scheme 4.2.8 – Synthesis of N,S-diacetyl-L-cysteine (181) and N,N’-diacetyl-L-cystine 
(183).  Reagents and conditions:  i. Ac2O, KOH, water, pH 10-10.5, 0 °C, 24 %;  ii. 
Ac2O, NaOH (30 %, aq.), 0 °C, 98 %. 
 
4.2.3  Inositol Section 
 
The synthesis of epi-mycothiol (164) requires a L-2,3,4,5,6-O-protected glycosylation 
acceptor, such as 167 (Scheme 4.2.9). Synthesis of myo-inositol derivatives that have this 
enantiopure pattern of protection has been extremely difficult to achieve within the 
literature (see Section 4.1.2).21,151 With 1-bis(phenyloxy)phosphoryl-L-myo-inositol (116) 
readily available, it was possible to envisage a concise route to an optically pure 
derivative of this type (Scheme 4.2.9).   
 
 
Scheme 4.2.9 – Proposed route to a protected glycosylation acceptor (167).  Reagents 
and conditions:  i. Benzylation;  ii. hydrolysis. 
 
 128
Protection of the five hydroxyls with a suitable group, would allow cleavage of the 
dibenzyl phosphate to reveal the free alcohol (167).  Ideally, the cleavage of the dibenzyl 
phosphate would be conducted in one hydrolysis step.  The group used to protect the 
hydroxyl groups should therefore be stable to acid or base hydrolysis.  Initially, a benzyl 
group was chosen as an ideal candidate. 
 
The benzylation of the five hydroxyl groups proved to be extremely difficult to achieve.  
One of the main issues associated with the attempted benzylation was the poor solubility 
of the starting material.  The 1-bis(phenyloxy)phosphoryl-L-myo-inositol (116) could 
only be dissolved in water and methanol.  Whilst methods of benzylation do exist for 
reaction in protic polar solvents, they are not ideal due to the potential quenching of 
reactive intermediates. 
 
Initial attempts at the perbenzylation were made using pyridine as a potential solvent.  
The starting material was not soluble in pyridine, but it was hypothesised that if some 
reaction was to occur then the partially benzylated product would be taken up by this 
solvent and the reaction could then proceed more rapidly.  Using an excess of benzyl 
bromide (50 equivalents) as a benzylation reagent did not furnish any reaction at all.  
Addition of tetrabutylammonium iodide (TBAI) did nothing to help the situation, and 
again no reaction was observed.   
 
Previously, phenyldiazomethane (115) had been used as a reagent for the selective 
benzylation of the phosphate group.  It was hypothesised that with a tweak to the reaction 
conditions, this reagent could be used to achieve perbenzylation on either the L-myo-
inositol 1-phosphate (19) or 1-bis(phenyloxy)phosphoryl-L-myo-inositol (116).  Attempts 
at the perbenzylation of both of these substrates were conducted by treatment with an 
excess of the reagent in methanol at room temperature overnight.  1-
Bis(phenyloxy)phosphoryl-L-myo-inositol (116) failed to react with phenyldiazomethane 
and L-myo-inositol 1-phosphate (19) was converted efficiently into 1-
bis(phenyloxy)phosphoryl-L-myo-inositol (116), but the reaction did not progress past 
this point.   
 
Within the literature, Lewis acids have been shown to facilitate the benzylation of 
secondary hydroxyl groups by phenyldiazomethane with methanol as solvent.  
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Chittenden162 was able to effect the selective benzylation of the secondary hydroxyl 
group within glycerol (185) using tin (II) chloride as a Lewis acid (Scheme 4.2.10). 
 
 
Scheme 4.2.10 – Selective secondary alcohol benzylation using phenyldiazomethane and 
tin (II) chloride.162  Reagents and conditions:  i. Tin (II) chloride, MeOH, DCM, 48 hr, 
28 %. 
 
Unfortunately, efforts to conduct the Lewis base promoted benzylation of 1-
bis(phenyloxy)phosphoryl-L-myo-inositol (116) using phenyldiazomethane proved 
unsuccessful.  Tin (II) chloride and cerium (III) chloride were trialled for this purpose as 
they were readily accessible, but catalytic addition of neither of these Lewis bases 
afforded any benzylation of the substrate. 
 
An example was found in the literature of fluoroboric acid being used in conjunction with 
phenyldiazomethane to efficiently benzylate alcohols.163  Addition of this reagent to the 
reaction, however, proved unsuccessful with 1-bis(phenyloxy)phosphoryl-L-myo-inositol 
(116). 
 
Formation of a tin acetal with dibutyl tin oxide (nBu2SnO) and subsequent treatment with 
benzyl bromide is known as a method of selectively benzylating diols.48  This method can 
be used to obtain selectivity in which of the two hydroxyl groups are being protected, but 
also requires a diol for reaction due to the formation of the tin acetal.  This method should 
therefore lend itself to reaction within methanol. 1-bis(phenyloxy)phosphoryl-L-myo-
inositol (116) was refluxed with nBu2SnO in a mixure of methanol and toluene for 6 hours 
to form the tin acetal.  The reaction was concentrated before dissolution in toluene and 
addition of benzyl bromide and tetrabutylammonium bromide.  The mixture was refluxed 
overnight, however, no benzylated product was observed, and it appears as though the tin 
acetal was not formed in the first instance.  The reaction was also attempted in 
acetonitrile with the same result. 
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With the benzylation of 1-bis(phenyloxy)phosphoryl-L-myo-inositol (116) proving 
elusive, a different protecting group was sought to effect the protection of the five inositol 
hydroxyls.  Ideally, a protecting group would be chosen that is stable at pH extremes 
whilst being able to be introduced with water or methanol as the solvent.  There was no 
ideal candidate with this chemistry that could be removed at the end of the epi-mycothiol 
(164) synthesis without major effects on the rest of the molecule.   
 
With reconsideration of the phosphate cleavage, acetylation of the hydroxyl groups 
looked like a viable option.  Treatment of 1-bis(phenyloxy)phosphoryl-L-myo-inositol 
(116) with acetic anhydride, pyridine and DMAP furnished the pentaacetate 187 (Scheme 
4.2.11) in a 22 % yield.  Repetition of the reaction with freshly distilled pyridine and a 
new bottle of acetic anhydride pushed the yield up to only 27 %.  Unfortunately, it did not 
seem possible to achieve a higher yield for this step.  As the reaction progressed, a side 
product was being formed in the reaction, which meant that formation of the product 
seemed to be capped at 27 %.  The side product was not observed by thin-layer 
chromatography (TLC) until roughly 5 hours after beginning, but after this point it 
appeared that no more of the desired product was being produced.  Exclusion of DMAP 
from the reaction mixture had little to no effect on the reaction outcome.  Conducting the 
reaction overnight, with the DMAP absence still produced the side product and a 
similarly low yield of the desired pentaacetate 187.  It is hypothesised that this side 
product is the result of some type of rearrangement occurring with the phosphate moiety,  
although the identity of this compound is not clear from crude 1H NMR data.  If time had 
allowed, further investigation into this side product would have been investigated. 
 
 
Scheme 4.2.11 – Peracetylation of 1-bis(phenyloxy)phosphoryl-L-myo-inositol (116).  
Reagents and conditions:  i. Ac2O, pyridine, DMAP, 27 %. 
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Alternative methods to acetylate 1-bis(phenyloxy)phosphoryl-L-myo-inositol (116) 
proved unsuccessful.  These methods involved trying to acetylate in aqueous conditions, 
as conducted for the cystine 183, and using different solvents, DMF and DMSO.  Whilst 
not exhaustive, time constraints meant that the low yielding acetylation product was taken 
forward. 
 
With the five acetyl groups in place, it was necessary to remove the phosphate group.  
With hydrolysis originally being highlighted as an efficient method to do this, this was 
attempted first.  Obviously, the acetyl groups will cleave under basic hydrolysis 
conditions, so it was envisaged that by using aqueous hydrofluoric acid the phosphate 
could potentially be selectively cleaved.  The fluoride ion in aqueous hydrofluoric acid is 
much less nucleophilic, it therefore presents a much milder method for hydrolysis.  
Unfortunately, treatment of the pentaacetate 187 with hydrofluoric acid (48 %, aq.) at -15 
°C did not produce phosphate hydrolysis.  An increase in temperature to 0 °C and an 
extended reaction time of 3 days, was still not successful.  Even treatment of the substrate 
with hydrofluoric acid (48 %, aq.) at room temperature overnight, failed to produce any 
reaction at all, as monitored by TLC. 
 
An increase in nucleophilicity of the acid’s anion was sought, and it was hypothesised 
that by switching to hydrochloric acid in methanol and lowering the temperature to           
-15 °C it may be possible to obtain selective phosphate hydrolysis.  However, this was 
not the case and, even at this lower temperature, the acetyl groups were also removed. 
 
Turning once again to biology, phosphatases are a class of enzymes that have been widely 
used within synthesis to cleave phosphate groups from substrates.  Acid phosphatase from 
potato is commercially available as a lyophilised powder, and it was envisaged that this 
could be used as a mild and selective method of phosphate cleavage.  Initial attempts 
using the acid phosphatase were conducted with the phosphate still protected as the 
dibenzyl species 187.  No reaction was observed with this substrate and it was necessary 
to remove the benzyl groups prior to reaction. 
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Scheme 4.2.12 – Synthesis of glycosylation acceptor 189.  Reagents and conditions:  i. 
H2, Pd-C, EtOAc;  ii. acid phosphatase from potato, sodium acetate buffer (50 mM, pH 
5.2), DMSO, 37 °C, 79 % over 2 steps. 
 
The benzyl groups were removed by hydrogenolysis, furnishing the free phosphate 188 
(Scheme 4.2.12).  The acid phosphatase could then be used to cleave the phosphate and 
produce alcohol 189.  The reaction was conducted with shaking at 37 °C and pH 5.2 in a 
sodium acetate buffer (50 mM).  Addition of DMSO was necessary to aid the solubility of 
the phosphate 188 in the reaction, and the final product could be extracted into ethyl 
acetate.  Overall, this gives the desired glycosylation acceptor 189 in 4 steps and 21 % 
yield from the biocatalytically produced L-myo-inositol 1-phosphate (19).   
 
 
4.3  Conclusions 
 
Each of the three components outlined within the retrosynthesis of epi-mycothiol (164) 
have been produced.  The route to the glucosamine derived building block very closely 
follows work from within the literature, with the more reliable imidazole-1-sulfonyl azide 
(170) being used to introduce the azide functionality.  Use of N,N’-diacetylcystine (183) 
as a method of introducing the L-cysteine moiety has not been attempted within the 
literature.  The real strength of our synthesis has been demonstrated with the concise and 
enantiopure synthesis of the glycosylation acceptor 189.   
 
The 4-step route conducted to furnish 189 is a vast improvement on the long, tedious and 
low yielding routes within the literature.  Unfortunately, the yield of the acetylation is low 
and causes an overall yield of 21 %.  However, even with this taken into account, our 
route is still more concise and efficient.  With further work on this project, it is believed 
that a more efficient method of protection of the five hydroxyl groups could be 
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discovered.  One possibility is the use of benzyl trichloroacetamidate as a benzylating 
reagent.164 
 
 
Scheme 4.3.1 – Envisaged route to epi-mycothiol (164).  Reagents and conditions:  i. 
Glycosylation;  ii. a. reduction;  b. amide coupling;  iii. a. selective O-acetate 
deprotection;  b. disulfide reduction. 
 
With the three building blocks in hand, it is envisaged that the synthesis of epi-mycothiol 
(164) can be completed rapidly (Scheme 4.3.1).  Unfortunately, time constraints meant 
that this work could not be completed. 
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Chapter Five 
 
5  Conclusions 
 
Derivatives of myo-inositol (1) can be observed within a plethora of important and 
fundamental biological roles throughout nature.  They are incredibly important within 
cellular signalling as inositol phosphates and phosphatidylinositols and their phosphates.8  
Glycosylphosphatidylinositol (GPI) tethers proteins to the cell membrane,17 and the myo-
inositol core can be found within natural products such as mycothiol (16).21  
 
The synthesis of myo-inositol derivatives is challenging.  Inositol is a carbohydrate, 
although it contains no anomeric carbon, and as such faces the regioselective difficulties 
of classical carbohydrate chemistry.  In addition to this, myo-inositol chemistry is further 
complicated by the complex symmetry associated with this molecule, and the associated 
need for enantioselectivity within synthesis.8 
 
Trypanosoma brucei L-myo-inositol 1-phosphate synthase (TbINO1) is particularly 
efficient at converting D-glucose 6-phosphate (18) into L-myo-inositol 1-phosphate (19), 
due to the parasite’s dependence on this protein for survival (Scheme 5.1).22  This protein 
was highlighted as a potential synthetic tool to produce highly valuable L-myo-inositol 1-
phosphate (19).  This enantiopure material should then be amenable to classical sugar 
chemistry protecting group strategies to produce highly complex protected myo-inositols 
for use within the synthesis of biologically important molecules. 
 
 
Scheme 5.1 – Action of TbINO1. 
 
Previous work within the Smith group22 had recombinantly expressed TbINO1 and shown 
the protein’s activity within a screen for potential inhibitors.102  The amount of D-glucose 
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6-phosphate (18) being used within each of the reactions was as small as 0.4 mg.  We 
wanted to be working on a scale that was 1000 times greater than this, and several 
considerations had to be taken into account.   
 
The main issue with the process is achieving complete conversion to L-myo-inositol 1-
phosphate (19).  Without full conversion to the product, the remaining D-glucose 6-
phosphate (18) would be very difficult to remove.  It was, therefore, paramount that full 
conversion within the biocatalysis was achieved in order to obtain a pure product.  With 
the introduction of ammonium bicarbonate as the buffer salt, the process could be 
streamlined and optimised, giving complete conversion to L-myo-inositol 1-phosphate 
(19) on a 10 mg scale. 
 
Further scale-up of the process was not viable within the in-batch process being used.  
Although modifications were made to the procedure and 76 % conversion could be 
achieved on a 100 mg scale, ultimately, TbINO1 was not stable at 37 °C for enough time 
to achieve complete conversion or in an in-batch process product inhibition was an issue. 
 
It was hypothesised that a flow system could facilitate the scale-up of this process.  The 
immobilisation of TbINO1 onto a Ni2+-Sepharose column via its His-Tag provided a 
proof of this principle, even with the immobilisation method being unoptimised.  Using a 
5 mL Ni2+-Sepharose column saturated with TbINO1 (~200 mg), it was possible to 
produce 400 mg of enantiopure L-myo-inositol 1-phosphate (19) in flow at 37 °C. 
 
The current system is far from optimal, and suffers significant loss of catalytic activity 
after 36 hours.  With investigation into immobilisation methodologies and precise 
reaction and stability tuning, the biocatalytic flow system would become more efficient 
and viable on an industrial scale. 
 
This biotransformation will be a great asset to the synthesis of myo-inositol derivatives.  
The production of 400 mg of L-myo-inositol 1-phosphate (19) over a 30 hour period 
(13.3 mg hr-1) is on a scale that has never been seen before.  The enzyme is able to 
produce the enantiopure product in one step, whereas synthetic methods have only been 
able to reduce the number of steps down to five.  Even then, this route requires the 
synthesis of a polypeptide catalyst.70 
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An industrial production of L-myo-inositol 1-phosphate (19) would greatly benefit 
research into a vast number of biological areas.  This biotransformation has the potential 
to produce L-myo-inositol 1-phosphate (19), which costs £163 mg-1 (Cayman Chemical), 
from starting materials that effectively cost nothing.  The substrate for this enzyme, D-
glucose 6-phosphate (18), could be produced by a glucose phosphorylase.  In turn, the D-
glucose used in this reaction could be produced from starch.  Ultimately, the most 
expensive part of this process would be the cofactors adenosine triphosphate (ATP) and 
nicotinamide adenine dinucleotide (NAD+).  NAD+ is reduced and reoxidised in the 
course of the TbINO1 reaction, and is tightly held by the enzyme in a Rossman fold.22  
This means that it may be possible to dramatically reduce the amount of NAD+ required 
for this process, and recycle it without the need for any modification.  ATP can be 
recycled using enzymes in parallel to the process,128 so this is not a major concern. 
 
The concept of using a chiral inositol phosphate derivative as a synthetic starting point 
has not been realised within the literature.  This can be attributed to lack of availability 
and the prohibitive cost of such phosphates.  This process provides a cheap and efficient 
route to an optically pure myo-inositol phosphate, which has been shown to undergo 
selective phosphate benzylation to yield 1-bis(phenyloxy)phosphoryl-L-myo-inositol 
(116).  
 
The synthetic advantages of this process have been demonstrated with the synthesis of 
1,2,4,5,6-penta-O-acetyl-D-myo-inositol (189) from the biocatalytically produced L-myo-
inositol 1-phosphate (19).  This compound can act as a glycosylation acceptor within the 
synthesis of epi-mycothiol (164).  This diastereomer of mycothiol (16) could help address 
important questions in the function of mycothiol (16) within Mycobacterium tuberculosis.  
It differs from the natural product in only the point of connection to the myo-inositol 
moiety, and its synthesis was completed in only 4 steps from L-myo-inositol 1-phosphate 
(19) in 21 % yield.  We envisage that the synthetic route to the mycothiol glycosylation 
acceptor (143), could be completed in 6 steps (Scheme 5.2).  Without the need for a 
chemical resolution, this synthetic route would be a drastic improvement over the 
literature.  
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Scheme 5.2 – Envisaged route to mycothiol glycosylation acceptor 143.  Reagents and 
conditions:  i. a. PhCHN2, Et2O, MeOH, 0 °C;  b. acetal formation; ii. a. phosphate 
cleavage; b. benzylation;  iii. a. acetal cleavage;  b. selective benzylation. 
 
The cis-protection of alcohols on C-2 and C-3 of the myo-inositol ring using an acetal 
(Scheme 5.2) is desirable because it would allow access to different protection patterns of 
the alcohols.  Within the literature,50 there are a large number of protection strategies that 
can be used to selectively protect and produce different protection patterns on myo-
inositol derivatives.  With careful consideration of these protection methodologies, we 
believe that access can be granted to any desired myo-inositol derivative from L-myo-
inositol 1-phosphate (19).  In some cases, the resulting routes may be lengthy, but with an 
optically pure starting point the need for a low yielding resolution is removed. 
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Chapter Six 
 
6  Experimental 
 
6.1  General Experimental Protocols 
 
1H NMR   
Spectra were recorded on Bruker Avance 300 (300.1 MHz), Bruker Avance II 400 (400.1 
MHz) or Bruker Avance III 500 (500.1 MHz) instruments, and referenced using 
deuterated chloroform to 7.26 ppm or deuterated water at 4.79 ppm.  The chemical shifts 
were recorded in parts per million (ppm) on the delta (δ) scale (δTMS = 0).  The 
multiplicity of each signal is indicated by: s (singlet), br. s (broad singlet), d (doublet), dd 
(doublet of doublets), ddd (doublet of doublets of doublets), dt (doublet of triplets), t 
(triplet), app. t (apparent triplet) or m (multiplet).  The coupling constant (J) is measured 
in Hz and reported to the nearest 0.1 Hz.  The number of protons (n) for a given 
resonance is indicated by nH. 
 
13C NMR 
Spectra were recorded on Bruker Avance 300 (75 MHz) or Bruker Avance III 500 (126 
MHz) instruments, at ambient room temperature and internal deuterium lock.  The 
chemical shifts were recorded in ppm on the δ scale (δTMS = 0) and referenced using 
deuterated chloroform to 77.00 ppm.  The coupling constant (J) is measured in Hz and 
reported to the nearest 0.1 Hz. 
 
31P NMR 
Spectra were recorded on a Bruker Avance III 500 (202 MHz) instrument using 
broadband proton decoupling pulse sequences and deuterium internal lock.  The chemical 
shifts were recorded in ppm on the δ scale (δTMS = 0). 
 
Infrared (IR) 
Spectra were recorded on a Shimadzu IRAffinity-1 FTIR spectrometer, using attenuated 
total reflectance (ATR) as the sampling technique.  Absorption maxima are reported in 
wave numbers (cm-1). 
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Optical Specific Rotations 
Measured using a Perkin Elmer Model 341 automatic polarimeter instrument and 589 nm 
(sodium D line), in a cell with a path length of 1 dm and are reported as: , 
concentration (c in g / 100 mL) and solvent. 
 
High Resolution Mass Spectrometry (HRMS) 
Recorded by the EPSRC National Mass Spectrometry Service at Swansea on a Thermo 
Fisher LTQ Orbitrap XL mass spectrometer using the Electrospray Ionisation (ES) 
technique. 
 
Analytical Thin Layer Chromatography (TLC) 
Conducted on pre-coated (25 µm) Merck Kieselgel 60 F254 plates with visualization by 
ultraviolet (UV) light at 254 nm and/or heating the plate after staining with a solution of 
20 % ceric ammonium molybdate w/v in water. 
 
Flash Column Chromatography 
Conducted on Merck Silica gel 60 (40-63 µm) under a positive pressure of compressed 
air. 
 
Reagents and Solvents 
Purified by standard methods.  Diethyl ether (Et2O), dichloromethane (DCM) and 
tetrahydron furan (THF) were dried by passage through two columns of alumina using a 
MBRAUN SPS-800 solvent purification system.  Methanol and acetonitrile were distilled 
from calcium hydride in a recycling still under argon.  Pyridine was purchased from 
Fisher Scientific and dried by distillation from 4 Å molecular sieves.  Dimethylsulfoxide 
(DMSO) was dried over calcium hydride, distilled under high vacuum and stored over 
4 Å molecular sieves.  All other reagents were purchased from Sigma Aldrich UK, Alfa 
Aesar UK, Acros Organics UK or TCI Europe and were used as received, unless 
otherwise stated.  Reactions were performed under anhydrous conditions when 
appropriate and in an inert atmosphere of argon, using a vacuum manifold with argon 
passed through a calcium chloride and self-indicating silica gel column.  Room 
temperature (RT) refers to a temperature of approximately 20 °C. 
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Miscellaneous 
The term “brine” refers to a saturated aqueous solution of sodium chloride in deionized 
water. 
 
  
6.2  Chapter 2 Experimental 
 
6.2.1 Trypanosoma brucei L-myo-Inositol 1-phosphate Synthase (TbINO1) 
Expression and Purification22 
 
Recombinant expression of TbINO1 was conducted using the pET15b-TbINO1 construct 
within BL21 Rosetta (DE3) cells (Invitrogen).  TbINO1 was purified by Ni2+ affinity 
chromatography, eluted with an increasing step gradient of imidazole (10, 20, 50, 100, 
250 and 400 mM) in 20 mM ammonium bicarbonate (pH 8.5) and 250 mM NaCl.  The 
His-tagged protein was dialysed against 20 mM ammonium bicarbonate (pH 8.5), 50 mM 
NaCl and 5 mM DTT.  The resulting solution could be stored with 10 % glycerol at -
80 °C for up to 6 months.  In a typical expression, 600 mg of TbINO1 was collected from 
8 L of cell culture (75 mg L-1). 
 
6.2.2  In-Batch Reactions 
 
IMPase assay22 
A sample from the TbINO1 reaction mixture was added to a solution containing Tris-
acetate (50 mM, pH 8.0), 1.25 mU of IMPase from bovine brain (Sigma) and MgCl2 (4 
mM).  The reaction was incubated at 37 °C for 3 hours.  The amount of free phosphate 
was determined by the malachite green method165 and compared with a standard curve of 
KH2PO4 solution. 
 
Initial Experiments 
To water (70 µL) were added solutions of ammonium bicarbonate (500 mM, pH 8.5, 15 
µL), D-glucose 6-phosphate (18, 100 mM, 15 µL), NAD+ (20 mM, 15 µL), DTT (10 mM, 
15 µL) and TbINO1 (4.35 µg / µL, 20 µL) in order.  The mixture was incubated at 37 °C 
overnight.  The IMPase assay determined the conversion of the reaction as 92 %. 
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10 mg Scale 
To D-glucose 6-phosphate (18, 10 mg, 38 µmol) in water (458.0 µL) were added 
solutions of ammonium bicarbonate (500 mM, pH 8.5, 60 µL), NAD+ (200 mM, 6 µL), 
DTT (100 mM, 6 µL) and TbINO1 (4.35 µg / µL, 70 µL) in order.  The mixture was 
incubated at 37 °C overnight.  The IMPase assay determined the conversion of the 
reaction as 98 %. 
 
100 mg Scale 
To D-glucose 6-phosphate (18, 100 mg, 384 µmol) in water (1664 µL) were added 
solutions of ammonium bicarbonate (500 mM, pH 8.5, 240 µL), NAD+ (200 mM, 48 µL), 
DTT (100 mM, 24 µL) and TbINO1 (4.35 µg / µL, 400 µL) in order.  The mixture was 
incubated for 6 days with shaking at 37 °C in the dark and under an argon atmosphere.  
The IMPase assay determined the conversion of the reaction as 76 % and no further 
reaction progress was observed. 
 
 
6.3  Chapter 3 Experimental 
 
6.3.1  Set up of flow system 
 
Frozen pellets from 4 L of growth media were suspended in a lysis buffer of 20 mM 
ammonium bicarbonate (pH 8.5), 200 mM NaCl and 3 mM 2-mercaptoethanol.  Cells 
were lysed by sonication (7 x 20 second bursts, 40 second rests) and the supernatant 
cleared by centrifugation (40,000 rcf, 20 minutes, 4 °C).  The supernatant was filtered 
(0.45 µm) prior to loading onto a freshly charged, new 5 mL Ni2+-Sepharose column.  
The column was washed with 25 mL of a solution containing 10 mM imidazole, 50 mM 
ammonium bicarbonate (pH 8.5) and 1 mM 2-mercaptoethanol to elute the unwanted cell 
extracts.  The column was finally washed with a solution containing 50 mM ammonium 
bicarbonate (pH 8.5) and 1 mM 2-mercaptoethanol, before fitting a Sepharose column 
that had been previously stripped of any Ni2+ ions by washing with 50 mM EDTA 
solution. 
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6.3.2  L-myo-Inositol 1-phosphate (19) 
 
 
 
Procedure A 
A solution containing 18 mM D-glucose 6-phosphate (18), 1 mM NAD+, 50 mM 
ammonium bicarbonate (pH 8.5) and 1 mM 2-mercaptoethanol was passed through the 
previously prepared flow system at a rate of 2.5 mL hr-1.  25 mL fractions were collected 
and each fraction was separately acidified to pH <2 using concentrated HCl, before being 
lyophilised to produce crude L-myo-inositol 1-phosphate (19).  1H NMR was used to 
determine which fractions contained no D-glucose 6-phosphate (18), which were 
combined and dissolved in methanol, filtered and concentrated under reduced pressure to 
yield L-myo-inositol 1-phosphate (19, 341 mg) with a small impurity. 
 
Procedure B 
A solution containing 15 mM D-fructose 6-phosphate (120), 1 mM NAD+, 50 mM 
ammonium bicarbonate (pH 8.5) and 1 mM 2-mercaptoethanol was passed through the 
previously prepared flow system at a rate of 2.5 mL hr-1. The eluted solution was 
acidified to pH <2 using concentrated HCl, before being lyophilised to produce crude L-
myo-inositol 1-phosphate (19).  
 
 -4.60 (c 1.00, H2O at pH 9); IR (ATR) 3262, 3041, 2965, 2936, 1634, 1033, 999; 
1H NMR (500 MHz, D2O) δ 4.24 (1H, t, J = 2.8 Hz, H-2), 3.94 (1H, ddd, J = 9.8, 8.8, 
2.8 Hz, H-1), 3.73 (1H, t, J = 9.7 Hz, H-6), 3.63 (1H, t, J = 9.7 Hz, H-4), 3.54 (1H, dd, 
J  = 10.0, 2.9 Hz, H-3) and 3.31 (1H, t, J = 9.4 Hz, H-5); 13C NMR (126 MHz, D2O) δ 
75.7, 73.8, 72.2, 71.4 (d, J = 6.1 Hz), 71.1 and 70.7; 31P NMR (202 MHz, D2O) δ -0.19; 
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HRMS (ES-) Calc. for C6H12O9P [M-H]- 259.0224, found 259.0222.  The data are in 
good agreement with the literature values.69,166 
 
6.3.3  2,4,6-Triisopropylbenzenesulfonyl hydrazide (118)167 
 
 
 
To a stirred solution of 2,4,6-triisopropylbenzenesulfonyl chloride (117, 2.00 g, 
6.60 mmol) in THF (10 mL) was added hydrazine monohydrate (0.64 mL, 13.21 mmol, 
2 equiv.) slowly dropwise at 0 °C.  The reaction was stirred for 4 hours at this 
temperature.  The precipitate was dissolved by addition of water (20 mL) and the product 
was extracted in diethyl ether (2 x 30 mL).  The organic phases were combined and 
washed with water (30 mL) and brine (30 mL) before being dried over magnesium 
sulfate, filtered and concentrated under reduced pressure to give hydrazide 118 as a white 
solid (1.88 g, 6.28 mmol, 95 %). 
 
1H NMR (300 MHz, CDCl3) δ 7.20 (2H, s, H-4), 5.49 (1H, s, H-9), 4.17 (2H, septet, 
J = 6.8 Hz, H-7), 3.66 (2H, br. s, H-10), 2.92 (1H, septet, J = 7.0 Hz, H-2), 1.27 (12H, d, 
J = 6.8 Hz, H-8) and 1.26 (6H, d, J = 7.0 Hz, H-1); 13C NMR (75 MHz, CDCl3) δ 154.0, 
152.0, 128.7, 124.2, 122.9, 34.4, 30.0, 25.1 and 23.7. The data are in good agreement 
with the literature values.167 
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6.3.4  N’-Benzylidine-2,4,6-triisopropylbenzenesulfonyl hydrazide (119)168  
 
 
To a solution of 2,4,6-triisopropylbenzenesulfonyl hydrazide (118, 1.50 g, 5.03 mmol) in 
methanol (20 mL) was added benzaldehyde (0.51 mL, 5.03 mmol, 1 equiv.).  The 
reaction was stirred at room temperature for 30 minutes before being stirred at 4 °C for 
16 hours.  The precipitate was collected and washed with ice-cold methanol before dried 
in vacuo.  Recrystallisation in ethanol furnished pure hydrazide 119 (1.77 g, 4.59 mmol, 
91 %). 
 
1H NMR (300 MHz, CDCl3) δ 7.85 (1H, br. s, H-10), 7.60-7.50 (2H, m, H-13), 7.41-7.29 
(3H, m, H-12 and H-14), 7.18 (2H, s, H-4), 4.27 (2H, septet, J = 6.8 Hz, H-7), 2.89 (1H, 
septet, J = 6.9 Hz, H-2), 1.31 (12H, d, J = 6.8 Hz, H-8) and 1.24 (6H, d, J = 6.9 Hz, H-1); 
13C NMR (75 MHz, CDCl3) δ 153.5, 151.4, 146.4, 130.3, 128.6, 127.3, 123.9, 34.2, 30.1, 
24.9 and 23.5.  The data are in good agreement with the literature values.116 
 
 
6.3.5  Phenyldiazomethane (115)116 
 
 
 
To a stirred suspension of N’-benzylidene-2,4,6-triisopropylbenzenesulfonyl hydrazide 
(119, 1.78 g, 4.61 mmol) in methanol (30 mL) was added potassium hydroxide (0.52 g, 
9.22 mmol, 2 equiv.) and the mixture heated to reflux for 30 minutes in apparatus with 
flame-polished joints.  The reaction was allowed to cool to room temperature before ice-
cold water (30 mL) was added.  The product was extracted into diethyl ether (3 x 30 mL) 
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and subsequently washed with sodium bicarbonate solution (sat., aq., 30 mL), water 
(30 mL) and brine (30 mL) in glassware with flame-polished joints.  The 
phenyldiazomethane (115) was then used as an ethereal solution in further reactions. 
 
 
6.3.6  1-Bis(benzyloxy)phosphoryl-L-myo-inositol (116) 
 
 
 
To a stirred solution of L-myo-inositol 1-phosphate (19, 200 mg, 0.77 mmol) in methanol 
(600 mL) at 0 °C was added an excess of ethereal phenyldiazomethane solution (freshly 
prepared, 6 equivalents of hydrazide 119 used in preparation).  The reaction was stirred 
for 4 hours at 0 °C before being quenched with acetic acid (0.50 mL) and stirred for a 
further 10 minutes.  The reaction was concentrated before being dissolved in water 
(100 mL) and washed with diethyl ether (100 mL x 3).  The water was removed by 
lyophilisation to yield 1-bis(benzyloxy)phosphoryl-L-myo-inositol (116, 329 mg, 
0.75 mmol, 97 %) as a pale yellow solid. 
 
 +6.50 (c 0.10, H2O); IR (ATR) 3323, 3134, 3035, 2808, 1402, 1010, 999; 1H 
NMR (500 MHz, CDCl3) δ 7.48-7.34 (m, 10H, H-Ar), 5.12-5.06 (m, 4H, H-7), 4.16-4.10 
(m, 1H, H-1), 4.07 (t, J = 2.9 Hz, 1H, H-2), 3.76 (t, J = 9.7 Hz, 1H, H-6), 3.60 (t, 
J = 9.6 Hz, 1H, H-4), 3.40 (dd, J = 10.0, 2.8 Hz, 1H, H-3) and 3.25 (t, J = 9.5 Hz, 1H, H-
5); 13C NMR (126 MHz, CDCl3) δ 135.1, 129.1, 128.8, 128.4, 78.7, 73.6, 71.9, 70.8, 
70.8, 70.7, 70.7, 70.6, 70.5, 70.4, 70.3; 31P NMR (202 MHz, CDCl3) δ -1.95; HRMS 
(ES+) Calc. for C20H26O9P [M+H]+ 441.1309, found 441.1308.   
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6.4  Chapter 4 Experimental 
 
6.4.1  Imidazole-1-sulfonyl azide (170)157 
 
 
 
To a suspension of sodium azide (3.20 g, 50.0 mmol, 1 equiv.) in dry acetonitrile (50 mL) 
was added sulfuryl chloride (4.00 mL, 50.0 mmol, 1 equiv.) slowly dropwise at 0 ¹C.  
The reaction was stirred at room temperature overnight.  Imidazole (6.80 g, 100.0 mmol, 
2 equiv.) was added in portions over a 1 hour period at 0 ¹C, before the reaction was 
allowed to warm to room temperature.  The resulting slurry was stirred for 3 hours before 
being diluted with ethyl acetate (50 mL) and water (50 mL).  The phases were separated 
and the organic washed with water (50 mL), sodium bicarbonate solution (sat., aq., 
50 mL) and brine (50 mL) before being dried over magnesium sulfate, filtered and 
concentrated under reduced pressure to yield the pure product 170 (7.81 g, 45.1 mmol, 
90 %). 
 
Rf 0.88 (ethyl acetate); 1H NMR (500 MHz, CDCl3) δ 8.02 (s, 1H, H-2), 7.38 (app. t, 
J = 1.5 Hz, 1H, H-5) and 7.22 (d, J = 0.9 Hz, 1H, H-4); 13C NMR (126 MHz, CDCl3) δ 
136.8, 132.0 and 117.8.  The data are in good agreement with the literature values.169 
 
 
6.4.2  1,3,4,6-Tetra-O-acetyl-2-azido-D-glucopyranose (168) 
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Procedure A155,158 
To a stirred solution of sodium azide (6.03 g, 92.8 mmol, 10 equiv.) in water (32 mL) was 
added DCM (16 mL).  The biphasic mixture was cooled to 0 ⁰C before triflic anhydride 
(3.12 mL, 18.6 mmol, 2 equiv.) was added slowly dropwise.  The reaction was stirred at 
this temperature for 2 hours before the phases were separated and the aqueous layer 
washed with DCM (2 x 8 mL).  The organic phases were combined and washed with 
Na2CO3 solution (sat., aq., 10 mL). 
 
To a stirred solution of glucosamine hydrochloride (131, 2.00 g, 9.23 mmol, 1 equiv.) in 
water (32 mL) was added copper sulfate pentahydrate (23.0 mg, 0.09 mmol, 0.01 equiv.), 
potassium carbonate (1.92 g, 13.9 mmol, 1.5 equiv.) and methanol (32 mL).  The triflic 
azide solution (32 mL) was added slowly at 0 ⁰C before more methanol (75 mL) was 
added.  The reaction was allowed to warm to room temperature and stirred overnight. 
 
The reaction was concentrated before being taken up in pyridine (30 mL) and acetic 
anhydride (6.98 mL, 73.8 mmol, 8 equiv.) was added at 0 °C.  The mixture was stirred for 
16 hours before being quenched with sodium bicarbonate solution (sat., aq., 10 mL), 
extracted into DCM (3 x 50 mL), washed with sodium bicarbonate (sat., aq., 50 mL), HCl 
(2 M, aq., 50 mL), water (50 mL) and brine (50 mL).  The organic layer was dried over 
magnesium sulfate, filtered and concentrated under reduced pressure.  The crude product 
was purified by column chromatography (silica gel, 25 % ethyl aetate in hexane) to yield 
162 as a yellow oil (2.52 g, 6.75 mmol, 73 %). 
 
Procedure B157 
To a stirred suspension of D-glucosamine hydrochloride (131, 2.08 g, 9.64 mmol, 1 
equiv.) in methanol (40 mL) was added potassium carbonate (2.00 g, 14.5 mmol, 
1.5 equiv.), copper sulfate pentahydrate (20.8 mg, 0.10 mmol, 0.01 equiv.) and imidazole-
1-sulfonyl azide (170, 2.00 g, 11.6 mmol, 1.2 equiv.).  The reaction was stirred at room 
temperature for 2 hours before being concentrated under reduced pressure and co-
evaporated with toluene (2 x 20 mL). 
 
Acetic anhydride (9.11 mL, 96.4 mmol, 10 equiv.) was added to the residue in pyridine 
(30 mL) and the mixture was stirred for 16 hours.  The reaction was concentrated before 
being diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL).  The 
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combined organic phases were washed with water (50 mL) and brine (50 mL) before 
being dried over magnesium sulfate, filtered and concentrated under reduced pressure.  
The crude product was purified by column chromatography (silica gel, 25 % ethyl acetate 
in hexane) to give 168 as a colourless oil (2.46 g, 6.58 mmol, 68 %). 
 
Rf  0.33 (30 % ethyl acetate in hexane); 1H NMR (500 MHz, CDCl3, α/β = 33:67) δ 6.29 
(d, J = 3.7 Hz, 0.33H, H-1α), 5.55 (d, J = 8.6 Hz, 0.67H, H-1β), 5.45 (dd, J = 10.5, 
9.4 Hz, 0.33H, H-3α), 5.14-5.02 (m, 1.67H, H-3β and H-4), 4.30 (dt, J = 12.7, 4.3 Hz, 
1H, H-6a), 4.11-4.02 (m, 1.33H, H-5α and H-6b), 3.80 (ddd, J = 9.7, 4.4, 2.1 Hz, 0.67H, 
H-5β), 3.70-3.63 (m, 1H, H-2), 2.19 (s, 1H, AcO), 2.18 (s, 2H, AcO), 2.10 (s, 1H, AcO), 
2.09 (s, 2H, AcO), 2.07 (s, 3H, AcO), 2.04 (2, 1H, AcO) and 2.02 (s, 2H, AcO); 13C 
NMR (126 MHz, CDCl3) δ 170.7, 170.2, 169.9, 169.8, 169.7, 168.7, 168.6, 92.7, 90.1, 
72.9, 72.8, 70.9, 69.9, 68.0, 67.9, 62.7, 61.5, 60.4, 21.1, 21.0, 20.9, 20.8, 20.7 and 20.6.  
The data are in good agreement with the literature values.170 
 
 
6.4.3  3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-glucopyranose (169)171 
 
 
 
To a stirred solution of 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranose (168, 
0.20 g, 0.54 mmol, 1 equiv.) in diethyl ether (5 mL) was added benzylamine (0.12 mL, 
1.08 mmol, 2 equiv.).  The reaction was stirred for 16 hours before being concentrated 
under reduced pressure and the residue dissolved in chloroform (10 mL).  The solution 
was washed with sodium bicarbonate solution (sat., aq., 10 mL), water (10 mL) and brine 
(10 mL) before being dried over magnesium sulfate, filtered and concentrated under 
reduced pressure.  The crude product was purified by column chromatography (silica gel, 
50 % ethyl acetate in hexane) to yield 169 (0.14 g, 0.41 mmol, 77 %). 
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Rf  0.23 (30 % hexane in ethyl acetate); 1H NMR (500 MHz, CDCl3, α/β = 36:64) δ 5.51 
(dd, J = 10.5, 9.3 Hz, 0.65H, H-3α), 5.39 (t, J = 3.5 Hz, 0.65H, H-1α), 5.08-5.00 (m, 
1.35H, H-3β and H-4), 4.73 (dd, J = 8.1, 3.8 Hz, 0.35H, H-1β), 4.29-4.08 (m, 3H, H-5, 
and H-6), 3.74-3.69 (m, 0.35H, H-5β), 3.42 (dd, J = 10.5, 3.4 Hz, 1H, H-2), 2.10-2.07 (m, 
6H, AcO), 2.04 (s, 2H, AcO) and 2.02 (s, 1H, AcO).  The data are in good agreement 
with the literature values.172–174 
 
 
6.4.4  3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-glucopyranosyl fluoride (165)171 
 
 
 
To a stirred solution of 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-glucopyranose (169, 0.85 g, 
2.55 mmol) in THF (50 mL) at -30 °C was added DAST (0.40 mL, 3.06 mmol, 
1.2 equiv.) dropwise.  The reaction was stirred at this temperature for 10 minutes, before 
being allowed to warm to room temperature and stirred for 1 hour.  The reaction was 
quenched by addition of methanol (20 mL) at 0 °C and stirred for 20 minutes before 
being concentrated.  The crude material was dissolved in chloroform (50 mL) and washed 
with sodium bicarbonate solution (sat., aq., 2 x 50 mL) and brine (50 mL), before being 
dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield 
the fluoride 165 (0.74 g, 2.22 mmol, 87 %). 
 
Rf  0.27 (30 % ethyl acetate in hexane); 1H NMR (500 MHz, CDCl3, α/β = 18:82) δ 5.72 
(dd, J = 51.8, 2.7 Hz, 0.18H, H-1α), 5.48 (dd, J = 10.5, 9.4 Hz, 0.82H, H-3α), 5.16 (dd, 
J = 51.4, 7.3 Hz, 0.82H, H-1β), 5.16-5.03 (m, 1.82H, H-3β and H-4), 4.33-4.28 (m, 
0.18H, H-6aα), 4.28 (ddd, J = 12.5, 4.9, 0.9 Hz, 0.82H, H-6aβ), 4.23-4.20 (m, 0.18H, H-
5α), 4.17 (dd, J = 12.6, 2.4 Hz, 0.82H, H-6bβ), 3.84-3.76 (m, 1H,       H-6bα and H-5β), 
3.71-3.63 (m, 0.82H, H-2β), 3.51 (ddd, J = 25.6, 10.5, 2.6 Hz, 0.18H, H-2α) and 2.11-
2.03 (m, 9H, AcO); 19F NMR (282 MHz, CDCl3, α/β = 18:82) δ -139.42 (dd, J = 51.5, 
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12.5 Hz, Fβ) and -147.27 (dd, J = 52.0, 25.8 Hz, Fα).  The data are in good agreement 
with the literature values.175 
 
 
6.4.5  L-Thiazolidine-4-carboxylic acid (171)176 
 
 
 
Formaldehyde (37 wt %, aq., 1 mL) was added to a stirred solution of L-cysteine (132, 
1.16 g, 9.64 mmol) in water (4 mL), and the reaction was stirred for 2 hours.  Pyridine 
was added until a pH of 7 was obtained and the product crashed out of solution.  L-
Thiazolidine-4-carboxylic acid (171, 1.00 g, 7.51 mmol, 78 %) was collected by filtration 
and washed with ice-cold ethanol. 
 
1H NMR (300 MHz, D2O) δ 4.47-4.29 (m, 3H, H-2 and H-4), 3.40 (dd, J = 12.1, 7.4 Hz, 
1H, H-5) and 3.29 (dd, J = 12.1, 5.8 Hz, 1H, H-5); 13C NMR (126 MHz, D2O) δ 172.0, 
64.3, 49.1 and 32.1.  The data are in good agreement with the literature values.176 
 
 
6.4.6  N-Acetyl-L-thiazolidine-4-carboxylic acid (172)177 
 
 
 
To a stirred solution of L-thiazolidine-4-carboxylic acid (171, 50 mg, 0.38 mmol) in 
pyridine (4 mL) was added acetic anhydride (0.5 mL, 5.30 mmol, 14 equiv).  The reaction 
was stirred for 1 hour before being concentrated under reduced pressure and the residual 
pyridine removed by co-evaporation with toluene three times to yield N-acetyl-L-
thiazolidine-4-carboxylic acid (172, 66 mg, 0.37 mmol, 99 %) as a white solid. 
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M.P. 143-144 °C; 1H NMR (500 MHz, CDCl3) δ 5.04 (dd, J = 7.0, 3.5 Hz, 1H, H-4), 
4.66-4.49 (m, 2H, H-2), 3.47 (dd, J = 12.1, 3.5 Hz, 1H, H-5), 3.24 (dd, J = 12.1, 7.0 Hz, 
1H, H-5) and 2.24 (s, 3H).  The data are in good agreement with the literature 
values.178,179 
 
 
6.4.7  N-Boc-S-acetyl cysteine (179) and N-Boc-S,O-diacetyl cysteine (180)151 
 
 
 
Zinc (dust, 417 mg, 6.42 mmol, 10 equiv.) was added in portions over a 1 hour period to 
N,N’-bis(Boc)-L-cystine (178, 283 mg, 0.64 mmol) in acetic acid (4.5 mL).  The reaction 
was stirred for 2 hours before being filtered and concentrated under reduced pressure.  
The residue was taken up in pyridine (4.5 mL) before acetic anhydride (0.61 mL, 
6.45 mmol, 1.05 equiv.) was added.  The reaction was stirred overnight before being 
quenched with HCl solution (2 M, aq., 2 mL).  The product was extracted into ethyl 
acetate (3 x 10 mL), washed with HCl solution (1 M, aq., 20 mL) and brine (20 mL), and 
dried over magnesium sulfate, filtered and concentrated under reduced pressure.  N-Boc-
S-acetyl-L-cysteine (179) was obtained in a mixture with its anhydride 180 in 27 % yield. 
 
 
6.4.8  N,N’-Diacetyl-L-cystine (183) 
 
 
 
To a stirred solution of L-cystine (182, 1.00 g, 4.16 mmol) in water (5 mL) was added 
sodium hydroxide solution (30 % aq., 5 mL) at 0 °C.  At this temperature, acetic 
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anhydride (1 mL) was added slowly dropwise before sodium hydroxide solution (30 % 
aq., 1 mL) was added slowly dropwise.  This process was repeated six times before 
stirring the reaction at 0 °C for 2 hours.  The reaction was concentrated under reduced 
pressure and the residue taken up in acetic anhydride.  Filtration and concentration under 
reduced pressure yielded N,N’-diacetyl-L-cystine (183, 1.32 g, 4.08 mmol, 98 %) as a 
white solid. 
 
1H NMR (500 MHz, CDCl3) δ 4.68 (dd, J = 8.8, 4.4 Hz, 1H, H-2), 3.21 (dd, J = 14.3, 
4.4 Hz, 1H, H-1a), 3.00 (dd, J = 14.3, 8.8 Hz, 1H, H-1b) and 2.06 (s, 3H, AcN); HRMS 
(ES+) Calc. for C10H17N2O6S2 [M+H]+ 325.0523, found 325.0527.  The data are in good 
agreement with the literature values.180 
 
 
6.4.9  2,3,4,5,6-Penta-O-acetyl 1-bis(benzyloxy)phosphoryl L-myo-inositol (187) 
 
 
 
To a stirred suspension of 1-bis(benzyloxy)phosphoryl L-myo-inositol (116, 100 mg, 
0.23 mmol, 1 equiv.) in pyridine (5 mL) was slowly added acetic anhydride (1.06 mL, 
11.21 mmol, 50 equiv.) and 4-dimethylaminopyridine (3 mg, 0.02 mmol, 0.1 equiv.) at 
0 °C.  The reaction was stirred at this temperature for 10 minutes before being stirred at 
room temperature for 5 hours.  The reaction was concentrated under reduced pressure and 
the residue dissolved in dichloromethane (10 mL).  The solution was washed with water 
(10 mL), HCl solution (1 M, 2 x 10 mL), water (10 mL) and brine (10 mL) before being 
dried over magnesium sulfate, filtered and concentrated under reduced pressure.  The 
crude product was purified by column chromatography (silica gel, 50 % ethyl acetate in 
hexane) to yield 187 as a colourless oil (40 mg, 0.06 mmol, 27 %). 
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Rf  0.35 (50 % ethyl acetate in hexane);  +13.00 (c 1.00, CHCl3); IR (ATR) 3036, 
2965, 1749, 1210, 1009, 999; 1H NMR (500 MHz, CDCl3) δ 7.34-7.18 (10H, m, Ar), 
5.66 (1H, t, J = 3.0 Hz, H-2), 5.46-5.36 (2H, m, H-6 and H-4), 5.03 (1H, t, J = 9.9 Hz, H-
5), 5.98-4.83 (5H, m, H-3 and 2 x CH2), 4.50 (1H, dt, J = 3.0, 9.8 Hz, H-1), 2.07 (3H, s, 
Ac-2), 1.94 (3H, s, Ac-4), 1.93 (6H, s, Ac-3 and Ac-5) and 1.79 (3H, s, Ac-6); 13C NMR 
(126 MHz, CDCl3) δ 169.9, 169.7, 169.7, 169.7, 169.5, 128.7, 128.7, 128.7, 128.6, 128.0, 
128.0, 73.0 (d, J = 5.3 Hz), 70.7, 70.0 (d, J = 5.0 Hz), 69.9 (d, J = 5.9 Hz), 69.6 (d, 
J = 5.7 Hz), 69.3, 68.9 (d, J = 2.81 Hz), 68.5, 20.7, 20.6 and 20.5; 31P NMR (202 MHz, 
CDCl3) δ -1.76; HRMS (ES+) Calc. for C30H36O14P [M+H]+ 651.1837, found 651.1823.   
 
 
6.4.10  2,3,4,5,6-penta-O-acetyl 1-phosphoryl L-myo-inositol (188) 
 
 
 
To a stirred solution of pentaacetate 187 (6.3 mg, 9.73 µmol) in ethyl acetate (3 mL) was 
added palladium on carbon (10 wt % loading, 10 mg, 0.09 mmol).  The reaction was 
purged with hydrogen and left under a positive pressure of hydrogen with stirring 
overnight.  The reaction was filtered through Celite and washed through with ethyl 
acetate, before being concentrated under reduced pressure.  The product 188 (4 mg) was 
used in the next step without further purification. 
 
Rf  0.05 (10 % methanol in DCM).  
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6.4.11  1,2,4,5,6-penta-O-acetyl D-myo-inositol (189) 
 
 
 
Crude phosphate 188 (4 mg, 8.9 µmol) was taken up in a mixture of sodium acetate 
buffer (50 mM, pH 5.2, 860 µL) and DMSO (40 µL) before lyophilised acid phosphatase 
(from potato, 3.3 Umg-1, 1 mg) was added and the reaction incubated with shaking at 
37 °C overnight.  The product was extracted into ethyl acetate (1 mL x 5) before being 
concentrated under reduced pressure to yield 189 (3 mg, 7.7 µmol, 79 % over 2 steps). 
 
Rf  0.56 (10 % methanol in DCM);  +3.00 (c 0.20, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 5.62 (1H, t, J = 3.0 Hz, H-2), 5.48 (1H, t, J = 10.2 Hz, H-4), 5.33 (1H, t, 
J = 10.0 Hz, H-6), 5.17 (1H, t, J = 9.8 Hz, H-5), 4.99 (1H, dd, J = 10.6, 2.8 Hz, H-3), 3.91 
(1H, dd, J = 10.1, 3.0 Hz, H-1), 2.24 (3H, s, Ac), 2.12 (3H, s, Ac), 2.05 (3H, s Ac), 2.04 
(3H, s, Ac) and 2.02 (3H, s, Ac); 13C NMR (126 MHz, CDCl3) δ 171.1, 170.3, 169.9, 
169.8, 169.8, 72.5, 70.7, 70.5, 69.4, 69.1, 69.0, 20.9, 20.8, 20.6, 20.6 and 20.6.  The data 
are in good agreement with the literature values.181,182 
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	2,3,4,5,6-Penta-O-acetyl 1-bis(benzyloxy)phosphoryl L-myo-inositol (187) 1H NMR 
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	1,2,4,5,6-penta-O-acetyl D-myo-inositol (189) 13C NMR 
 
 
